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Abstract 
Systemic sclerosis is a multisystem connective tissue disease characterised by skin 
thickening and widespread, but variable, visceral fibrosis. The aetiopathogenesis is likely to 
involve immunological activation and microvascular dysfunction leading to excessive 
accumulation of extracellular matrix (ECM) with increased production of collagen type I in 
lesional tissues. This implies a dysregulated repair process probably as a consequence of 
aberrant crosstalk between fibroblasts and inflammatory cells. It has been proposed that a 
hierarchical cascade of soluble mediators in which initial induction of proinflammatory 
cytokines expressed by the inflammatory infiltrate may lead to expression of profibrotic 
mediators including TGFβ. A salient feature of the inflammatory response is directional 
migration of leucocytes into subendothelial tissues orchestrated by chemokines in a 
spatially and temporally-regulated multistep process. Work described in this thesis explores 
the expression of chemokine, monocyte chemoattractant protein-3 (MCP-3/CCL7) in SSc 
and in murine models for SSc: type 1 tight skin mouse (Tsk1) and a transgenic mouse strain 
(TβRIIΔk) in which there is fibroblast-directed disruption of TGFβ signalling. The 
hypothesis that crosstalk between MCP-3 and TGFβ may modulate the signalling response 
in the fibrotic microenvironment was also explored. 
 
Overexpression of MCP-3 was demonstrated on cDNA expression profiling and protein 
analysis of neonatal Tsk1 and TβRIIΔk fibroblasts. This was supported by 
immunohistochemical studies on dermal tissues. Similar upregulation dermal patterns of 
MCP-3 protein expression were observed in the early stage of diffuse cutaneous SSc. 
Activation of collagen reporter genes by MCP-3 in transgenic mouse fibroblasts and 
wildtype neonatal mouse fibroblasts harbouring proα2(Ι)collagen promoter reporter gene 
constructs is mediated via sequences within the proximal promoter and is partly dependent 
on TGFβ. This coinduction between the two factors in the fibrotic response is also 
demonstrated by activation of TGFβ signalling pathways by MCP-3 leading to type I 
collagen secretion. In addition, MCP-3 gene expression is stimulated by TGFβ. 
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Comparison of downstream signalling pathways that regulate collagen gene activation by 
both cytokines confirms the central role of MAPK pathway activation in mediating the 
effects of both factors. An additive effect of these two agonists was demonstrated for key 
TGFβ-regulated genes on comparative microarray analysis.   
 
Overall, these results demonstrate that overexpression of MCP-3 is a key biochemical 
feature of early stage SSc and murine models of SSc, and suggest a novel role for this 
chemokine as a profibrotic mediator in addition to its role in regulating leucocyte 
recruitment. Furthermore, there is a potentially important interplay between MCP-3 and 
TGFβ in modulation of the signalling response in the fibrotic microenvironment.    5
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CHAPTER 1: INTRODUCTION 
 
1.1 Systemic Sclerosis: An Overview 
1.1.1 Epidemiology  
The 1980 Systemic Sclerosis (SSc) classification criteria have greatly facilitated 
epidemiological studies by providing a common definition for this disease(Subcommittee 
for scleroderma criteria of the American Rheumatism Association Diagnostic and 
Therapeutic Criteria Committee, 1980). Earlier studies did not have this benefit and 
therefore, it was difficult to make direct comparisons between pre- and post- 1980 studies. 
In addition, the 1980 classification scheme is likely to miss 10% of individuals who have 
limited disease and most studies are hospital-based. 
Overall SSc should be considered uncommon rather than rare, with a prevalence of 31 per 
million (Silman & Black, 1988) and an incidence of 3.7 per million per year. Recent 
population studies suggest that SSc occurs more frequently in the US than in UK with a 
prevalence estimated to be 242 cases per million adults with an annual incidence rate of 
19.3 new cases per million per year but this has remained relatively stable(Mayes et al., 
2003). Women are affected more frequently than men and this is reflected in the UK 
Central Registry with Royal Free Hospital, with over 1500 cases with a female:male ratio 
of 5:1. The factors responsible for this are not apparent. Limited cutaneous SSc (lcSSc) is 
approximately twice as common as the diffuse subtype.   
 
Overall survival has improved over the past few decades with a mean survival of 12 years 
from diagnosis, with 78% at 5 years and 55% at 10 years(Mayes et al., 2003). This may be 
related to earlier diagnosis and recognition of mild limited cases which may prejudice 
studies in the direction of increased survival. In addition, it is likely that increased 
sensitivity of antibody detection leading
 to the diagnosis of milder forms of SSc (with better 
outcome),
 which may previously not have been recognised may contribute to improvement 
in survival. Nonetheless, advances in treatment, most notably the use of angiotensin 
converting enzyme (ACE) inhibitors in renal crisis have led to a real decrease in the 
mortality from hypertensive renal disease from 25% to 10%. The mortality rate is partially   24
dependent on organ involvement and pulmonary disease including pulmonary fibrosis and 
pulmonary hypertension has now emerged as a major cause of death. Among patients with 
severe ventilatory
 restriction (forced vital capacity <50% of predicted) as
 a result of SSc-
related interstitial lung disease mortality
 approaches 42% within 10 yrs after the onset of 
the disease(Tashkin et al., 2006). In general patient survival in lcSSc is greater than that
 in 
diffuse cutaneous SSc (dcSSc). A Swedish series with 250 patients demonstrated 
standardized mortality ratios (95% Confidence Interval) of
 3.72 (2.41–5.32) in lcSSc and 
6.06 (4.09–9.02) in
 dcSSc(Hesselstrand et al., 1998). In lcSSc, most deaths are from the 
usual causes such as cancer, heart disease and old age. Of those who die of SSc-related 
deaths, 50% die of pulmonary hypertension and 25% die of pulmonary fibrosis. In the 
entire SSc population, 50% die of SSc-related deaths die of pulmonary disease. Cardiac 
disease is also correlated with a poorer outcome. Gastrointestinal involvement contributes 
to the morbidity of the disease but the extent of this contribution to mortality is less clear. 
 
1.1.2 Classification criteria for SSc and subgroups 
The word scleroderma is derived from Greek roots literally meaning, hard (skleros) skin 
(derma). The spectrum of scleroderma encompasses Raynaud’s phenomenon, localised 
subtypes of skin fibrosis and the clinically important systemic sclerosis which shares the 
three key aspects of inflammatory, vascular and fibrotic pathogenic mechanisms. Although 
the basic principles of classification of scleroderma spectrum diseases remain, the 
traditional boundaries between the different clinical subgroups of the scleroderma spectrum 
are being broadened. It is now appreciated that there is a major distinction between patients 
with skin-based sclerosis, localised forms of SSc and those in whom there is visceral 
involvement, termed systemic sclerosis. The current classification of the scleroderma 
spectrum is shown in Table 1.1. There is a subset of patients with the clinical features of 
isolated Raynaud’s phenomenon with evidence of microvasculopathy based upon nailfold 
capillaroscopy or have serum autoantibodies against nuclear antigens. Several studies have 
demonstrated that these patients with autoimmune Raynaud’s phenomenon have a 10-15% 
likelihood of developing a defined connective tissue disease(Spencer-Green, 1998). It has 
been suggested that the presence of Raynaud’s with scleroderma-related capillaroscopic 
findings and/or SSc specific antibodies against hallmark antigens identifies a group of   25
patients who may later develop features of limited cutaneous systemic sclerosis. Based 
upon the absence of skin changes at presentation, the term ‘limited systemic sclerosis’ has 
been proposed for this group(LeRoy & Medsger, Jr., 2001). In addition, there is a small 
number of patients with vascular symptoms and SSc-specific antibodies who develop major 
organ-based complications in the absence of significant skin sclerosis; these cases are 
designated systemic sclerosis sine scleroderma(Poormoghim et al., 2000). Based on clinical 
characteristics of the disease(LeRoy et al., 1988), systemic sclerosis was subdivided into 
limited and diffuse cutaneous scleroderma (lcSSc and dcSSc respectively). This system is 
now widely accepted and it proposes that the extent of skin involvement defines the disease 
subset in systemic sclerosis. Thus, those with sclerosis of skin proximal to the neck, elbows 
and knees have dcSSc, but those with distal involvement to these areas are designated 
lcSSc.  26
Subsets       Key  Clinical  Features 
 
Raynaud’s Phenomenon 
 
Primary Raynaud’s Phenomenon  Vasospasm predominantly affects the extremities without any features of connective tissue 
disease 
Autoimmune Raynaud’s Phenomenon    Vasospasm of the extremities in the presence of antinuclear antibodies 
 
Systemic forms 
 
Limited Systemic Sclerosis  Absence of clinical skin sclerosis with specific SSc-associated antibodies 
Limited Cutaneous Systemic Sclerosis  Skin sclerosis restricted to extremities, face and neck. Prominent vascular features 
Diffuse Cutaneous Systemic Sclerosis  Extensive skin sclerosis proximal to elbows and knees 
Systemic sclerosis sine scleroderma  Visceral features of SSc (especially gut and lung fibrosis) and Raynaud’s phenomenon. Skin 
sclerosis absent. 
Scleroderma overlap syndromes  Coexistent with features of other autoimmune diseases including SLE, rheumatoid arthritis, 
dermatomyositis or Sjogren’s Syndrome 
 
Localised forms 
 
Localised Morphoea  One or more circumscribed patches of sclerotic skin. Indurated inflammatory margin indicative of 
active progression 
Generalised Morphoea  Multiple areas of indurated sclerotic skin, often on trunk and limbs with similar clinical and 
histological features as above, but more extensive 
Linear Scleroderma  One or more elongated sclerotic areas of skin typically asymmetrical and orientated along the 
affected limb. Commonest form of childhood onset scleroderma and associated with growth 
impairment of affected extremity 
En coup de sabre  Linear sclerotic lesion, usually childhood onset, involved the skin and underlying tissues. Often 
lesions involve the scalp or face. 
 
 
Table 1.1 Classification of the Scleroderma spectrum of disorders   27
1.1.3 Clinical features  
 
1.1.3.1 Skin involvement 
The extent of skin involvement is the single major criterion for the subclassification of SSc 
into its two principal subsets – diffuse (dcSSc) and limited (lcSSc) SSc. This 
subclassification is closely related to the time of onset, pace of development and patterns of 
internal organ involvement and is accordingly strongly linked to survival. 
 
The skin changes appear to evolve in sequential stages: 
1. Early progression with tissue and systemic immune activation and inflammatory changes 
2. Plateau or stabilization with reduced local and systemic resolution, 
3. Late improvement with postinflammatory and post-fibrotic atrophy and remodelling of 
previously fibrosed tissue. 
 
To estimate the degree of skin thickening, modified Rodnan skin scoring (mRSS) system is 
widely used in which 17 body areas are examined by clinical palpation and scored based on 
skin thickness on a 4-point ordinal scale (0=normal thickness, 1=mild thickening, 
2=moderate thickness and 3=severe thickness) as shown in Figure 1.1. There is a strong 
correlation between mRSS skin
 scores and skin biopsy weights and histological extent of 
fibrosis, supporting
 the usefulness of the skin scores in differentiating SSc diseases
 
subtypes(Verrecchia et al., 2007;Furst et al., 1998) (Figure 1.2). Shand et. al. demonstrated 
that most dcSSc patients develops the maximal skin score early(Shand et al., 2007). It is 
recognised that worsening skin scores are associated with a higher risk of renal 
involvement (DeMarco et al., 2002;Steen et al., 1984;Steen & Medsger, Jr., 2001)and death 
and that improving the skin score is associated with better functional capacity and 
survival(Clements et al., 2000). In addition, subclassification of patients with early dcSSc 
according to the longitudinal skin score across time may help to define subsets of patients 
with distinct morbidity and mortality(Shand et al., 2007).   28
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Figure 1.1. Modified Rodnan Skin Score. Semiquantitative estimates by clinical palpation 
of the extent and severity of SSc skin change.  
 
 
 
Figure 1.2 Change in mRSS correlates with change in the histological extent of dermal 
fibrosis, indicating that skin score reflects the underlying pathology of SSc. Dermal fibrosis 
is graded from mild to severe: mild sclerosis indicates less than 25% sclerosis with focal 
dense deep dermal fibrosis, and in severe dermal fibrosis, the reticular dermis is replaced by 
dense compact collagen without normal fascicular bundles or dermal appendages. Low 
power full thickness biopsies taken from dcSSc skin sites with different skin score grades.  
Original magnification x2.5.  H & E stain.  
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1.1.3.2 Vascular involvement 
The pathological changes in the vascular tree range from endothelial activation with 
increased expression of adhesion molecules to capillary necrosis and intimal proliferation 
of arterioles to occlusion of blood vessels. Various circulating soluble markers reflecting 
the endothelial injury are overexpressed and these include inter-cellular adhesion molecule 
1 (ICAM-1), endothelin-1 (ET-1), nitric oxide, Von Willebrand factor and antiendothelial 
cell antibodies(Wigley, 2009). Among these mediators, endothelin represents the most 
potent vasoconstrictor and is additionally considered to be an important mediator in vessel 
remodelling
 ultimately leading to major changes in cellular and tissue architecture in SSc. 
ET-1 was shown to be associated with high levels of soluble ICAM-1 and Von Willebrand 
factor in the blood of SSc patients(Kahaleh, 1991;Kadono et al., 1995;Vancheeswaran et 
al., 1994). Elevated levels of soluble ICAM-1 from serum of diffuse SSc patients were 
shown to correlate with pulmonary fibrosis and overall disease severity(Ihn et al., 1997). 
Raised sera ET-1 levels were demonstrated to be inversely correlated with diffusing 
capacity on lung function(Becvar et al., 2005). In contrast, altered circulating levels of NO 
and production in SSc have been reported(Matucci & Kahaleh, 2002;Dooley et al., 2006). 
The presence of anti-endothelial
 cell antibodies may also contribute to endothelial cell 
injury
 and apoptosis(Bordron et al., 1998). Whilst there is strong evidence of vascular 
pertubation from studies of peripheral blood in SSc, little is known about the ability of 
these biomarkers to
 predict vascular outcomes. Progressive reduction of the size of 
microvascular beds in particular the arteriolar segments of the capillary beds in association 
with reduction of organ blood flow ultimately leads to organ ischaemia. This would 
encompass the clinical manifestations of Raynaud’s phenomenon, digital ulcers and 
telangiectasia.  
 
Such generalised endothelial dysfunction has been shown to
 predict future cardiovascular 
events in many clinical situations via
 the development of macrovascular atherosclerosis
 
over time(Bolad & Delafontaine, 2005), and it has been reported in some studies that 
cardiovascular deaths contribute to 20–30%
 of all premature deaths in SSc(Hesselstrand et 
al., 1998;Bryan et al., 1996;Jacobsen et al., 1998). In these studies, the macrovascular
 cause 
of death was either cardiac, cerebral or limb ischaemia
 in approximately one-third of the   30
cases. Apart from autopsy studies, atherosclerosis was also demonstrated on arteriography 
and non-invasive vascular assessments with carotid duplex scanning and measurement of 
ankle brachial blood pressure index(Belch et al., 1993;Dick et al., 2001). Arterial occlusion 
is common particularly in the ulnar arteries in patients with lcSSc and in association with 
anti-centromere antibodies.  
 
1.1.3.3 Gastrointestinal involvement 
Gastrointestinal involvement is second in frequency to the skin with oesophageal 
dysmotility and its associated complications occurring in 75-90% of patients, small bowel 
involvement in 40-70%, colon involvement in 20-50% and anorectal involvement in 50-
70%. The underlying pathophysiology involves dysmotility of smooth muscles of the tract 
and the earliest defect may lie in the cholinergic nerves which supply the muscle rather than 
a primary muscular defect. Such dysmotility problems are likely to increase with frequency 
and severity with the duration of the disease. Hypomotility in the oesophagus leads to 
delayed transit down the oesophagus and in a reduced lower oesophageal sphincter 
pressures. The repeated bathing of the distal oesophagus by hydrochloric acid may result in 
erosive oesophagitis and stricture. In the small bowel, stagnation of food flow allows 
secondary colonic bacterial to migrate upstream into the small intestine, where the bacteria 
breakdown bile acids necessary to absorb fats. Failure of fat absorption leads to 
malabsorption, weight loss and diarrhoea, and in severe cases, pseudo-obstruction. Large 
bowel involvement encompasses prolonged transit time leading to constipation, hypotonic 
internal and external sphincter of the anorectum with faecal incontinence. 
 
1.1.3.4 Pulmonary Involvement  
The two major features of lung involvement are interstitial lung disease (ILD) and 
pulmonary hypertension (PAH), the latter occurring either as an isolated event or secondary 
to advanced ILD.  
 
SSc is one of the few connective tissue diseases is associated with pulmonary parenchymal 
involvement which contributes directly to about 30% of deaths in SSc. Although 
scleroderma-associated ILD (SSc-ILD) is frequently reported in most autopsy cases,   31
clinically significant SSc-ILD occurs in less than 50% of SSc patients. ILD is characterised 
by early alveolar inflammation evolving slowly or rapidly to pulmonary fibrosis. The major 
symptoms may occur at a relatively late stage and these include dyspnoea, cough with the 
characteristic physical sign of fine inspiratory crepitations over the lung bases.  
 
Chronic inflammatory response to an unknown injury with immunological activation is 
believed to underlie the pathogenesis of SSc-ILD. However, experimental evidence points 
towards that lung inflammation per se is not sufficient to cause pulmonary fibrosis. Mice 
deficient in αvβ6 integrin, a ligand that binds to and activates latent TGFβ, develop 
exaggerated inflammation but are protected from fibrosis after bleomycin 
treatment(Munger et al., 1999). In a recent study, transgenic mice developed exaggerated 
pulmonary fibrosis after bleomycin treatment, independently of neutrophilic 
inflammation(Hoyles et al., 2008). Other pathogenic mechanisms have therefore been 
postulated. For example, activation of coagulation pathway as a consequence of endothelial 
cellular injury generates thrombin release that in turn induces myofibroblast differentiation, 
activates endothelial cells and releases profibrotic factors, including TGFβ. Apart from 
endothelial involvement, epithelial cell injury, like in renal fibrosis, may also increase 
myofibroblast numbers via epithelial mesenchymal transition (EMT)(Willis et al., 2006), 
promoted by TGFβ and ET-1 expression(Jain et al., 2007). Focal pulmonary inflammation 
may play a role in stimulating chemokine-mediated fibrocyte chemotaxis. Experimental 
evidence reveals that in response to chemokines including CXCL12, circulating fibrocytes, 
which are circulating progenitors of fibroblasts implicated in wound healing and fibrosis, 
may traffic to the lungs in a murine model of bleomycin-induced lung fibrosis. In this 
model, treatment with neutralising anti-CXCL12 antibodies abrogated intrapulmonary 
fibrocyte recruitment and attenuated lung fibrosis(Phillips et al., 2004). These findings 
were replicated in a recent paper in humans with idiopathic lung fibrosis. Andersson-
Sjoland et al. reported that CXCL12 were expressed by alveolar epithelial cells and 
increased numbers of fibrocytes were stained with combination of CXCL12 and 
mesenchymal markers (procollagen-I and prolyl-4-hydroxylase) compared with 
combinations using CD34 or CD45RO with mesenchymal markers(Andersson-Sjoland et 
al., 2008).   32
 
Similar to the changes observed in the skin of SSc, other pathogenic mechanisms including 
interaction between inflammatory infiltrate and fibroblasts driven by cytokines and 
chemokines may regulate the fibrotic response. Inflammatory cells including neutrophils, 
eosinophils, macrophages, and lymphocytes are present in the bronchoalveolar lavage 
(BAL) fluid of SSc-ILD patients(Bolster et al., 1997). Fibroblasts explanted from SSc-ILD 
lungs are phenotypically different from control lung fibroblasts and similar to the dermal 
SSc fibroblasts in that they demonstrate a degree of heterogeneity(Varga & Abraham, 
2007). Serum levels of collagen metabolites including N-terminal propeptide of type III 
procollagen levels, cross-linked carboxyterminal telopeptide of collagen I are associated 
with ILD. Other potential lung specific markers for ILD include KL-6, a glycoprotein 
expressed by alveolar type II epithelial cells and the surfactant proteins A and D which are 
also secreted by Clara cells.  
 
Despite the multiplicity of mechanisms described above, no major therapeutic advances 
have been achieved in SSc-ILD in recent years. Compared to idiopathic lung fibrosis, SSc-
ILD deteriorates insidiously and even when low-grade inflammation drives disease 
progression, lung involvement is predominantly fibrotic. This is also mirrored in the 
infrequent histological changes with predominantly inflammatory abnormalities at lung 
biopsy, being present in less than 20% of cases. Therefore, prevention of disease 
progression appears to be the most realistic therapeutic goal with immunological 
modulation. This is emphasised in the outcome of two major prospective, randomised, 
placebo-controlled trials on the use of cyclophosphamide in SSc-ILD(Hoyles et al., 
2006;Tashkin et al., 2006). Although the results suggests that there was a treatment effect 
on forced vital capacity (FVC), this effect was lost a year following completion of 
treatment. In addition, the treatment effect was due to a selective decline in FVC in the 
placebo group in patients with more extensive disease on HRCT in which, paradoxically, 
inflammation is a minor histological component. 
 
Unlike SSc-ILD whereby stability of extensive disease is deemed as therapeutic success, 
there have been significant advances in the management of PAH. PAH is defined as a mean   33
pulmonary arterial pressure (PAP) above 25 mmHg at rest or above 30 mmHg during 
exercise, with normal pulmonary artery wedge pressure. Recent studies using right heart 
catheterisation to confirm the diagnosis suggest that the prevalence of PAH in SSc is 
estimated to be 10-15% with a five-year cumulative survival of 10% compared with 80% in 
those without PAH(Mukerjee et al., 2003). Indolent exertional dyspnoea is the major 
symptom, with disease progression characterised by impaired exercise tolerance and 
fatigue. Whilst the aetiology of PAH in SSc is likely to be complex and the nature of the 
initial lesion is unclear, a plausible sequence of events would involve a predisposed 
individual, including genetic predispositions as a result of interaction of both protective and 
predisposing alleles at several loci. In recent years, genetic studies have significantly 
increased
 the understanding of the molecular basis of PAH with identification of mutations 
in the bone morphogenetic protein receptor-2 (BMPR2) encoding a TGF-β receptor, in 
about 60% of cases of familial PAH and 25% of sporadic PAH(Lane et al., 2000;Newman 
et al., 2001). However, most individuals who have PAH do not have an identifiable 
mutation. So far, these heterozygous germline mutations in BMPR2 have not been 
described in SSc-APH. Morse et al and Tew et al did not detect BMPR2 mutations in a 
cohort of SSc patients although the small size of the patient groups is a potential limitation 
of these studies(Morse et al., 2002;Tew et al., 2002). Nonetheless, there is a growing 
evidence to support potentially systemic alterations in TGFβ family ligand-receptor axis 
and the widespread vasculopathy with SSc. Vasoconstriction, vascular remodelling and 
thrombosis are hallmark pathogenic processes in PAH(Humbert et al., 2004). Endothelial 
cells activation markers including thrombomodulin and endothelin-1 may reflect 
endothelial dysfunction have been described in SSc-PAH suggesting that early endothelial 
pathology may be important(Stratton et al., 2000;Stratton et al., 1998). Histologically, the 
end-stage lesion of SSc-PAH is microvascular luminal obliteration/attenuation with medial 
and adventitial fibrosis and proliferative lesions and intimal hyperplasia. It is noteworthy 
that some of these characteristic changes are also observed in the vascular changes in 
digital arteries and hypertensive renal crisis consistent with generalised endothelial cell 
activation and damage in SSc. The existing therapeutic options for PAH address these 
different pathobiological pathways underlying this condition. The currently licensed   34
therapeutic agents include prostanoids, ET-1 receptor antagonists and phosphodiesterase 
type 5 inhibitors. 
 
1.1.3.5 Renal Involvement  
Scleroderma renal crisis represents an important link between the fibrotic aspect of SSc and 
vascular injury. Despite the introduction of ACE inhibitors that led to an impressive 
improvement in survival from 10% at one year to 65% at five years, mortality as high as 
30% at 3 years has been reported in particular in those requiring permanent dialysis. Apart 
from the accelerated phase hypertension and progressive renal impairment, the presence of 
hypertensive retinopathy and encephalopathy indicates systemic extrarenal endothelial 
dysfunction. Recent data also demonstrated upregulation of endothelin-1 and endothelin B 
receptors in renal tissues in addition to a recently described association between endothelin 
B receptor polymorphism and renal crisis suggesting a role of this signalling system in the 
pathogenesis of renal crisis(Kobayashi et al., 1999;Fonseca et al., 2006). Renal biopsy 
characteristically shows changes in the small interlobular and arcuate arteries. The earliest 
change is intimal oedema followed by intense proliferation of intimal cells and the 
production of mucinous ground substance composed of glycoprotein and 
mucopolysaccharide. Notably, vascular changes of mucoid intimal thickening and 
thrombosis are associated with poor outcome with half of those with these changes require 
permanent dialysis compared with 13% of those without. 
 
1.1.3.6 Cardiac Involvement 
SSc heart involvement may be either primary or secondary to lung/renal involvement. The 
pathological hallmark is myocardial fibrosis which affects both ventricles in a patchy 
distribution in the absence of any significant coronary artery disease. This may occur as a 
consequence of recurrent ischaemia, coexisting myositis or chronic inflammation leading to 
fibrosis. Clinically, this is manifested as diastolic dysfunction. Dysrhythmias and 
conduction disturbances are considered a hallmark for cardiac involvement, reflecting the 
underlying autonomic dysfunction. Cardiac involvement remains among the top predictors 
of mortality in SSc(Wynn et al., 1985;Steen & Medsger, Jr., 2000). Recent data from the 
Canadian registry suggested that any left heart involvement was associated with an   35
increased risk of death with cardiac involvement in 67% of those deceased compared with 
only 17% in those living(Al-Dhaher et al., 2008).  
 
1.1.4 Current Concepts of Scleroderma Pathogenesis 
Although the exact mechanisms involved in the pathogenesis of SSc remain unclear, there 
are three key features responsible for the major clinical and pathological manifestations of 
the disease (Figure 1.3): 
 
1. Functional and structural vasculopathy with endothelial dysfunction, intimal  
proliferation and vascular obliteration as an early feature of the disease, 
2. Humoral and cellular immunity dysregulation with inflammatory changes. This involves 
T-cell activation, autoantibody production and perivascular mononuclear infiltrate in the 
inflamed skin.  
3. Fibrotic phase with increased synthesis and deposition of matrix proteins form the 
ultimate basis for tissue and organ dysfunction. 
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Figure 1.3 Clinical and pathological correlates in Systemic Sclerosis   36
 
 
1.1.4.1 Genetics and Environment 
There is growing evidence for genetic contribution in the pathogenesis of SSc. Family 
history and ethnicity are two major factors in determining the genetic effects involved in 
SSc. Compared to an estimated population risk of 0.026%, SSc appears to occur in 1.6% of 
families of SSc cases in three separate cohorts(Arnett et al., 2001). The familial relative 
risk was approximately 15-fold higher for siblings and 13-fold higher for first-degree 
relatives. Further studies on multicase SSc families and monozygotic twins describe 
concordant SSc-specific autoantibodies(Cepeda & Reveille, 2004) associated with a high 
frequency of other autoimmune diseases such as primary biliary disease and Sjogren’s 
Syndrome(Bennett, 1990).  There are also differences in prevalence and clinical features 
among different ethnic groups of the greater relative of dcSSc in the African and American 
Indians populations (Tager & Tikly, 1999)and also among the Chowtaw Indians(Kuwana et 
al., 1999).The genetic contribution in in vitro fibroblast activation was demonstrated in 
gene expression microarray profiles of cultured fibroblasts from SSc twin subjects. 
Candidate gene association studies have identified several key genes in SSc: growth factors 
(endothelin), ECM components (TGFβ1, connective tissue growth factor [CTGF], secreted 
protein, acidic and rich in cysteine [SPARC]), allograft inflammatory factor-1, protein 
tyrosine phosphatase non-receptor 22, cytokines (macrophage migration inhibitory factor, 
tumour necrosis factor-alpha [TNFα], IL-1α and IL-1β) and chemokines (MCP-1/CCL2, 
RANTES/CCL5, MIP-1α/CCL3, IL-8/CXCL8)(Agarwal et al., 2008).  
 
Stratification of patients based on autoantibody profiles reveals strong associations with 
HLA polymorphisms (Table 1.2). For example, an association of HLA DRB1*1302, 
DQB1*0604/0605 haplotypes were found with anti-U3RNP positive patients, who are more 
often male African Americans, and the HLA DRB1*0301 haplotype has been shown to be 
associated with anti-PM-Scl antibody positivity in patients who are nearly exclusively 
white. However, many of these results have not been corroborated by replication studies 
with larger and well-characterised cohort of patients. For example, the association of HLA 
DQB1*0201 in patients with anti-RNA polymerase I, II and/or III antibodies has not been   37
observed in other studies(Fanning et al., 1998). In addition, it is likely that the multitude of 
biological signalling pathways involved in SSc suggests a complex regulatory network of 
genes in the development of the disease. In contrast to candidate-gene approach, genome-
wide approaches used in studies of complex diseases such as systemic lupus erythematosus 
(SLE) and rheumatoid arthritis will allow simultaneous identification of novel genes in this 
disease. Taken together, it would appear that genetic factors might provide a permissive 
environment that allows either the initiation of the disease process or its progression and 
development of distinct clinical manifestations. 
 
In addition, another possible mechanism that may explain the increased prevalence of SSc 
in females compared to males is the microchimerism hypothesis that postulates activation 
of engrafted fetal cells may lead to a graft-vs-host reaction towards the mother or foetus 
(Jimenez & Artlett, 2005). Although the pathological effect of such cells is unknown, 
microchimeric cells were found in the cellular infiltrate of sclerodermatous lesions(Sawaya 
et al., 2004). Circulating levels of CD4+ and CD8+ T cells were also found significantly 
higher in SSc patients than in controls. This is akin to the microchimeric CD4+ and CD8+ 
T cells detected in the lung tissues from patients with hypersensitivity pneumonitis(Bustos 
et al., 2007). Furthermore, patients with diffuse SSc have significantly more CD4+ 
microchimeric T cells than controls(Randone et al., 2008). In those with circulating 
microchimeric T cells, the endothelium represents an allotypic stimulus to those cells and 
this may mimic the same pathway transplanted T cells follow in graft-versus-host disease.  
 
A variety of chemical and environmental agents have been associated with SSc and SSc-
like conditions for nearly a century. The earliest description was the manifestation of 
scleroderma in five stonemasons exposed to silica and scleroderma-like cutaneous 
manifestations described in association with vinyl chloride and organic solvent exposure in 
the 1950s(Nietert & Silver, 2000). Exposure to silica dust (silicon dioxide SiO2) among 
coal and gold miners and related occupations confers a high risk of development of SSc, 
and it has been estimated that the incidence of scleroderma is increased at 81.8 per million 
in silica exposed black South African gold miners compared to 3.4 per million in the 
general black South African population(Cowie, 1987). Another study has estimated the   38
relative risk of developing scleroderma following silica exposure is 25 and may be up to 39 
times higher in patients with radiologically documented silicosis(Haustein et al., 1990). 
Serologically, antibodies to DNA topoisomerase I (anti-Scl 70) are found in the majority of 
silica associated scleroderma patients(McHugh et al., 1994). The list of chemicals and 
environmental agents continue to grow considerably and more recently, a rapidly 
progressive form of fibrosing disease, nephrogenic systemic fibrosis (NSF) has been 
described in individuals with renal impairment, usually in those requiring dialysis(Cowper 
et al., 2007). Free, unchelated gadolinium is highly toxic and it is detected in the affected 
skin of patients with NSF, in some cases for months following its administration(High et 
al., 2007). Importantly, despite the link with renal disease, the fibrosing process may be 
evident within muscles, myocardium, lungs and testes(Ting et al., 2003). Interestingly, 
apart from the striking fibrogenic response with appearances similar to those observed in 
scleromyxedema, abnormal vasculopathy is observed with increased thickness of the 
adventitial layer of small and medium-sized arterioles(Mendoza et al., 2006). Presence of 
dermal CD34+ staining fibroblast-like epitheliod or stellate cells suggests that these cells 
may be circulating fibrocytes and may result from active chemotaxis from the bone 
marrow. Indirect evidence to support this is the association of erythropoietin use in these 
patients, which has the ability to mobilise haematopoietic progenitors including 
mesenchymal precursors from the bone marrow, but its role in the pathogenesis of NSF is 
unclear(Swaminathan et al., 2006).  
 
There is some evidence from animal models of fibrosis to implicate infectious agents in the 
development and progression of the pathological features of SSc. Whilst the infection rates 
compared to control populations do not differ significantly, increased antibody titres, a 
preponderance of specific strains in SSc and indirect evidence of molecular mimicry 
inducing autoimmune responses suggest that infections present as potential environmental 
triggers for SSc. Herpesviruses, in particular cytomegalovirus (CMV) has been 
demonstrated to induce neointimal lesions in the vascular wall, a feature shared by SSc in 
immunosuppressed mice although the experimental lesions were only apparent in the large 
vessels compared to predominant microvascular abnormalities in SSc(Hamamdzic et al., 
2001). Recently, infection with gammaherpesvirus in contrast to adenovirus, may   39
exacerbate pre-existing lung fibrosis in a model of fluorescein isothiocyanate–induced
 
pulmonary fibrosis in mice. This is due in part to upregulation
 of chemokines (MCP-1 and 
CCL12, a murine chemokine with homology to human MCP-1), leading to a profibrotic 
environment
 with increased fibrocyte recruitment and collagen deposition(McMillan et al., 
2008).  Other viruses that have been investigated in the context of SSc pathogenecity 
include parvovirus B19 and Hepatitis G(Seemayer et al., 2001;Ferri et al., 2005). While it 
is clear that infections alone do not exclusively lead to development of SSc, it is likely that 
the interaction between host factors and infections determine the susceptibility to disease in 
response to these triggers. 
  
 
Antibody  HLA  Ethnic  group 
DRB1*1104 
DPB1*1104 
White 
DQB1*0301 
DPB1*1301 
African Americans 
DRB1*1502 
DQB1*0601 
DPB1*0901 
Japanese 
ATA 
DRB1*1602 
DQB1*0301 
DPB1*1301 
Choctaw 
ACA DQB1*0501 
U3-RNP DRB1*1302 
DQB1*0604/0605 
PM-Scl DRB1*0301 
 
 
Table 1.2 Genetic associations based on autoantibody subsets in SSc. ATA: Anti-
topoisomerase I antibody, ACA: Anti-centromere antibody.   40
1.1.4.2 Vasculopathy  
Vascular disease is an early and possibly primary disease component in SSc(Kahaleh et al., 
1979). Studies with nailfold capillaroscopy in patients and histopathological analysis of 
vessels within lesional tissue indicate that vascular damage occurs before fibrosis. For 
example, Raynaud’s disease precedes the other disease manifestations as a result of 
dysregulation in blood vessel constriction and dilatation (vasomotor regulation), arising 
from altered production of, and responsiveness to, key vasodilatory (nitric oxide) and 
vasoconstrictive (endothelins) factors. Other important clinical manifestations of vascular 
abnormality include digital ulcers, pulmonary hypertension, gastrointestinal vascular 
ectasia, cutaneous telangiectasia and renal crisis. Triggered by inflammatory cytokines, 
endothelial cell–specific autoantibodies, vasculotropic viruses, or reactive oxygen radicals 
generated during ischaemia/reperfusion, endothelial injury results in increased microvessel 
permeability, enhanced trans-endothelial leucocyte migration and activation of coagulation 
and fibrinolytic cascades(Cerinic et al., 2003). Vascular endothelial injury predominantly 
affects the microcirculation and arterioles with most marked changes occurring over the 
arteriolar segments of capillary beds and these morphological changes are therefore easily 
demonstrated on nailfold capillaroscopy.   
 
These events lead to vascular remodelling, with hypertrophy of the intimal and medial 
layers and adventitial fibrosis resulting in progressive luminal narrowing and 
obliteration(Kahaleh, 2008). Studies in the University of California Davis (UCD)-200 
chickens model for SSc, have also highlighted the role of endothelial dysfunction as an 
early acute disease feature. The microvascular alterations include impaired vessel response 
to vasodilators, and circulating anti-endothelial cell antibodies provoke endothelial cell 
injury, a primary event in the vascular pathogenesis of SSc(Sgonc et al., 1996). However, 
the avian model does not recapitulate capillary rarefaction. 
 
Combined with endothelial cell apoptosis, the process progresses over time to culminate in 
a striking absence of blood vessels in lesional skin biopsies and on angiograms of patients 
with late stage disease. Loss of microvasculature is associated with tissue hypoxia, which 
normally induces strong expression of vascular endothelial growth factor (VEGF) and its   41
receptors(Mackiewicz et al., 2002). In addition to pro-angiogenic factors, there is a 
paradoxical switch to anti-angiogenic drive in the face of tissue hypoxia resulting in 
progressive disappearance of blood vessels. To support this, SSc patients with more 
advanced disease have fewer circulating bone marrow-derived CD34+ endothelial 
progenitor cells when compared with patients with less advanced disease, as well as 
impaired differentiation into mature endothelial cells(Del et al., 2006;Cipriani et al., 2007). 
These studies suggest that abnormalities in the bone marrow mononuclear cell 
responsiveness and function may contribute to some of the dysregulated angiogenesis and 
tissue repair in SSc.   
 
1.1.4.3 Immunological Dysregulation  
The presence of specific autoantibodies is one of the most common manifestations of SSc 
and autoantibody production as a result of activation of the humoral immune system is 
associated with different clinical manifestations of the disease (Table 1.3). However, it is 
not generally accepted that these antibodies are not directly involved in the clinical 
manifestations of the disease and their titres do not correlate with disease activity or clinical 
severity. The presence of prominent inflammatory mononuclear infiltrate in the skin and 
lungs of active SSc is well recognized with macrophages and CD14+ T cells in these early 
infiltrate(Kraling et al., 1995;Prescott et al., 1992). In the later stages of the disease, T cells 
predominate with CD4 cells expressing the activation marker Class II MHC antigen 
DR(Chizzolini, 2008). The expanded T cell populations in affected SSc tissues may release 
cytokines and chemokines, which initiate and perpetuate the fibrotic process as well as the 
endothelial and vascular alterations. These stimulated T cells produce more TNFα, IL-1 and 
IL-2 than healthy controls and the serum concentrations of IL-2, IL-4, IL-6 and IL-8 and 
soluble IL-2 receptors are elevated(Chizzolini, 2008;Sakkas et al., 2006;Bruns et al., 
1994;Sato et al., 2001). However, this finding is not replicated in a recent study which did 
not demonstrate a strong signature from CD3+ T cells or other CD20+ B cells on 
immunohistochemical analysis of SSc biopsy specimens(Gardner et al., 2006). SSc patients 
also demonstrate intrinsic B cell abnormalities. Analysis of gene expression using DNA 
microarrays has revealed upregulation of genes related to B cells in SSc lesional 
skin(Whitfield et al., 2003). In addition, peripheral B cell homeostasis and subsets are   42
altered with expansion of naïve B cells and diminished memory B cells which are 
chronically activated in vivo, possibly due to CD19 overexpression(Sato et al., 2004). The 
latter is a key cell-surface signal transduction molecule of B cells and transgenic mice that 
overexpress this positive regulator lose tolerance and generate autoantibodies 
spontaneously(Tedder et al., 1997). Similarly, B cells from a tight-skin mouse show 
augmented CD19 signalling and chronic B cell activation, CD19 loss results in elimination 
of autoantibody production which is associated with improvement in skin fibrosis(Saito et 
al., 2002) and a parallel decrease in IL-6 production by B cells. This would suggest that 
augmented cytokine production by B cells might be important in induction of skin 
sclerosis.  
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Antibody Usual  subset
a  Predominant clinical features 
Anti-centromere (ACA)  Limited  Pulmonary arterial hypertension (PAH), small 
and large bowel involvement late in disease 
Anti-Th/To Limited  Early interstitial lung disease (ILD), PAH, 
Small bowel disease 
Anti-topoisomerase I (Scl 
70)  Diffuse  Early ILD, diffuse skin involvement 
Anti-RNA polymerase III  Diffuse  Severe cutaneous disease, renal crisis 
Anti-U3-RNP Diffuse  Myositis, cardiac disease, PAH, small bowel 
involvement, peripheral neuropathy 
Anti-PM-Scl Limited  Myositis, cardiac disease, renal crisis, ILD 
Anti-mitochondrial Limited  Associated with primary biliary cirrhosis 
Anti-Ku Limited  Myositis, arthritis with lack of vascular 
features 
Anti-nRNP Limited  Overlap myositis and lupus 
Anti-U1-RNP Limited  Myositis, cardiac disease, renal crisis, ILD 
 
Table 1.3 Hallmark autoantibodies in SSc and their clinical associations.  
aAny antibody may occur in either subset but clinical associations persist (Madani et al., 
2008).   44
 
1.1.4.4 Fibrosis 
Fibrosis is the pathological hallmark in SSc. Critical for wound repair, and integrity of 
connective tissue matrix, fibroblasts are mesenchymally derived spindle-shaped cells that 
synthesise the major interstitial fibrillar collagens that provide structure to organs and 
tissues of the body(Chang et al., 2002). Uncontrolled production of collagens and other 
ECM components by fibroblasts in the skin, lungs and other organs leads to excess 
connective tissue accumulation. A unique feature of fibroblasts explanted from lesional SSc 
tissues is the retention of an abnormal phenotype, characterised by enhanced ECM 
synthesis and the expression of the myofibroblast marker, α-smooth muscle actin (α-SMA). 
Myofibroblasts are highly contractile and are essential for tissue contraction which 
precedes tissue atrophy and organ failure and α-SMA plays a major role in effecting these 
contractile properties. Myofibroblasts are also a major, yet transient cell population within 
the granulation tissue during normal tissue repair in wound healing(Tomasek et al., 2002). 
 
Recently, it has been recognised that not all fibroblasts are the same and that 
myofibroblasts in SSc might arise from multiple cellular compartments, all contributing to 
fibrogenesis. This heterogeneity appears to be even more profound within inflamed tissues 
and during wound repair and fibrogenesis(Postlethwaite et al., 2004). 
As demonstrated in Figure 1.4, interplay among the three pathological processes initiates 
and sustains progressive tissue damage in SSc. The increased production of ECM which 
underlies the fibrotic response in SSc also serves as the major reservoir for secreted growth 
factors including TGFβ and CTGF which together with the connective tissue compartment 
provide the cues that control differentiation, proliferation, function and survival of resident 
cells.   45
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Figure 1.4 The pathogenic triad of SSc. The pathogenesis of SSc involves autoimmunity, 
vasculopathy and fibrosis. Both autoimmunity and vascular damage precede the onset and 
contribute to the fibrogenesis. Vascular injury and fibrosis enhance and maintain the 
chronic autoimmunity and inflammation (Varga & Trojanowska, 2008).   46
 
1.1.5 Animal models in Scleroderma 
 
Animal models have been developed to study the evolution of different pathological 
responses in SSc but none of them exhibit all of the cardinal manifestations of the disease 
However, these models do offer valuable research opportunities for the elucidation of key 
cells, mediators and signalling pathways that are relevant in human SSc. Additionally, they 
provide important preclinical models for the testing of hypotheses as well as potential 
therapies. These can be classified into naturally occurring models, immunologically 
mediated and genetically determined mutant strains (Table 1.4). 
 
1.1.5.1 Naturally-occurring models 
The tight skin mouse phenotype occurs as a result of reduplication of a central portion of 
the fibrillin-1 (Fbn1) gene (exons 17-40)(Bona et al., 1997). Biochemical characterisation 
confirmed many of the key pathological features of SSc including extracellular matrix gene 
overproduction with excessive accumulation of collagen in the skin, lung and heart (Green 
et al., 1976). In addition, these mice display humoral immune alterations with presence of 
autoantibodies against topoisomerase I and centromeres in the plasma. There are now 
increasing evidence to suggest that fibrillin-1 has a key role in regulating TGFβ activation. 
Fibrillin-1 is a member of a family of matrix-binding proteins that sequester the large latent 
TGFβ complexes. Fibrillin-1 deficiency causes excessive amounts of active TGFβ to be 
liberated from the matrix. The precise mechanisms by which fibrillin-1 controls TGFβ 
activation remains unclear but it has been shown that fibrillin-1 interacts with the latent 
TGFβ binding proteins in a tissue specific fashion(Isogai et al., 2003). 
 
The Tsk2/+ is a mutant that appeared in the offspring of a 101/H mouse after the 
administration of the mutagenic agent ethylnitrosourea (Christner et al., 1995). The Tsk2 
mutation is also inherited as an autosomal dominant trait and the mutation has been mapped 
on chromosome 1. While homozygous (Tsk2/Tsk2) mice have not been reported and are 
believed to die in utero, heterozygous animals (Tsk2/+) develop skin fibrosis that is 
apparent as tightness of the skin in the interscapular region at 2-3 weeks of age. Cultured   47
dermal fibroblasts from Tsk2/+ mice have an elevated steady state level of α1(I) and 
α1(III) procollagen mRNA. Transcription factors Sp1 and nuclear factor 1 (NF-1) or their 
homologs have been implicated in the upregulation of transcriptional activity of the Col1a1 
promoter in Tsk2/+ fibroblasts. More recently, it has been demonstrated that Tsk2/+ dermal 
fibrosis is associated with an elevation of collagen transgene expression at the cellular level 
as well as an increase in the total number of cells actively expressing the transgene, these 
findings are consistent with elevated Col1a1 transcription(Barisic-Dujmovic et al., 2008). 
While the molecular defect in the Tsk mutation is known, the genetic locus that is 
dysfunctional in the Tsk2/+ and the molecular basis of the genetic defect are unknown.  
 
The UCD-200 chicken develops vascular occlusion, severe perivascular lymphocytic 
infiltration of the skin and viscera, fibrosis of the skin and internal organs, anti-nuclear 
antibodies, anti-cardiolipin antibodies, rheumatoid factor and polyarthritis (Gruschwitz et 
al., 1991;van de & Gershwin, 1985). Immuno-histochemical analysis of UCD 200 chicken 
skin sections show that the apoptosis of endothelial cells is an early event in pathogenesis 
preceding the mononuclear perivascular infiltration and collagen deposition (Nguyen et al., 
2000). More recent observations suggest endothelial induced apoptosis in this model is 
mediated by anti-endothelial cell antibodies (Worda et al., 2003). This supports the 
hypothesis that auto-antibodies to intra-cellular proteins and endothelial cell apoptosis are 
primary events in the disease process. Apoptotic endothelial cells from fibrotic human skin 
have been detected in the early inflammatory disease stages of SSc (Sgonc et al., 2000). 
The UCD 200 appears to be good model for the early vascular aspects of the SSc disease 
process and supports the theory of vascular damage being an early event in disease 
progression. 
 
1.1.5.2 Induced animal models 
Bleomycin-induced pulmonary and dermal fibrosis have been established as an 
experimental model for SSc. Inflammatory changes and fibrosis are noted to occur by first 
week with altered activation of Smad signalling, possibly via TGFβ even after the 
inflammation has resolved. In the latter model of dermal fibrosis, overexpression of MCP-1 
and CCR2 were demonstrated in mononuclear cells at early inflammatory stages and in   48
fibroblasts at the later sclerotic stage in the skin(Yamamoto & Nishioka, 2003). The same 
group of investigators also suggested that altered apoptosis signals involving differential 
temporal expression of Fas/FasL system and Caspase-3 activation to be important in the 
pathogenesis of bleomycin induced SSc. Induction of dermal sclerosis was demonstrated 
with repeated subcutaneous injections of bleomycin at week 4.This was supported on 
histopathological and biochemical analysis and it was noted that the sclerosis varied in its 
intensity among the various murine strains (Yamamoto & Nishioka, 2005). In this model, 
immunohistological analysis showed that TGFβ was detected on the infiltrating cells, 
which were predominantly composed of macrophages as well as fibroblasts at sclerotic 
stages. TGFβ1 and TGFβ2 mRNA were also detected on the lesional skin. Rat lung 
fibroblast cultures treated with bleomycin results in elevated TGFβ and it was shown that 
TGFβ mediates the fibrotic effect of bleomycin at the transcriptional level and that the 
TGFβ response element is required for bleomycin stimulation of the proα1(I) collagen 
promoter. However, the skin sclerosis observed in this model is transient in response to the 
subcutaneous injections and occurs only in animals with a susceptible genetic background, 
and the effect diminishes once the injurious stimulus is removed. It has also been recently 
reported, using the bleomycin-induced lung fibrosis, that chemokine, CXCL12 helped to 
recruit and localised fibrocytes to the injured lungs. In addition, the administration of anti-
CXCL12 antibody reduced the accumulation of lung fibrocytes and collagen(Phillips et al., 
2004). These fibrocytes have also been identified in SSc skin biopsies and it is probable 
that similar mechanisms may operate in driving recruitment of fibrocytes to the affected 
skin (Aiba et al., 1994). 
 
In the chronic graft vs. host disease (GVHD), which occurs across minor histocompatibility 
barriers, severe cutaneous fibrosis is observed with loss of dermal fat, atrophy of dermal 
appendages, mast cell depletion and mononuclear cell infiltration (Claman et al., 
1985;Jaffee & Claman, 1983) and it has been suggested that SSc may be a form of chronic 
GVHD. Mice that harboured microchimeric cells from previous pregnancies when injected 
with vinyl chloride, showed remarkable histopathological changes with cutaneous 
inflammatory changes and fibrosis(Christner et al., 2000;Atamas et al., 2003). Murine Scl-
GVHD model was produced by transplanting B10.D2 bone marrow and spleen cells into   49
BALB/c mice after lethal gamma irradiation of recipients (McCormick et al., 1999). In this 
model, skin fibrosis is preceded by mononuclear cell infiltration and elevation of TGFβ and 
chemokines including MCP-1, CCL3 and CCL5(Zhang et al., 2002). Scl-GVHD mice 
exhibited profound cutaneous thickening and pulmonary fibrosis by 21 days after bone 
marrow transplantation. However, the severity of the phenotype is variable and is generally 
self-limiting. In contrast, a modified model of GVHD SSc with transfer of donor spleen 
cells from wild-type B10.D2 mice into RAG2-deficient mice demonstrates the key aspects 
of the human disease(Ruzek et al., 2004). The results were similar to a graft-versus-host 
model using irradiated mice with skin and lung fibrosis. Renal, gastrointestinal and hepatic 
fibrosis was also demonstrated. Overexpression of both type VII and type III collagens in 
the skin and type III collagen in the kidneys was also observed. Vasoconstriction of dermal 
and renal blood vessels with overexpression of ET-1 was also reported. This was associated 
with altered immune response with ANA and Scl-70 antibodies detected in a majority of 
the mice. 
 
1.1.5.3 Genetically engineered mice 
The advent of transgenic and knockout technologies has enabled the engineering of novel 
murine strains. These approaches are increasingly used in SSc research to address the 
pathogenetic roles of candidate molecules and pathways. Transgenic mice represent 
genetically modified mice in which the DNA has been altered using genetic engineering 
techniques. Using recombinant DNA technology, DNA molecules from a foreign source 
are combined into one molecule to create a new set of an expression casette which 
represents a DNA construct from which expression of one or more exogenous genes is 
driven. This DNA is then microinjected into fertilised oocytes or embryonic stem cells and 
transferred into foster mothers generating modified or novel genes. The progeny are then 
backcrossed with wildtype mice to establish lines, or intercrossed to provide transgenic 
strains with greater transgene dose that can be maintained on double copy or homozygous 
strains.  
 
Another useful approach in using the concept of transgenesis is to introduce reporter 
transgenes such as bacterial β-galactosidase (LacZ) or firefly luciferase (Luc) into   50
established murine models. This may be achieved by backcrossing reporter transgenic 
strains with the established mutant model strains. Similar results can be obtained with 
transient transfection methodology in which the reporter transgene is transduced directly 
into cultured wildtype cells. The reporter transgene serves as a marker for another gene of 
particular interest and an ideal reporter gene is one that is not endogenously expressed in 
the cell of interest. Thus, reporter genes that are incorporated within the transgene construct 
are generally used to determine whether the transgene of interest has been taken up by or 
expressed in the cell population and they are frequently used as indicators of transcriptional 
activity in cells. Typically, a reporter gene is joined to a promoter sequence in an 
expression vector that is transferred into cells. Following transfer, the cells are assayed for 
the presence of the reporter by directly measuring the enzymatic activity of the reporter 
protein. Reporter vectors also allow functional identification and characterisation of 
promoter and enhancer elements because expression of the reporter gene correlates with 
transcriptional activity of the promoter driving the reporter gene. The promoter-reporter 
gene fusion is introduced into cultured cells by standard transfection methods or into a 
germ cell to produce transgenic organisms. 
 
The selective expression of transgenes to specific cell or tissue types arise from 
experiments aimed at identifying promoter/enhancer elements responsible for the restricted 
expression and one of the early studies by Storb et al. reported that an immunoglobulin 
kappa chain gene may be expressed exclusively in B cells(Storb et al., 1984). The use of 
transgenic mice has recently also led to substantial progress toward understanding collagen 
gene regulation. Expression patterns of reporter transgenes controlled by different promoter 
constructs from mouse collagen genes suggests a modular arrangement of regulatory 
elements, with certain critical sequences directing expression of collagen genes to specific 
mesenchymal cell types at the appropriate time in embryonic development(Rossert et al., 
1995). Reporter transgenes regulated by such cis-acting sequences therefore function as 
differentiation markers for mesenchymal cell lineages. Similar studies have identified a 
fibroblast-specific transcriptional enhancer located in the far-upstream region of the murine 
pro 2(I) collagen (Col1a2) gene(Bou-Gharios et al., 1996). A 6-kb sequence (-19.5 kb to -
13.5 kb upstream of the transcription start site) was shown to endow high-level fibroblast-  51
specific expression to reporter genes linked to endogenous and heterologous minimal 
promoters in transgenic mouse embryos(De et al., 2002). These embryonically defined 
lineage-specific cis-acting enhancer elements are therefore useful for directing expression 
of a gene of interest to a specific cell-type such as fibroblasts. This novel concept is 
explored further with the transgenic TβRIIΔk murine strain in this thesis and will be 
discussed in subsequent chapters. 
 
Several transgenic murine models for SSc have been described. The identification of the 
intragenic duplication of the Fbn-1 gene in the Tsk1/+ mice led to the development of a 
transgenic mouse expressing a mutated Fbn-1 transcript(Saito et al., 2000). In this study, 
the DNA fragment containing the mutant Fbn-1 gene was injected into ova obtained from 
fertilised C57BL/6 mice of which several founders were obtained and crossed with 
C57BL/6J mice to establish the transgenic lines. These transgenic mice develop 
autoantibodies including anti-topoisomerase and anti-Fbn1 antibodies as well as cutaneous 
hyperplasia. Compared to the Tsk mice, these transgenic mice do not develop lung 
emphysema or cardiac hypertrophy, suggesting that the Tsk phenotype is more complex 
than initially thought. Similarly, other authors reported that transgenic mice overexpressing 
CD19 spontaneously develop high titers of topoisomerase I–specific antibodies 
characteristically associated with SSc, although they do not develop clinical features of the 
disease(Sato et al., 2000). Recent studies focussing on manipulation of the TGFβ receptors 
provide solid support for the critical role of the TGFβ pathway in the pathogenesis of 
fibrosis and vascular damage in SSc. This was demonstrated using a transgenic mice with 
conditional, fibroblast-specific gene expression of a constitutively active TGFβ receptor 
type I(Sonnylal et al., 2007). These mice display features similar to SSc including dermal 
fibrosis, structural vasculopathy and evidence for generalised abnormalities in ECM 
deposition. 
 
Knockout mice are usually generated by germline deletion of targeted sequence of gene by 
homologous recombination. Such germline deleted progeny can be backcrossed by 
background to provide strains deficient in specific gene products. This approach has been a 
milestone in understanding many mouse models of human diseases and for dissecting   52
potential pathogenetic mechanisms. Other knockout models with mice lacking the genes 
encoding relaxin(Samuel et al., 2005), caveolin(Galdo et al., 2008), Thy-1(Hagood et al., 
2005) and Fli-1(Kubo et al., 2003) have been studied and they demonstrate certain fibrotic 
or vascular features of SSc or show enhanced sensitivity to fibrosis induced by bleomycin. 
Mice with targeted deletion of relaxin developed spontaneous dermal and lung fibrosis but 
did not demonstrate vascular or immunological features of SSc.  
 
Transgenic and gene deleted murine strains have been invaluable in not only by de novo 
incorporation of a mutant gene but also by back-crossing established genetically 
determined mouse models of SSc with other transgenic mice. The latter strategy is 
illustrated with back-crossing Tsk1 mice with other mutant strains to explore the 
dependence on an intact immune response repertoire and upon a number of candidate 
mediators and pathways. Genetic complementation with a collagen-defective transgenic 
strain for Col5a2 gene was shown to reduce the degree of cutaneous fibrosis in Tsk1 
mice(Phelps et al., 1998;Andrikopoulos et al., 1995) and Tsk1 mice transgenic for a T cell 
receptor Vβ8.2 segment fail to develop cutaneous hyperplasia(Ong et al., 1999), suggesting 
that the T cells that mediate this aspect of the tight skin syndrome use distinct T cell antigen 
receptors. In another genetically-modified murine model, back-crossing IFNγ-receptor-
deficient mice into lupus-prone MRL/lpr murine strain generated striking histological 
findings with accumulation of collagen in connective tissue of various organs and a 
vasculopathy characterised by vascular intimal thickening(Le et al., 1999). In summary, 
these transgenic and knockout mice provide robust novel experimental tools for advancing 
future studies in the pathogenesis of SSc.   53
Model  Aspects of SSc pathogenesis that are reproduced  Key features 
 Vascular  Inflammation Autoimmunity  Fibrosis   
Naturally-occurring   
Tsk1  √ –  √  √ 
Genetic in-frame duplication of the fibrillin-1 gene, which leads to ECM 
development. Altered B-cell signalling, due to elevated expression of 
CD19. Fibrosis abrogated by IL-4 receptor deficiency. 
Tsk2 –  √  √  √  Unknown genetic defect leading to tissue fibrosis. Early inflammatory 
cell infiltrate noted in some studies. 
UCD-200  √  √  √  √  Inbred strain of chickens. Prominent vascular involvement with 
inflammation and widespread fibrosis. 
Induced          
Bleomycin –  √ –  √ 
Production of reactive oxygen species, endothelial cell damage and 
adhesion molecule expression. Some apoptosis of mononuclear cells. 
Severity is mouse strain-dependent. Activation of TGFβ axis 
GvHD I (B10.D2 vs 
Balb/C)  √  √ –  √ 
Transfer of spleen cells from B10.D2 mice into irradiated Balb/C, 
causing skin and lung fibrosis and infiltrates of CD3
+ T cells, monocytes 
and macrophages. 
GvHD II (B10.D2 vs 
Rag-2
−/−)  √  √  √  √  Transfer of spleen cells from B10.D2 mice into RAG-2 null mice induces 
systemic fibrosis, inflammation and autoantibodies. 
Genetically engineered          
MRL/lpr/IFNgR-/- –  √  √  √ 
Lupus prone MRL/lpr strain develops dermal and visceral including  
pulmonary inflammation and fibrosis when lacking IFNγ receptors. 
Conditional TGFβRI  √  √ –  √  Fibroblast-restricted conditional expression of TGFβRI induces 
generalised fibrosis and inflammation. 
Table 1.4.  Selected murine models for systemic sclerosis (Varga & Abraham, 2007).  54
1.1.6 Extracellular Matrix in SSc 
1.1.6.1 ECM – Composition and Function 
The extracellular matrix is comprised of proteoglycans like decorin and fibromodulin; 
fibrous proteins including collagen, fibrillin and elastin; adhesion molecules like 
fibronectin and laminin; and different subtypes of matrix metalloproteinases (MMPs). ECM 
is a complex structure offering a scaffold for cells as well as influencing cellular phenotype 
and functions, cell migration, shape, proliferation, differentiation and biosynthesis of 
connective tissue macromolecules. The deposition of ECM is a pivotal event during wound 
healing as well as within pathological conditions such as keloid formation and tumour 
progression. 
 
1.1.6.2 Collagen and SSc 
Collagens constitute the major fibrous proteins in ECM. According to the primary structure 
of different α chains and their assembly into collagen molecules, twenty seven different 
types of collagen, encoded by more than 40 genes, are currently recognised. These include 
the subfamily of fibrillar collagen (I, II, III, V, XI), network-forming collagen IV gene 
products, the fibril-associated collagens with interrupted triple-helix (FACIT) molecules, 
transmembrane collagens, beaded-filament-forming Type VI collagen, anchoring-filament 
collagen VII and short-chain, hexagonal-lattice-forming collagens VIII and X. Type I 
collagen is the most fibrous form and comprises close to 84% of the collagen synthesised 
by fibroblasts. Type I collagen, the main constituent of the ECM, is a triple helix composed 
of two α-1 and one α -2 chains, the products of COL1A1 and COL1A2 genes. The 
excessive deposition of Type I collagen leads to skin and internal organ fibrosis. Early 
studies suggested that patients with early onset SSc demonstrated increased amounts of 
type III collagen in the lower dermis whereas type I collagen deposition occurs in the later 
stage of the disease(Fleischmajer et al., 1978;Prockop & Kivirikko, 1995). The type I 
collagen genes are often used as a surrogate marker for disease activity because the 
excessive production of extracellular matrix by SSc fibroblasts is due in part to increased 
transcription of the type I collagen genes. The expression of these genes is regulated at 
multiple levels by numerous cytokines and transcription factors.  
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1.1.6.3 Regulation of ECM by cytokines/chemokines in SSc 
The regulation of ECM accumulation and collagen gene expression in SSc is tightly 
controlled. This process is modulated by paracrine/autocrine mediators, cell-to-cell contact, 
hypoxia and contact with the surrounding ECM. The collagen genes contain key cis-acting 
regulatory elements with conserved nucleotide sequences that are recognised specifically 
by DNA-binding transcription factors(Ghosh, 2002). In response to extracellular cues, Sp1, 
Ets1, Smad3, Egr-1, and CCAAT-binding factor (CBF) stimulate collagen expression. In 
contrast, Sp3, C/EBP and Fli1 suppress it. Transcription factors may interact with one 
another, and with non-DNA-binding cofactors, scaffold proteins, and chromatin-modifying 
enzymes including p300/CBP and histone deacetylases(Ghosh et al., 2007). Alterations in 
the expression levels, activities or interactions among the various transcription factors and 
cofactors may contribute to the persistent fibroblast activation in SSc.  
 
At the same time, it is possible that disruption of normal negative regulation of matrix 
occurs in SSc, leading to tissue fibrosis. Several studies have focused on TNFα, IFNγ and 
recently Hepatocyte Growth Factor (HGF). HGF was shown to reduce collagen production 
in SSc fibroblasts by enhancing MMP-1 expression and this is facilitated by increased 
autocrine TGFβ signalling leading to overexpression of HGF-receptor c-met(Jinnin et al., 
2005). Collagen suppression by TNFα is likely to occur via several mechanisms and may 
involve induction of NFκB which in turn interferes with Sp-1-mediated activation of 
collagen transcription(Rippe et al., 1999;Jinnin et al., 2005). The mechanism by which 
IFNγ causes collagen gene suppression may lie in its induction of Interferon Regulatory 
Factor-1. Transient transfection experiments in human fibroblasts revealed a region 
between -129 and -109 may mediate IFNγ mediated suppression of the human α1(I) 
collagen activity(Yuan et al., 1999). Functional impairment of Smad7 has been 
demonstrated in SSc fibroblasts. Recent studies have also implicated altered expression or 
dysregulation of other cell-intrinsic endogenous repressors of collagen synthesis including 
the transcription factors Fli-1 and the nuclear hormone receptor peroxisome proliferator-
activated receptor (PPAR)-γ. The resultant defect in suppression of fibrogenic responses 
may contribute to failure to limit fibroblast activation, thereby contributing to ECM 
accumulation and fibrosis.   56
 
Several chemokines are involved in the fibrotic processes by upregulating production of 
collagen. MCP-1 increases collagen expression in dermal and lung fibroblasts probably via 
autocrine TGFβ effect(Gharaee-Kermani et al., 1996). This is consistent with the results 
from another study using a renal model of fibrosis induced by
 a unilateral ureteral 
obstruction in CCR2 gene-targeted mice in which transcripts
 and protein of MCP-1, 
transforming growth factor-β,
 and type I collagen were decreased compared to wildtype 
mice(Kitagawa et al., 2004). Receptor blockade against CCR1, which binds to several 
MCP chemokines including MCP-3, has been shown to reduce collagen and smooth muscle 
actin expression expression, in addition to abrogation of inflammatory cell infiltrate in 
several animal models of fibrosis(Anders et al., 2002;Anders et al., 2004;Eis et al., 2004). 
Recent data showed that CCL18 stimulate collagen mRNA and protein production by 
dermal and lung fibroblasts through activation of transcription factors Sp1 and c-
Myb(Atamas et al., 2003). This is in contrast to a study which revealed that systemic 
administration of CXCL11 reduced pulmonary collagen deposition, procollagen gene 
expression and extracellular matrix deposition in the lung of bleomycin-treated 
mice(Burdick et al., 2005). The authors reported that this effect is related to the reduction in 
angiogenic activity with decrease in number of endothelial cells with no direct functional 
effect on lung fibroblasts or leucocyte populations. Recent reports have suggested in 
addition to local tissue fibroblasts responsible for fibroproliferative process, circulating
 
cells of haematopoietic origin or fibrocytes have been shown to express ECM proteins, 
such as pro-Col I and pro–Col
 III, and migrate in response to chemokines such as CXCL12
 
and traffic to the lungs in a murine model of bleomycin-induced
 pulmonary fibrosis(Phillips 
et al., 2004). 
 
There is increasing evidence for the role of Akt in regulation of fibrotic response(Wu et al., 
2007;Vittal et al., 2005;Somanath et al., 2008). Akt is a key enzyme in signal transduction 
pathways involved in cell survival, glycogen synthesis, cell-cycle progression, angiogenesis 
and migration. The three Akt isoforms are ubiquitously expressed and are likely to have 
overlapping functions. Akt is activated downstream of phosphatidylinositol 3-kinase 
(PI3K) by growth factors, stimulators of G-protein-coupled receptors (GPCR) and   57
integrins. Following PI3K activation, Akt is recruited at the plasma membrane via binding 
of phosphoinositol lipids to the Akt pleckstrin homology domain. TGFβ increases Akt 
phosphorylation in dermal fibroblasts and Akt is constitutively phosphorylated in SSc 
biopsies suggesting an important role for Akt activation in collagen synthesis in SSc 
fibroblasts(Jun et al., 2005). More recently, Akt activation has been shown to mediate the 
downregulation of the collagen protease MMP1(Bujor et al., 2008). 
 
1.1.6.4 Fibroblasts in SSc 
Mesenchymal fibroblasts that contribute to excessive tissue repair or fibrogenesis (the 
production of ECM, notably collagen type I, and the development of contractile 
myofibroblasts) in SSc can be derived from at least three types of progenitor populations. 
In addition to resident connective tissue fibroblasts which may be activated directly along 
the myofibroblast lineage as discussed in 1.1.6.3, fibrocytes or mesenchymal stem cells 
from the bone marrow and circulation may be recruited, in response to chemokines, into the 
extravascular tissues at sites of injury(Varga & Abraham, 2007). Fibrocytes are CD34+ 
bone marrow-derived mesenchymal cells normally present in small numbers in the 
peripheral blood. They express CD14+ and chemokine receptors, CCR3, CCR5 and 
CXCR4 that facilitates trafficking into specific tissues including fibrotic lesional tissues 
whereby they undergo specialisation into fibroblasts and myofibroblasts, losing the CD14 
and CD34 markers in the process(Quan et al., 2006). Other studies have also identified 
multipotent monocyte-derived mesenchymal progenitor cells in peripheral blood(Gomer, 
2008). 
 
Other resident cell populations, such as epithelial cells, might also potentially serve as 
alternative sources of fibroblast-like cells. EMT is a well characterised phenomenon 
involved in the generation of mesenchymal cells in several models of renal fibrosis and 
Crohn’s disease (Bataille et al., 2008;Baum et al., 2008). Another potential fibroblast 
progenitor in SSc is the pericyte. Being integral cells of microvessels, pericytes maintain 
microvascular integrity and function, both regulating, and being regulated by, the 
endothelium. In response to endothelial cell injury, pericytes are activated under the 
influence of endothelin-1 (ET-1) or platelet-derived growth factors (PDGFs) and are able to   58
express a distinct splice variant of fibronectin (ED-A or FN), which, in the presence of 
TGFβ, is crucial for myofibroblast differentiation. Transition of vascular pericytes into 
myofibroblast-like cells not only contributes directly to fibrosis but also promotes the 
expansion and differentiation of resident ‘immature’ fibroblasts into 
myofibroblasts(Rajkumar et al., 1999). Therefore, the origins of the myofibroblasts in SSc 
also appear diverse and the relative commitment of mesenchymal cells towards this lineage 
will determine which cell populations predominate in fibrosis in SSc. 
 
1.2 Chemokines 
1.2.1 Classification 
Chemokines constitute a family of 42 small, heparin-binding mainly secreted proteins, 
smaller than cytokines with a molecular weight of 8-14 kDa which chemoattract cells by 
engaging 19 transmembrane heptathelial GPCRs (Figure 1.5). Induction of chemotaxis 
depends predominantly on coupling to pertussis toxin-sensitive Giα proteins, but some 
chemokine receptors couple to additional G proteins. Chemokines were originally 
identified by their chemotactic activity on bone marrow-derived cells as key mediators in 
recruitment of innate immune cells and effector T cells to inflammatory sites. 
Approximately 80% of these proteins have from 66 to 78 amino acids in their mature form. 
The remainder are larger with additional amino acids occurring upstream of the protein 
core or as part of an extended C-terminal segment. They played a key role in leucocyte 
trafficking (Figure 1.6), recruiting and recirculation. In addition, they are also important in 
many pathophysiological processes including allergic responses, infectious and 
autoimmune diseases, lymphoid trafficking (Luther & Cyster, 2001), lymphoid organ 
development, angiogenesis (Belperio et al., 2000), inflammation, tumour growth and 
haemapoietic development (Youn et al., 2000).  
 
They are characterised by a conserved protein scaffold that is strictly dependent on two 
conserved disulfide bonds connecting NH2-terminal cysteine residues, whose relative 
position determines the identification of four subfamilies. The majority of chemokines fall 
into CC (CCL1-28), CXC (CXCL1-16) subfamilies, while the C family contains only 2 
members (XCL1 and XCL2) and CX3C only 1 member (CX3CL1) (Murphy et al.,   59
2000;Murphy, 2002) as shown in Table 1.5. In the CXC chemokine subfamily the cysteine 
residues are separated by a single intervening amino acid, while in the CC chemokine 
subfamily, the first two cysteine residues are in adjacent position. The C subfamily presents 
a single cysteine residue, and CX3C chemokines, with three amino acid groups separating 
the cysteine tandem. These subfamilies have also different location in the genome: most CC 
chemokines are coded by a large multigenic cluster on chromosome 17q11.2, while most of 
the CXC chemokines are coded by two large multigenic clusters on chromosome 4q21. C 
and CX3C chemokines are encoded by single genes located on chromosome 1q23, and 
16q13 for the CXC chemokine. 
 
This group of chemoattractants continues to grow and chemokines were identified in cell-
culture media by classical protein chemistry, followed by cDNA cloning and over last few 
years, through broad-based searches from sequence homology in expressed sequence tag 
databases. The chemokines are identified with their original names derived from their 
function or from the cell type that produced them as well as the new systematic 
classification (Zlotnik & Yoshie, 2000). In analogy to their ligands, four subfamilies of 
receptors distinguished: 10 for CC chemokines (CCR1 to 10), 6 for CXC chemokines 
(CXCR1 to 6), and 1 for C chemokines and CX3C chemokines  (XCR1 and CX3CR1 
respectively). They are identified through the cloning and characterisation of numerous 
“orphan” receptors.  
 
One of the key in vitro characteristic features of chemokines is that several chemokines 
bind to more than one receptor and the majority of chemokine receptors have multiple 
possible ligands, although not shared between CXC and CC subfamilies. This pleiotropic 
feature, characteristic of the chemokine family, is responsible for their redundant action on 
target cells, which accounts for the biochemical robustness of the chemokine system. For 
example, in animal model of allergic airway responses, the production of chemokines is 
organised in a coordinated fashion that is dependent upon multiple chemokines for the 
recruitment and activation of different cell populations at distinct stages of disease 
evolution. Similarly, in relapsing remitting experimental autoimmune encephalomyelitis, 
the rodent model for multiple sclerosis, it was shown that CCL3/MIP-1α is involved in the   60
onset of the disease, whereas CCL2/MCP-1 has a key role in relapses(Kennedy et al., 
1998). Temporal expression of chemokines has also been demonstrated in animal models of 
arthritis: MCP-1 appeared to be involved in the later course of rat adjuvant-induced 
arthritis, a model for rheumatoid arthritis(Kasama et al., 1995). Another group of 
investigators observed elevated CCL5/RANTES and CCL3/MIP-1α production in murine 
collagen-induced arthritis compared with that in normal mice (Thornton et al., 1999).  
 
Determining the time course of chemokine expression during these inflammatory diseases 
should aid in pinpointing therapeutic intervention points in disease. 
In addition, on the level of chemokine receptor-ligand interaction much promiscuity can be 
found as many chemokines and chemokine receptors show cross reactivity. A single cell 
may produce multiple different chemokines that have the same function. This particular 
type of redundancy is termed polyspeirism (Mantovani, 1999). Similar feature has been 
observed with other cytokine networks and provides a certain degree of robustness as 
alterations of the individual components will not greatly influence immune function. Taken 
together, redundancy, promiscuity and polyspeirism protect the chemokine network from 
excessive modulation. Although the in vitro evidence suggests that the chemokine network 
exhibits much redundancy, several chemokine actions in vivo are not at all redundant. 
Studies in chemokine receptor knockout animals suggest that several apparently redundant 
chemokine receptor knockout reveal altered immune responses (Carter, 2002). From this, it 
appeared that the chemokine network was less redundant as initially assumed and that 
several factors contribute to fine-tuning of the chemokine response(Devalaraja & 
Richmond, 1999).   61
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Figure 1.5 Chemokines adopt a characteristic fold that consists of an N-terminal 
unstructured domain that is critical for signalling, a three-stranded β-sheet connected by 
loops and turns, and a C-terminal helix as shown in A in which the highlighted region of N-
terminal signalling domain is postulated to insert into the helical bundle of the receptor, 
shown in B. Chemokine receptors are seven-transmembrane molecules coupled to the 
heterotrimeric G proteins comprised of three subunits:α, β and γ. The β- and γ-subunits are 
assembled into γβ-dimers that act as functional units (O'Hayre et al., 2008).   62
 
 
 
Figure 1.6 Schematic representation of model of chemokine involvement in leucocyte 
trafficking into discrete stages. The initial stage involves rolling of leucocytes along the 
vessel wall through transient interactions between specific selectin proteins and their 
carbohydrate ligands. The next stage involves activation of the leucocyte resulting in a firm 
adhesion to the endothelial surface mediated by integrin molecules. The final stage involves 
extravasation of the leucocyte which includes crawling along the endothelium, diapedesis 
and migration into the interstitial space (Allen et al., 2007).   63
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.5 The chemokine system. The ligands are identified with one old acronym and the 
current nomenclature, in which the first part of the name identifies the family and L stands 
for ligand, followed by a progressive number. Chemokines present only in humans or mice 
are prefixed with ‘h’ or ‘m’ respectively. 
Systematic Names Original Names Receptors
CC family
CCL1
CCL2
CCL3
CCL4
CCL5
mCCL6
CCL7
CCL8
mCCL9
mCCL10
CCL11
mCCL12
hCCL13
hCCL14
hCCL15
CCL16
CCL17
hCCL18
CCL19
CCL20
CCL21
CCL22
hCCL23
hCCL24
CCL25
hCCL26
CCL27
CCL28
I-309
MCP-1
MIP-1α, LD78α
MIP-1β
RANTES
C10
MCP-3
MCP-2
MIP-1γ
MIP-1γ
Eotaxin-1
MCP-5
MCP-4
HCC-1
HCC-2, Lkn-1, MIP-1δ
HCC-4, LEC
TARC
PARC, DC-CK1, AMAC
ELC, MIP-3β, exodus-3
LARC, MIP-3α, exodus-1
SLC, 6Ckine, exodus-2
MDC, STCP-1
MPIF-1, CKβ8
Eotaxin-2, MPIF-2
TECK
Eotaxin-3
CTACK-ILC
MEC
CCR8
CCR2
CCR1, CCR5
CCR5
CCR1, CCR2, CCR5
CCR1
CCR1, CCR2, CCR3
CCR3
CCR1
CCR1
CCR3
CCR2
CCR2, CCR3
CCR1
CCR1, CCR2
CCR1, CCR2, CCR5
CCR4
Unknown
CCR7
CCR6
CCR7
CCR4
CCR1
CCR3
CCR9
CCR3
CCR10
CCR3, CCR10
Systematic Names Systematic Names Original Names Original Names Receptors Receptors
CXC family CXC family
CXCL1 CXCL1 GROα GROα CXCR1, CXCR2 CXCR1, CXCR2
CXCL2 CXCL2 GROβ, MIP-2 GROβ, MIP-2 CXCR2 CXCR2
CXCL3 CXCL3 GROγ GROγ CXCR2 CXCR2
CXCL4 CXCL4 PF4 PF4 CXCR3B CXCR3B
CXCL5 CXCL5 ENA-78 ENA-78 CXCR2 CXCR2
CXCL6 CXCL6 GCP-2 GCP-2 CXCR1, CXCR2 CXCR1, CXCR2
hCXCL7 hCXCL7 NAP-2 NAP-2 CXCR2 CXCR2
hCXCL8 hCXCL8 IL-8 IL-8 CXCR1, CXCR2 CXCR1, CXCR2
CXCL9 CXCL9 Mig Mig CXCR3A/B CXCR3A/B
CXCL10 CXCL10 IP-10 IP-10 CXCR3A/B CXCR3A/B
CXCL11 CXCL11 I-TAC I-TAC CXCR3A/B CXCR3A/B
CXCL12 CXCL12 SDF-1α/β SDF-1α/β CXCR4, CXCR7 CXCR4, CXCR7
CXCL13 CXCL13 BCA-1 BCA-1 CXCR5 CXCR5
CXCL14 CXCL14 BRAK BRAK Unknown Unknown
mCXCL15 mCXCL15 Lungkine Lungkine Unknown Unknown
CXCL16 CXCL16 SR-PSOX SR-PSOX CXCR6 CXCR6
C family C family
XCL1 XCL1 Lymphotactin α, SCM-1α Lymphotactin α, SCM-1α CXR1 CXR1
hXCL2 hXCL2 SCM-1β SCM-1β CXR1 CXR1
CX3C family CX3C family
CX3CL1 CX3CL1 Fractalkine Fractalkine CX3CR1 CX3CR1  64
 
1.2.2 Chemokines receptors and Signalling 
 
One of the key features of chemokines which distinguishes them from other cytokines is 
that they are the only members of the cytokine family that act on the receptor superfamily 
of GPCRs. These represent single polypeptide chains with three extracellular and three 
intracellular loops with an acidic N-terminal extracellular domain involved in ligand 
binding, and a serine/threonine-rich intracellular C-terminal domain. The external interface 
contributes to the ligand-recognition specificity, while conserved transmembrane 
sequences, the cytoplasmic loops and the C-terminal domain are involved in receptor 
signalling and internalisation.  
 
Like other GPCR agonists including bacteria-derived formyl-peptides, the complement 
fragments C5a and C3a, bioactive lipids (sphingosine, leukotrienes and platelet-activating 
factor), activation of Gi PCR when bound to chemokines requires their functional coupling 
to the heteromeric Gi proteins (Thelen, 2001;Gilman, 1987). After ligand binding the Gi 
protein rapidly exchanges GDP for GTP, and the GTP-loaded Gα and βγ subunit dissociate 
from the receptor to activate downstream effectors. Pertussis toxin treatment causes 
uncoupling of the Gi protein from the receptor (Kurose et al., 1983;Van Dop et al., 1984) 
and abolishes most receptor-mediated responses, but does not prevent receptor 
phosphorylation and internalisation (Amara et al., 1997;Giannini & Boulay, 1995). The 
latter are now considered to be the main mechanisms for termination of receptor-mediated 
responses (Haribabu et al., 1997;Aragay et al., 1998). Pharmacological inhibitors have been 
used to investigate the regulation of chemokine-mediated activities such as chemotaxis of 
monocytes. Downstream of G proteins, chemokines induce activation of kinases, including 
PI3K and extracellular signal regulated kinase and p38 kinase (Tilton et al., 2000;Jones et 
al., 1995). The free Gβγ activates the small G protein Ras which in turn directly activates 
PI3K, promoting conversion of the membrane phospholipid PIP2 into PIP3. Once generated, 
PIP3 will then recruit proteins including Akt/PKB to the plasma membrane. This step is 
required for chemotaxis including gradient sensing and cell polarisation for neutrophils and 
fibroblasts(Haugh et al., 2000;Wang et al., 2002).     65
 
It is also increasingly recognised that there is a subfamily of chemokine receptors that binds 
the chemokines but do not facilitate cellular migration or activate conventional signalling 
pathways(Comerford et al., 2007). This characteristic is unique to several receptor 
members including Duffy Antigen Receptor for Chemokines (DARC), D6 and CCX-CKC. 
In these ‘silent receptors’, there is no conserved DRY motif with the triplet amino acid 
sequence (aspartic acid, arginine and tyrosine) within the second intracellular loop which is 
necessary required for receptor signalling. For example, DARC which is expressed on 
vascular endothelial cells of postcapillary venules and veins in many organs including skin 
shares 40% similarity with chemokine receptors and is able to bind to the pro-inflammatory 
chemokines in both CC and CXC chemokines (Figure 1.7). In vitro data reveals that 
DARC is able to internalise the ligands upon chemokine binding but it does not support 
ligand-induced signalling or migration(Mantovani et al., 2006;Nibbs et al., 2003). 
Similarly, D6 which are selective for CC chemokines and are expressed by lymphatic 
endothelial cells in different organs including the skin does not demonstrate sustained 
signalling and functional activities that are typically observed after chemokine receptor 
signalling(Mantovani et al., 2007). These studies support that such receptors may function 
as a sink/reservoir or decoy for chemokines by facilitating transfer of chemokines across 
cellular barriers and present them to leucocytes. However, there is evidence to suggest that 
members of this subfamily such as D6 may function in vivo by clearing chemokines from 
the tissue microcirculation acting as negative regulator of inflammatory response(Borroni et 
al., 2006). Chemokines are thus rapidly dissociated and degraded in intravesical, leaving 
the chemokine receptor free to recycle to the cell surface. However, it remains unclear if 
these decoy receptors indeed transduces any other signal in association with internalisation 
such as non-G protein mediated pathways. 
 
Apart from the cognate GPCR as the main receptor, the chemokine ligand also binds to the 
glycosaminoglycans(GAG) present on the cell surface or ECM. While the localisation of 
receptor binding site is highly conserved, there are four possible GAG binding clusters on 
the chemokine and these may or may not overlap with the receptor binding domain. Thus, 
GAG may potentially control receptor selectivity. Among these molecules, heparin sulphate   66
was thought to provide the substratum to which chemokines bind to create a high local 
concentration of chemokine. In vivo experiment with peritoneal recruitment assay with 
engineered mutants of MCP-1/CCR2 confirms that engagement with GAGs is necessary to 
elicit cell migration(Proudfoot et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Silent chemokine receptors ligand specificity and tissue/cell-type distribution. 
DARC and D6 are mainly expressed on the endothelium; DARC is also expressed by 
erythrocytes. CCX-CKR is expressed by various tissues. 
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1.2.3 Chemokines and Autoimmune Diseases 
The cellular infiltrate of immune cells and proinflammatory mediators in SSc forms a 
complicated network between fibroblasts and immune cells via cell-cell communications. A 
growing body of evidence points towards the role of chemokine-driven networks in 
leucocyte activation in autoimmune diseases including SSc. Chemokines mediate 
leucocyte-endothelium interaction and transmigration at multiple steps and this is 
accompanied by an inflammatory response with various cell types releasing inflammatory 
mediators to promote the recruitment of inflammatory cells. For example, MCP-1, CCL11 
and CCL17 are critical in T cell polarisation and recruitment into the lesional skin and 
MCP-1 skews T cell differentiation toward Th2 phenotype. These chemokines also recruit 
macrophages, which in turn release fibrogenic mediators such as TGFβ and PDGF. 
Activation of mast cells by MCP-1 and CCL5 releases cytokines and growth factors that are 
capable of activating fibroblasts or endothelial cells. Moreover, these cellular infiltrate also 
expresses chemokines, which may play a part in the induction of fibrosis.  
 
As discussed in 1.1.4.1, patients with SSc have a strong genetic predisposition. Previous 
studies have identified a variety of genetic polymorphisms in the genes encoding 
chemokines, and have found significant associations of these polymorphisms with the risk 
of SSc (Table 1.6). A small study of 18 patients with SSc identified an association of the -
2518 GG genotype of MCP-1 with SSc. This polymorphism lies within the promoter region 
and is also associated with increased MCP-1 production in vitro(Karrer et al., 2005). 
However, this was not replicated in other European and Far East patient populations(Carulli 
et al., 2008;Lee et al., 2007;Navratilova et al., 2008). Lee reported that the two genetic 
polymorphisms (non-polymorphic +113C/T and +459C/T) for CCL3 were not implicated 
in the development of SSc. However, in a Caucasian study group, 2 polymorphisms 
occurring close to each other in the CXCR-2 gene (+785 C/T and +1208 T/C) were 
associated with SSc, independent of the presence of lung fibrosis(Renzoni et al., 2000). 2 
coding polymorphisms for CX3CR1, the key receptor for fractalkine was associated with 
SSc-associated pulmonary arterial hypertension(Marasini et al., 2005). In addition, a 
significant gene-gene interaction between polymorphisms in the genes CXCL8 -353 A/T   68
and CCL5 -403 G/A, and both of these were associated with an increased risk of SSc. This 
data is interesting in that it suggests the importance of potential gene-gene interactions in 
SSc. However, there was no association demonstrated with polymorphisms for CCR2 and 
CCL5(Lee et al., 2007).  Interestingly, NSF as described in Section 1.1.4, has been shown 
to be associated with upregulation of dermal MCP-2/CCL8 on immunofluorescence 
analysis. In addition, in vitro activation of macrophages treated with gadolinium also 
resulted in transcript overexpression for MCP-2/CCL8, MCP-1, CXCL10 and CXCL11. 
These strongly suggest the role of chemokines in SSc and SSc-like syndromes.   69
 
Gene  SSc  Control Populations Year  Reference 
MCP-1 (MCP-1) 
MCP-1 (MCP-1) 
MCP-1 (MCP-1) 
MCP-1 (MCP-1) 
CCL3 (MIP-1α) 
CCL5 (RANTES) 
CCR2  
CCR5  
CCR7  
CX3CR1 
CXCL8 (IL-8) 
CXCL8 (IL-8) 
CXCR1 (IL-8R1) 
CXCR1 (IL-8R1) 
CXCR2 (IL-8R2) 
18 
99 
94 
46 
99 
99 
99 
99 
100 
76 
128 
99 
128 
99 
128 
139 
199 
102 
449 
199 
199 
199 
199 
40 
204 
194 
199 
194 
199 
194 
Germany 
Korea 
UK 
Slovak 
Korea 
Korea 
Korea 
Korea 
Germany 
Italy 
UK 
Korea 
UK 
Korea 
UK 
2005 
2007 
2008 
2008 
2007 
2007 
2007 
2007 
2007 
2005 
2000 
2007 
2000 
2007 
2000 
(Karrer et al., 2005) 
(Lee et al., 2007) 
(Carulli et al., 2008) 
(Navratilova et al., 2008)
(Lee et al., 2007) 
(Lee et al., 2007) 
(Lee et al., 2007) 
(Lee et al., 2007) 
(Kahlmann et al., 2007) 
(Marasini et al., 2005) 
(Renzoni et al., 2000) 
(Lee et al., 2007) 
(Renzoni et al., 2000) 
(Lee et al., 2007) 
(Renzoni et al., 2000) 
          
 
Table 1.6 Candidate chemokine genes associated with SSc susceptibility. 
 
Studies in gene-targeted mice provided evidence for a non-redundant role for chemokines 
in leucocyte recruitment associated with inflammatory response. For example, CXCR2-/- 
mice demonstrated that a significant role of CXCL8 in sustaining neutrophils-mediated 
inflammatory disease, suggesting that CXCL-8-CXCR1/2 axis resulted in almost complete 
protection from multiple inflammatory challenges(Harada et al., 1994). Further studies 
support a non-redundant role of chemokine system in autoimmune diseases including 
rheumatoid arthritis(Koch, 2005), Sjogren’s Syndrome(Petrek et al., 2002), 
sarcoidosis(Kolek et al., 2002), autoimmune thyroiditis(Chen et al., 2005), multiple 
sclerosis(Tanuma et al., 2006), psoriasis(Nickoloff et al., 2007) and autoimmune 
uveoretinitis(Takeuchi et al., 2005). In addition, activity of these diseases is related to 
presence and levels of the chemokines. For example, patients with rheumatoid arthritis 
show a correlation between clinical disease activity and MCP-1 and CCL5 levels, and the 
effect of methotrexate treatment on radiological erosions may be predicted by serum levels 
of CCL5 and CXCL1(Boiardi et al., 1999). Similarly, raised sera levels of CXCL10 have 
been associated with disease activity in SLE, and CCR4 and its ligand CCL17 have been   70
described to play a role in leucocytes recruitment in cutaneous lupus erythematosus(Wenzel 
et al., 2005).  
 
In addition to autoimmune diseases, chemokines and their receptors have been described to 
be involved in different aspects of tumourogenesis and these can be divided into three 
board categories: providing directional cues for migration or metastases, shaping the 
tumour microenvironment and providing survival and growth signals. In numerous cancers, 
malignant cells demonstrate aberrant expression of chemokine receptors relative to their 
normal counterparts notably CXCR4, CCR7 and CCR10(O'Hayre et al., 2008). CXCR4 
expression reflects tumour progression, and it is also associated with lymph node metastasis 
in oral squamous cell carcinoma, human nasopharyngeal carcinoma, pancreatic cancer, 
non-small lung cancer and human colorectal cancer. The altered chemokine/receptor 
expression may be related to the tumour microenvironment and altered signalling in the 
cancer cell itself. Antibodies targeted against CXCR4 have been demonstrated to abrogate 
metastasis in a murine model of breast cancer.  
 
The altered tumour microenvironment represent a state of chronic inflammation with the 
presence of tumour cells, development of aberrant vascular network and the persistence of 
inflammatory mediators: all these factors may help in the progression of cancer. 
In addition to facilitating migration from the primary tumour to a metastatic site, 
chemokine receptor signalling may also provide a survival advantage. Chemokines are 
ideal migratory signals to control the homing of lymphocytes to protective niches in the 
bone marrow and lymph nodes, and they may also promote survival of cancer cells. The 
molecular strategies for survival and growth are often the result of utilising and 
reprogramming of existing physiological pathways.  
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1.2.4 Chemokines/Chemokines receptors as targets for therapies 
Evidence for the role that many chemokines and receptors play in the pathogenesis of 
different acute and chronic inflammatory diseases is rapidly increasing(Anders et al., 
2002;Horuk et al., 2001), and there is now increasing interest in targeted therapeutics 
against chemokines and their receptors. The first pharmacological approach was based on 
the inhibition of chemokine production through classical anti-inflammatory agents. For 
example, IL-8 and MCP-1 production were blocked by cyclosporin and FK506. The 
apparent redundancy of the chemokine network and the lack of fidelity many receptors 
display for their ligands may render targeting chemokines difficult and may potentially lead 
to lack of specificity and side effects. However, results from research using knockout mice, 
specific monoclonal antibodies and receptor antagonists have largely allayed such fears. 
For example, studies in CCR2 knockout mice suggested a potential role for this receptor in 
both inflammation and fibrosis since mice lacking CCR2 display impaired mononuclear 
cell recruitment to sites of inflammation (Kuziel et al., 1997)and are resistant to 
experimental fibrosis(Moore et al., 2001). This in vivo results indicate that a nonredundant 
role of individual chemokines in specific pathological circumstances. This would suggest 
that spatial and temporal regulation might be more functionally relevant than would be 
expected by extrapolating from in vitro results and suggest a role for chemokines in 
modulating other aspects of the inflammatory response beyond simple leucocyte 
recruitment including cross talk with other cytokines and growth factors.  
 
Other studies have demonstrated the success of targeting key proteins such as the antibody 
neutralisation of the TNFα in autoimmune diseases. There are several ways in which the 
chemokine network may be targeted for therapeutic interventions (Figure 1.8). As for other 
cytokines, blocking antibodies interfering with the chemokine binding to the receptors have 
also been developed. However, the need for parenteral administration is a major limitation 
to widespread clinical use of such agents. As discussed in the following Section 1.2.5, 
chemokine variants with N-terminal processing are one of the main chemokine inactivation 
mechanisms and several N-truncated chemokines have been reported. Modification of the 
structure of CCL5 with an additional methionine reside at the N-terminal, Met-RANTES 
retains receptor binding but fails to induce receptor activation. (Ponath et al.,   72
1996;Proudfoot et al., 1996). This analogue has been shown to have profound effects on 
several models of inflammation including Th-1-mediated inflammatory disorders such as 
murine collagen-induced arthritis(Ponath et al., 1996) and organ-transplant rejection(Grone 
et al., 1999) as well as those mediated by Th2 proinflammatory cytokines such as allergic 
lung airway inflammation (Gonzalo et al., 1998). The CCR1, 3 and 5 antagonist, Met-
RANTES has been shown to antagonise effector functions of human eosinophils stimulated 
with MCP-3 with inhibition of actin polymerisation and intracellular calcium flux transients 
and release of reactive oxygen species (Chvatchko et al., 2003;Elsner et al., 1997;Elsner et 
al., 1999). The latter processes have been observed to occur in SSc (Gabrielli et al., 2008) 
and chemokine inhibition is potentially useful in this aspect of the disease. 
 
The most frequently targeting approach is small molecules that prevent the interaction of 
the chemokine ligand with its receptor, which is the basis for numerous drug discovery 
programs in the pharmaceutical industry. The first small molecule targeting the chemokine 
system was approved for the prevention of HIV infectivity: maraviroc, a small molecule 
targeting CCR5 developed by Pfizer. Biologicals in the guise of neutralising antibodies are 
also being developed although to date there are no positive trial outcomes. However 
neutralising antibodies have been used extensively in the validation of the chemokine 
system in animal models of disease. 
 
Among the chemokine receptor antagonists that are currently in trials (Table 1.7), a recent 
trial with a human blocking antibody against CCR2, MLN1202 in patients with rheumatoid 
arthritis reduced the levels of free CCR2 on synovial monocytes but it did not alter the 
clinical course(Vergunst et al., 2008). In this study, however, there was no analysis on 
chemokine expression on the fibroblasts which are likely to be the key effector cells in 
fibrotic diseases. CCR1 antagonists are currently studied in clinical trials for treatment of 
multiple sclerosis and CCR5 antagonists that block HIV entry into cells are being used in 
advanced clinical trials as adjuvant treatment for AIDS. Small molecule inhibitors of 
CX3CR1 are being used in phase I/II trials for psoriasis and rheumatoid arthritis, and 
CXCR4 antagonists are being evaluated in rheumatoid arthritis and cancer. More recently, a 
novel compound which selectively targets the production of MCPs including MCP-3,   73
bindarit, an indazolic derivative was described(Mirolo et al., 2008). It was demonstrated to 
interfere with monocyte recruitment in several in vivo experimental models of 
inflammation for pancreatitis, arthritis and lupus nephritis. 
 
Whilst chemokine and receptor inhibition remains a promising area and an unexplored 
approach, the possible adverse effects of such therapy need careful consideration. 
Experimental studies with CCR1(-/-) mice have indicated that such approach may not only 
affect the recruitment phase of the inflammatory cellular infiltrate but also the effector 
phase of the pathological processes, and therefore may exacerbate or provoke the 
underlying disease(Topham et al., 1999). 
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Figure 1.8 Pharmacological inhibition of the chemokine system. Different pharmacological 
strategies are used to interfere with the chemokine receptor signalling. Blocking 
monoclonal antibodies sterically impair ligand binding (A). N-terminal truncated 
chemokines bind the receptor and compete with the biologically active full length ligand 
(B). Small molecule competitive antagonists compete with the chemokine for the binding 
site of the receptor (C). In all these cases, the ligand recognition is impaired. Receptor 
signalling may also be blocked by non-competitive inhibitors (D), which binds the receptor 
in an allosteric site preventing receptor conformational change and activation without 
interfering with chemokine binding.   74
 
Target Compound  and  Company  Diseases  Reference 
CCR1 
 
CCR2 
 
 
 
CCR3 
CCR5 
 
CXCR2 
 
CXCR3 
CXCR4 
BX471(Berlex) 
 
INCB-3284 (Incyte) 
 
MLN1202 (Millennium) 
 
766994 (GSK) 
Sch-D (Schering-Plough) 
TAK-799 (Takeda) 
656933 (GSK) 
 
T-487 (Amgen) 
AMD3100 (Anormed) 
MS, Renal 
fibrosis(Phase II) 
RA(Phase I) 
 
RA(Phase II) 
 
Asthma (Phase II) 
AIDS, Cancer 
(Phase II) 
COPD (Phase I) 
 
MS, RA (Phase II) 
AIDS, Cancer 
(Phase IV) 
(Wells et al., 2006) 
 
(Brodmerkel et al., 
2005) 
(Vergunst et al., 
2008) 
(Allen et al., 2007) 
(Allen et al., 2007) 
 
(Mirzadegan et al., 
2000) 
(Allen et al., 2007) 
(Ribeiro & Horuk, 
2005) 
 
Table 1.7 Chemokine receptor antagonists currently in trial. This list is not exhaustive. 
MS, Multiple sclerosis; RA, Rheumatoid arthritis; COPD, Chronic Obstructive Airways 
Disease. 
 
1.2.5 Chemokines and Matrix Metalloproteinases (MMP)  
The MMPs are a group of zinc-dependent proteinases that are critical for ECM degradation 
and remodelling. They facilitate tissue degradation required for leucocyte infiltration during 
inflammation and tumour cell escape during metastases.  
Chemokines and MMPs have an interdependent relationship, since they control the function 
of one another. The action of MMPs releases GAGs that in turn will influence the nature of 
the interaction between chemokines and their receptors. In addition, cleavage of the ECM 
may allow the release of deposits of chemokines. For example, in a mouse model of 
neutrophil-mediated lung injury in response to bleomycin, MMP-7 has been shown to 
mediate the release of CXC chemokine associated with syndecan-1 and helping to recruit 
neutrophils into the alveolar space(Li et al., 2002). MCP-1 induces the expression of MMP-
12 by monocytes/macrophages and it also upregulates MMP-1, MMP-2 and TIMP-1 
expression in human dermal fibroblast at transcriptional level (Yamamoto et al., 2000;Wu 
et al., 2000). To extend this observation, recent study with MCP-1-/- mice when treated 
with subcutaneous injections of bleomycin, demonstrated increased expression of MMP-13, 
TIMP-2, and TIMP-3 levels(Ferreira et al., 2006). This supports the crucial role of both   75
MMPs and TIMPs in the maintenance of the normal balance between ECM synthesis and 
degradation. This equilibrium is thought to be disrupted in fibrosis with decreased levels of 
MMPs and increased levels of TIMPs to create an environment that favours collagen 
accumulation. It has also been shown that regulation of transepithelial chemokine gradient 
including MCP-3 is dependent on MMP9 in a mouse lung model of allergy resulting in 
altered inflammatory cell recruitment in bronchoalveolar lavage of affected mice(Corry et 
al., 2004). 
 
Conversely, proteolysis of chemokines within their N-terminal signalling domains by 
MMPs would allow fine-tuning of chemokine activity; examples include the MCPs, 
CXCL11, CXCL8 and CXCL12. In the case of the MCPs, the cleavage products have 
impaired activity in chemotaxis assay and reduced calcium signalling activity. In contrast, 
posttranslational modifications may be mandatory for receptor signalling or results in 
enhanced biological activity. For example, the cleavage of the six or seven N-terminal 
residues of CXCL8 by MMP-9 increases the activity of this chemokine(Van Den Steen et 
al., 2003). Truncated CCR1 ligands have been detected at high levels in synovial fluids 
from subjects with inflammatory joint disease and these chemokines may mediate the 
inflammatory responses(Berahovich et al., 2005). Similarly, NH2-terminal truncation of 
natural MCP-3 between the fourth and fifth amino acid with MMP-1,-2,-3,-13 and –14, will 
result in reduced chemotactic and calcium signalling but retained its receptor binding 
properties which essentially acts a as a chemotaxis antagonist(McQuibban et al., 2002). In 
contrast to MCP-3, the other MCPs are only cleaved by MMP-1 and MMP-3. Unlike the 
critical chemokine processing at the NH2 terminal leading to altered receptor-binding and 
activity, very few chemokines undergo processing at the COOH-terminal or other internal 
sites, and most of them have little or no consequence on activity. Overall, the ability of 
MMPs to dramatically alter the function of a given chemokine makes the full significance 
of their presence in the microenvironment difficult to define. 
 
1.2.6 MCP-3 
MCP-3 was identified in 1992 in the supernatant of stimulated cultured osteosarcoma (MG-
63) cells as an 11 kDa protein(Van Damme et al., 1992). It shares a high sequence   76
homology with MCP-1 (74%) and MCP-2 (58%). The cDNA and gene encoding human 
MCP-3 were cloned on the basis of the amino acid sequence determined for the purified 
MCP-3 protein. The cDNA for the putative murine homologue of human MCP-3 was 
isolated by different groups and was named MARC (mast cell activation-related 
chemokine), FIC (fibroblast-inducible cytokine) or murine MCP-3. Human and murine 
MCP-3 show 59% homology at the protein level.  
 
The gene encoding human MCP-3 is located on chromosome 17q11.2-12. clustered with 
the other CC chemokine genes. It comprises three exons and two introns, with the first exon 
containing the 5’ untranslated region and a sequence coding for the signal peptide and the 
first two amino acids of the mature protein. The second exon encoded 3 to 42 of the mature 
protein whereas the third exon consists of the coding sequence for the COOH-terminal 
region of the protein and the 3’untranslated region. A polyadenylation signal and several 
destabilising AT-rich sequences have been described in the 3’untranslated region of the 
human MCP-3 gene. The TATA-box present in the MCP-3 promoter region controls the 
rate of basal transcriptional activity and is characteristic of rapidly transcribed genes. Other 
regulatory elements including a CAAT-box, an AP-1 like sequence and an Ets-like motif 
have been described(Van et al., 1999). Human MCP-3 is synthesised as a precursor protein 
of 99 amino acids, including an aminoterminal hydrophobic signal sequence(Van et al., 
1999).  Cleavage of the signal peptide from the precursor protein yields a mature protein of 
76 amino acids (Figure 1.9). The primary structures of MCP-3 and the related CC 
chemokines are shown in (Figure 1.10).  
 
Other than stimulated osteosarcoma cells, several other tumour cell lines have been 
demonstrated to express MCP-3 mRNA (Table 1.8). These include promonocytic U937 
cells in which MCP-3 mRNA was found to be transiently induced by phorbol 12-myristate 
13-acetate (PMA). In addition, MCP-3 mRNA was also expressed in the myelomonocytic 
leukaemia THP-1 cell line after stimulation with PMA or lipopolysaccharide (LPS). Low 
levels of MCP-3 transcripts were expressed by monocytes when activated by IL-1β, TNF-α 
or IFN-γ. This was suppressed by anti-inflammatory cytokines IL-4, IL-10 or IL-13. 
Peripheral blood mononuclear cells from lung transplant recipients were shown to express   77
high levels of MCP-3 protein and this may suggest that these patients are likely to progress 
to transplant rejection (Hodge et al., 2005). Secretion of MCP-3 protein by mononuclear 
leucocytes was also demonstrated after stimulation with IL-1β, IFN-α, IFN-β and measles 
virus.  
 
Synergistic induction of MCP-3 protein was observed in fibroblasts stimulated with a 
combination of IL-1β and IFN-γ. Physical stress is another mechanism in which MCP-3 
may be induced. Cyclic mechanical stretch significantly elevated MCP-3 secretion from 
cultured human uterine cervical fibroblast cells. The stretch-induced augmentation of MCP-
3 expression was significantly suppressed by an activator protein-1 (AP-1) inhibitor, 
curcumin(Takemura et al., 2004). Stimulation of human umbilical vein endothelial cells 
(HUVEC) with IL-1β, IFN-γ or TNF-α resulted in expression of the MCP-3 gene. In airway 
smooth muscle cells, IL-1β, IFN-γ and TNF-α were found to induce MCP-3 mRNA. 
Dexamethasone significantly inhibited this cytokine-induced accumulation of MCP-3 
mRNA, in contrast to IL-4, IL-10 and IL-13 which had no inhibitory effect. Corticosteroids 
also reduced the number of MCP-3 mRNA-positive cells in the epithelium and 
subepithelium in endoscopic biopsy specimens from patients with asthma (Fukakusa et al., 
2005). Finally, platelets constitutively expressed low levels of MCP-3 mRNA. 
 
Like other MCP chemokines, MCP-3 recruits and activates mononuclear phagocytes and 
dendritic cells, and to a lesser degree, T lymphocytes and NK cells and occasionally other 
cell types. The most sensitive cells are lymphocytes and monocytes. MCP-3 elicits a type 1 
T-cell dependent immunity ie Th1 type immune responses. MCP-3 gene transfer in P815 
mastocytoma cells elicits tumour rejection by activating type 1 T-cell dependent immunity 
resulting in reduced tumourigenicity and augmented leucocyte infiltration along with 
perivascular accumulation of dendritic cells in peritumoural tissue and neutrophil 
recruitment within the tumour (Fioretti et al., 1998). Recent work has also demonstrated 
that MCP-3 is regulated by β-catenin and dysregulation of MCP-3 associated with impaired 
β-catenin expression leads to increased tumourogenesis(Fujita et al., 2000). Oestrogen and 
progesterone downregulate MCP-3 expression individually or in synergy. MCP-3 induces 
signalling through three separate chemokine receptors,CCR1, CCR2 and CCR3; although   78
MCP-3 also binds CCR5 with high affinity this results in no detectable intracellular signal 
transduction, suggesting that MCP-3 may play a role in regulating its own 
production(Mueller et al., 2002). It is also noteworthy that CCL5 through its interaction 
with CCR5 is a major stimulus for the production of MCP-3.   79
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Figure 1.9 Organisation of the human MCP-3 gene, cDNA and protein. The shaded and 
empty boxes in the top panel indicate translated and untranslated regions of the exon 
sequences respectively. The intron sequences are indicated as horizontal lines. Length of 
segments are in bp. 
Exon/intron boundaries of the MCP-3 gene in comparison to the CC-chemokines MCP-1, 
MCP-2 and MCP-4. Nucleotides within exons are represented by capital letters. The size of 
the introns (number of nucleotides) is indicated.  
 
 
 
 
Figure 1.10 Primary structures of human MCP-3 compared to MCP-1, MCP-2 and MCP-4. 
The amino acid sequences are aligned with the conserved cysteine residues underlined 
(Murakami et al., 1997).   80
 
Cell type  Inducer(+)/Inhibitor(-)  Level  Reference 
+  IL-1β; TNFα; IFNγ; 
LPS;Colony 
stimulating factor-1 
mRNA (Van  et al., 
1999;Irvine 
et al., 2008) 
Monocytes 
- IL-4;  IL-10;  IL-13  mRNA  (Polentarutti 
et al., 1997) 
Mononuclear 
cells 
+  IL-1β; IFNγ; IFNβ  protein (Menten  et 
al., 1999) 
Fibroblasts +  IL-1β + IFNγ  protein (Menten  et 
al., 1999) 
Endothelial cells  +  IL-1β; TNFα; IFNγ; 
LPS 
mRNA (Polentarutti 
et al., 1997) 
+  IL-1β; IFNγ; TNFα  mRNA  Airway smooth 
muscle cells  - Dexamethasone  mRNA 
(Pype et al., 
1999) 
Platelets   constitutively  mRNA  (Power  et al., 
1995) 
Myelomonocytic 
leukaemia cells  
+ PMA  mRNA  (Van  et al., 
1999) 
+  IL-1β  Protein (Van  et al., 
1992) 
Osteosarcoma 
cells 
+  IL-1β; IFNβ; PMA  mRNA (Van  et al., 
1999) 
Promonocytic 
leukaemia cells 
+ PMA  mRNA  (Minty  et al., 
1993) 
 
Table 1.8 Cellular sources and regulators of MCP-3. PMA, phorbol 12-myristate 13-
acetate; LPS, lipopolysaccharide 
 
 
1.2.7 MCP Chemokines and Diseases 
Early studies have indicated a role for the pro-inflammatory MCP family of proteins in 
macrophage recruitment in inflammatory diseases and tumourogenesis. MCP-1 is produced 
by numerous tumours including breast, pancreas, lung, cervix, ovary, melanomas, sarcomas 
and glial cell tumours and by fibroblasts, endothelial cells and macrophages at the tumour 
site(O'Hayre et al., 2008). Its expression may correlate with the extent of macrophage 
recruitment and for some cancers, it may be of prognostic value. However, this relationship 
between chemokines and prognosis is complicated and is dependent on upon the cancer. 
For example, whilst in melanoma cell lines transfected with high levels of MCP-1 may   81
promote tumour rejection, higher levels of MCP-1 are associated with increased 
malignancy in experimental models of mammary adenocarcinomas. In addition, MCP-1 is 
found in bronchial epithelium of pulmonary fibrosis and asthma patients(Meloni et al., 
2004), tuberculous effusions, pleural infections and inflammatory skin diseases including 
psoriasis and atopic dermatitis (Vestergaard et al., 2004) and also in wound healing which 
correlates with collagen deposition, fibroblast proliferation and neovascularisation(Gillitzer 
& Goebeler, 2001;Habibipour et al., 2003). 
 
CCR2, the main receptor for MCP-1, 2 and 3 is associated with cancers of the breast, lung, 
prostate, glioma, melanoma and multiple myeloma. This receptor may either be directly 
expressed on cancer cells or function indirectly by recruitment of macrophages and 
fibroblasts, polarisation, invasion and metastases and angiogenesis. These processes may be 
driven by MMPs but it is clear that the roles of MMPs are complicated and may play both 
tumour-promoting and tumour-suppressing roles. For example, MCP-1 induces the 
expression of MMP-12 by macrophages.  
 
In addition to its major role in inflammatory cellular recruitment to sites of tissue injury, a 
novel role has been described for MCP-3 as a homing factor for mesenchymal stem cell 
(MSC) to sites of injury
 such as infarcted myocardium(Schenk et al., 2007). It is transiently 
expressed by the injured myocardium and MSC engraftment is associated with recruitment 
of myofibroblasts and cardiac remodelling. MCP-3 has been implicated in several 
autoimmune and inflammatory diseases. These include primary biliary cirrhosis 
(Tsuneyama et al., 2001) and inflammatory bowel disease (Helwig et al., 2000) and it has 
also recently been described to be elevated in peripheral blood monocytes from lung 
transplant recipients and persistent elevated levels may suggest early transplant 
rejection(Hodge et al., 2005). MCP-3 mRNA was significantly elevated in the bronchial 
mucosa of atopic and non-atopic asthmatics(Powell et al., 1996;Humbert et al., 1997), and 
elevated MCP-3 expression was associated with increased numbers of bronchial mucosal 
eosinophils in the atopic asthmatic patients(Powell et al., 1996). Moreover, MCP-3 was 
significantly increased in bronchoalveolar lavage fluid obtained from asthmatics(Rojas-
Ramos et al., 2003), and allergen challenge induced the expression of MCP-3   82
predominantly in the airway mucosa of experimental asthma epithelium(Stafford et al., 
1997). MCP-3 has been demonstrated in the oxidised low-density lipoprotein (LDL) 
stimulated foam cells, but not that of smooth muscle cells, in atherosclerotic plaques (Jang 
et al., 2004) and it was suggested that it can be involved in chemotaxis of inflammatory 
cells into the plaques. Recently, a number of studies have implicated MCP-3 in HIV-
1/AIDS pathogenesis. Moreover, the receptors for MCP-3, CCR2 and CCR3 have been 
demonstrated to bind HIV-1 in vitro but there is little evidence that they serve as HIV-1 
coreceptors in vivo. Immature dendritic cells exhibited potent chemotaxis in response to 
MCP-3(Lin et al., 1998), thus it may affect cellular differentiation and migration. 
Additionally, MCP-3 has been shown to have both inhibitory(Vicenzi et al., 2000) and 
stimulatory(Greco et al., 1999) effect on replication in peripheral blood mononuclear cells 
from HIV-1-infected individuals. Finally, one study has shown that MCP-3 stimulated anti-
HIV cytotoxic T cells(Hadida et al., 1998). 
 
A recent study has shown that MCP-3 is highly expressed in biopsies and pulmonary 
fibroblast lines obtained from patients with usual interstitial pneumonia (UIP) relative to 
patients without idiopathic interstitial pneumonia (IIP), and that this CC chemokine may 
have a major role in the progression of fibrosis in this IIP patient group(Choi et al., 2004).  
 
1.3 Transforming Growth Factor-β Superfamily 
Transforming Growth Factor-β (TGFβ) belongs to the TGFβ superfamily of peptides whose 
members include the bone morphogenetic proteins (BMPs), activins, inhibins, TGFβ and 
growth differentiation factors, glial derived neurotrophic factor and Mullerian inhibiting 
substance. The TGFβ superfamily is characterised by seven cysteine residues at the 
carboxyl terminal and conserved in the majority of the family members. Six of these 
cysteine residues form a characteristic cysteine ‘knot’. Synthesized as large precursor 
molecules, the superfamily members are proteolytically cleaved to yield the mature active 
protein. The mature proteins have been shown to mediate many aspects of development as 
well as play important roles within the adult. 
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1.3.1 TGFβ  
TGFβ is synthesised as prepropolypeptides that are proteolytically processed in the Golgi 
apparatus to a mature growth factor and its propeptide, also know as the latency associated 
peptide(LAP). Dimers of mature TGFβ and LAP form a tight complex termed the small 
latent complex(SLC), that is biologically inactive. The SLC is covalently bound to another 
protein called latent TGFβ binding protein (LTBP), forming the large latent complex(LLC). 
The LLC is secreted from cells to the extracellular space, where it binds to the extracellular 
matrix(Miyazono et al., 1991;Saharinen et al., 1996). 
 
1.3.2 TGFβ signalling pathway 
Members of the TGFβ superfamily signal through the sequential activation of 2 distinct 
serine/threonine kinase cell surface receptors that are expressed on virtually all cell types 
(Figure 1.11). Upon ligand binding, a type II receptor (TβRII) recruits and phosphorylates 
a type I receptor (TβRI), which is also known as activin receptor-like kinase (ALK). Of the 
7 known type I (ALK) receptors, ALK-5 is most specific for TGFβ, whereas the closely 
related ALK-4 and ALK-7 interact with other members of the 
TGFβ superfamily(Miyazawa et al., 2002). In addition, ALK-1 was recently shown to 
function as a type I TGFβ receptor, but it is expressed primarily on endothelial cells or at 
sites of epithelial-mesenchymal interactions(Oh et al., 2000). 
 
The Smads have been identified as major signalling molecules downstream of activated 
TβRI(Verrecchia et al., 2006). These highly conserved modular proteins function as signal 
transducers/transcriptional activators that shuttle between the cytoplasm and the 
nucleus(Gordon & Blobe, 2008). In response to TGFβ, ALK-5 phosphorylates Smad2 and 
Smad3 on serine residues, whereas ALK-1 activates Smad1 and Smad5. Activin signals are 
also transduced by Smad2 and Smad3, but via the ALK-4 and ALK-7 receptors, whereas 
Smads 1, 5, and 8 are substrates for the bone morphogenetic protein-activated ALKs. In 
contrast to these receptor-activated Smads (R-Smads) that are phosphorylated by type I 
TGFβ receptors, Smad4 serves as a Smad cofactor, and Smad7 functions as an inhibitor of 
TGFβ-Smad signalling. Upon activation, R-Smads interact with Smad4, and the   84
heteromeric complex is then imported into the nucleus. Within the nucleus, the DNA-bound 
Smad complex regulates the transcription of target genes directly or in association with 
transcription factors such as Sp-1 and forkhead activin signal transducer 1 (FAST-1), 
coactivators such as p300/CREB binding protein, or corepressors such as Ski and 
SnoN(Moustakas et al., 2001). Inhibitory Smad7 interacts with activated TβRI in 
competition with R-Smads and enhances receptor ubiquitination and proteasomal 
degradation in caveolae. 
 
In addition to the canonical Smad pathway, TGFβ also activates alternate signal 
transduction pathways in a cell type- and context-specific manner. Non-Smad signalling 
pathways induced by TGFβ in cell lines include protein kinase A, protein kinase C, 
calmodulin-dependent protein kinase II, the MAP kinases ERK, JNK, and p38, and 
PI3K(Derynck & Zhang, 2003) and the family of Rho GTPases(Wakefield & Roberts, 
2002). By regulating Smad activation or through intracellular cross-talk with the Smad 
pathway, these kinases can influence the amplitude and duration of Smad-dependent 
signalling and may directly induce Smad-independent TGFβ responses. The mechanisms 
linking non-Smad signalling pathways with activated TGFβ receptors are unknown. 
Furthermore, because most studies examining the cross-talk between ligand-induced Smad 
and non-Smad signalling pathways have been performed in transformed or immortalised 
cell lines, the biological consequences for non-Smad signalling in normal fibroblasts and 
their relevance in the physiological context remain incompletely understood. Studies into 
the delineation of Smad-dependent versus Smad-independent cellular responses to TGFβ 
have yielded conflicting results. For example, TGFβ stimulation of fibronectin and  -SMA 
expression has been shown to be Smad-dependent or Smad-independent in different studies 
and different cell types(Hu et al., 2003;Isono et al., 2002).  
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Figure 1.11 TGFβ signalling in fibroblasts via Smad pathway. TGFβ activate cell surface 
TGFβ-receptor, TβRI and TβRII, resulting in phosphorylation of downstream targets 
including Smads. Activated Smad2 and Smad3 form a complex with Smad4, and transit 
from the cytoplasm into the nucleus, bind to conserved DNA sequences and activate or 
repress transcription.   86
 
1.3.3 TGFβ and Fibrosis 
Tissue fibrosis represents a state of dysregulated wound healing which failed to terminate 
and involves activated mesenchymal cells including dermal and lung fibroblasts, hepatic 
stellate cells and mesangial cells. Fibrosis can therefore be defined as the replacement of 
the normal connective tissue architecture by disorganised ECM or scar tissue. 
 
Dysregulated expression of or response to TGF-β has been implicated in a variety of 
disease processes, including autoimmune disease, fibrosis and chronic inflammation. 
Transgenic and gene-targeted mutant mice have been invaluable for investigating the 
important roles of the TGFβ family in these diseases. For example, the predominant 
phenotype of the TGF-β1 knockout mouse suggests that the loss of this gene eliminates a 
critical regulator of immune and inflammatory responses. These mice show a substantial 
inflammatory response with a striking infiltration of leucocytes into numerous organs 
including the heart, lung, liver, salivary gland, pancreas, stomach, and intestine(Kulkarni et 
al., 1995). This overwhelming tissue inflammation is associated with several spontaneous 
manifestations of autoimmunity, including circulating antibodies to nuclear antigens, 
immune complex deposition, and increased expression of both class I and class II MHC 
antigens(Letterio et al., 1996). This suggests that dysregulation of TGF-β signalling in the 
TGFβ1 knockout mouse may potentially underlie a number of autoimmune disorders, 
including multiple sclerosis, experimental autoimmune encephalomyelitis, and 
inflammatory bowel disease.  
 
Found abundantly in platelets and released from activated macrophages or lymphocytes, 
TGFβ is a strong chemoattractant for fibroblasts. TGFβ increases the synthesis of ECM, 
such as collagen type-I and type –III or fibronectin, by fibroblasts, modulates cell-matrix 
adhesion protein receptors, promotes myofibroblast differentiation and regulates the 
production of proteins that can modify the ECM by proteolytic mechanisms such as 
plasminogen activator or procollagenase(Roberts et al., 1992). In addition, TGFβ is capable 
of stimulating its own synthesis by fibroblasts through autoinduction(Van Obberghen-  87
Schilling et al., 1988). TGFβ induces rapid fibrosis and angiogenesis when injected 
subcutaneously into newborn mice(Roberts et al., 1986).  
 
It has been demonstrated that in SSc, increased activity of TGFβ signalling pathways, 
altered expression of high and low affinity TGFβ receptors and autocrine overproduction of 
several TGFβ-regulated genes(Ihn, 2008). In addition, several recent studies suggest altered 
expression of TGFβ pathway signalling intermediates in SSc with basal level and TGFβ-
induced expression of Smad7 are selectively decreased, whereas Smad3 expression is 
increased(Dong et al., 2002). Gene transfer of Smad7 abrogated bleomycin-induced lung 
fibrosis in mice by intratracheal injection of a recombinant adenovirus containing Smad7 
cDNA(Nakao et al., 1999). In bleomycin-treated skin, fibroblasts showed predominantly 
nuclear localisation of Smad3 and intense staining for phospho-Smad2/3(Takagawa et al., 
2003). On the other hand, the expression of Smad7 was downregulated in bleomycin-
treated fibroblasts, which may account for sustained activation of TGFβ−Smad signalling 
in the lesional skin. In addition, gene transfer of Smad7 into unilateral ureteral obstruction-
induced renal fibrosis in rats significantly reduced the accumulation of extracellular matrix 
proteins (Terada et al., 2002). Inhibition of TGFβ signalling by Smad7 overexpression 
inhibited rat hepatic stellate cells transdifferention and block fibrosis induced by bile duct 
ligation in rats (Dooley et al., 2003). Gene profiling or polymerase chain reaction-based 
differential display experiments suggest that the gene expression pattern for SSc is similar 
to that of TGFβ-activated normal fibroblasts, thus supporting a role for TGFβ in SSc (Yang 
et al., 2003;Shi-Wen et al., 2000). For example, global analysis of gene expression has 
revealed that >95% of transcriptional responses induced by TGFβ in mouse embryonic 
fibroblasts were Smad3-dependent(Yang et al., 2003).  
 
Myofibroblasts are also shown to be more frequent in SSc skin and lung samples and the 
myofibroblast phenotype is maintained in explanted cultures from SSc skin or lung 
biopsies. In addition, a number of studies have shown that antagonising TGFβ1 prevents 
the development of tissue fibrosis(Noble, 2003). Furthermore, targeted overexpression of 
TGFβ1 has been shown to produce progressive fibrosis(Sime et al., 1997). Studies with rat   88
models revealed that TGFβ3 is associated with regular wound healing, whereas TGFβ1 is 
associated with fibrotic wound healing(Shah et al., 1995). 
 
1.3.4 TGFβ and Chemokines Crosstalk in fibrosis 
There is now accumulating evidence to suggest that an important regulatory loop between 
CC chemokines and TGFβ in experimental models of inflammatory diseases such as Thy-1 
nephritis(Wolf et al., 2002;Schneider et al., 1999). It has been demonstrated in that TGFβ 
regulates eotaxin(CCL11) expression by human airway smooth muscle cells in recruitment 
of eosinophils into the lung in the different phases of allergic asthma(Wenzel et al., 2002). 
In a murine model of gut fibrosis, direct transfer of MCP-1 by intramural injection of
 an 
adenoviral vector was associated with increased TGFβ expression and collagen 
deposition(Motomura et al., 2006). Recent immunohistochemical studies also showed 
colocalisation of CCR2 with TGFβ1 positive infiltrating epithelial cells in a renal model of 
fibrosis. Moreover, the authors reported that
 diminished CCR2 signalling may down-
regulate TGFβ
 expression, thereby attenuating progressive fibrosis in the
 diseased 
kidney(Kitagawa et al., 2004). CCR2 knock-out mice are protected from bleomycin-
induced lung fibrosis, and cultured fibroblasts demonstrated reduced TGFβ1-induced 
αSMA expression and decreased TGFβRII and Smad3 expression. Lower bioactive and 
total TGFβ levels were detected in fibroblasts from CCR2 knock-out murine model in a 
recent study(Lee et al., 2006). Similarly, there were reduced TGFβ levels in lesional skin of 
bleomycin-treated MCP-1 deficient mice(Ferreira et al., 2006).  This supports a convergent 
pathway between MCP-1 and TGFβ(Gharaee-Kermani et al., 2003). 
 
There have been few studies on the regulatory pathways underlying the crosstalk between 
chemokines and TGFβ. Recently, it has been reported that in lung fibroblasts and 
glomerular cells, MCP-1 can stimulate TGFβ via transcriptional mechanisms (Gharaee-
Kermani et al., 1996;Schneider et al., 1999). This may be in part related to monocyte 
infiltration mediated by MCP-1. This is further supported by recent evidence that in 
fibroblasts cultured from humans with UIP, MCP-1 may upregulate expression of TGFβRII 
and IL-13(Murray et al., 2008). In addition to the fibrotic response, abnormal angiogenesis   89
has been described in SSc and a recent study supported the role of MCP-1 in facilitating in 
vitro recruitment of vascular smooth muscle cells towards endothelial cells by 
TGFβ(Feinberg et al., 2004). It has been recently demonstrated that TGFβ via upregulation 
of CCR1 in neonatal murine astrocytes facilitates chemotaxis by MCP-3 in a dose-
dependent manner(Bandyopadhyay et al., 2007;Han et al., 2000) but it remains unclear if 
this effect occurs in fibroblasts. 
 
1.4 Role of individual mediators in SSc pathogenesis 
The fibrotic process is a final common pathway which involves an intricate interaction and 
activation of multiple cell types resulting in an increase in ECM of which collagen is the 
main component. Fibroblasts are often regarded as physiologically inert cells which are 
concerned with stromal function providing mechanical support and fillers of wounds or 
otherwise damaged tissues. However, recent studies from numerous laboratories revealed 
that such understanding of fibroblasts interact with ECM, immune cells and endothelial 
cells are subject to a range of locally acting cytokines and other soluble mediators including 
chemokines. Such factors include endothelin, prostanoids, nitric oxide, thrombin and 
others. This would form an autocrine or paracine loops or networks in SSc as outlined in 
Figure 1.12. Understanding the cytokine/chemokine network which forms an intricate and 
robust communication between these cells is important in fibrotic diseases including SSc. 
There are two key ways in which chemokines may promote fibrosis: 
a. recruitment and activation of  key inflammatory cells to express profibrotic mediators, 
b. direct profibrotic effect on fibroblasts. 
 
Circulating levels of cytokines and chemokines have also been measured in systemic 
sclerosis, and although there is variation between these studies, there is often measurable 
IL-10 and MCP-1, CXC chemokines including CXCL8, CXCL1 and Il-2, IL-6, SPARC 
and thrombospondin1 (TSP1). Some of these mediators have been shown to have 
clinicopathological significance. For example, presence of MCP-1 is correlated with 
eosinophilic infiltrate in the lung fibrosis of SSc, CXCL1 and CXCL8 with pulmonary 
involvement(Meloni et al., 2004). Upregulation of fractalkine (CX3CL1) was associated 
with digital ischaemia and pulmonary fibrosis (Furuse et al., 2003;Hasegawa et al., 2005).   90
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Figure 1.12 Pathophysiology of SSc.  
Fibrogenesis characterised by excessive ECM matrix is a major pathological feature of SSc. 
Distinct genetic and environmental influences including silica exposure may predispose 
individuals to development of SSc. Tissue damage initially involving the vascular 
endothelial cells evokes the release of chemokines, endothelins, platelet-derived growth 
factor and vascular endothelial growth factor; these alter endothelial permeability and 
promote the recruitment and proliferation of leucocytes. The interactions between 
endothelial cells, mononuclear cells and fibroblasts via the milieu of cytokines and growth 
factors result in accumulation of macrophages and neutrophils in the affected tissues. 
Endothelial-derived chemokines and growth factors recruit and activate mesenchymal 
progenitor cells and resident fibroblasts. Profibrotic factors including MCP-1, IL-4 and IL-
13 secreted by activated mononuclear cells promote fibroblast activation and the synthesis 
and secretion of ECM.  
CTGF, connective tissue growth factor; ECM, extracellular matrix; ET1, endothelin-1; 
MCP-1, Monocyte chemoattractant protein-1; MMP-9, Matrix metalloproteinase 9; IL, 
interleukin; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor.   91
1.4.1 CCN2/CTGF 
The matricellular protein connective tissue growth factor (CTGF/CCN2) has emerged as a 
key pathological mediator in fibrotic diseases.  CTGF levels are increased in almost all 
organ-specific fibroproliferative diseases such as idiopathic pulmonary fibrosis and 
systemic fibrotic disorders including SSc. Originally identified as a secreted growth factor 
in the conditioned media of cultured human umbilical vascular endothelial cells (Bradham 
et al., 1991), CTGF is a 36 to 38 kDa cystein-rich peptide containing 349 amino acid and 
belongs to the CCN family of matricellular proteins, which consist of six members that 
shares a similar predicted structure. It has been detected in endothelial cells, fibroblasts, 
cartilaginous cells, smooth muscle cells and some cancer cell lines. CTGF is induced by 
TGFβ and modulates fibroblast cell growth and ECM expression.  
 
Depending on the cell type, CTGF has diverse biological functions ranging from regulation 
of cell growth to tissue remodelling. In earlier studies, CTGF was demonstrated to have 
mitogenic and chemotactic effects on fibroblasts. Little or no detectable levels of CTGF are 
observed in normal adult skin tissue. However, during normal wound healing CTGF 
expression is activated by TGFβ at the wound site and this expression is turned off when 
the repair process is complete.  Recombinant CTGF protein was found to activate DNA 
synthesis and to upregulate collagen, fibronectin and integrin expression in 
fibroblasts(Frazier et al., 1996) in addition to promoting fibroblast proliferation, matrix 
production and granulation tissue formation. The current evidence suggests that whereas 
TGFβ or CTGF alone may only result in transient fibrosis, the combination of both factors 
together may result in a sustained fibrotic response. 
 
1.4.2 Platelet-Derived Growth Factor 
PDGF is a multifunctional growth factor with mitogenic activity for mesenchymal cells, 
regulation of matrix metabolism and wound healing, vasoactive and chemotactic properties 
and production of inflammatory cytokines(Heldin & Westermark, 1999). The PDGF 
system consists of four polypeptide chains including, PDGF-A and -B, and the newly-
discovered PDGF-C and –D chains. They signal through the tyrosine kinase receptors 
PDGF receptor α(PDGFRα) and receptor β (PDGFRβ). The biologically active PDGF   92
protein forms disulphide-bonded dimers, including four homodimers PDGF-AA, PDGA-
BB, PDGF-CC and PDGF-DD, and one heterodimer, PDGF-AB. PDGF-A and PDGF-B 
are secreted in their active forms while PDGF-C and -D are secreted in latent forms. Upon 
receptor binding, overlapping signal transduction pathways including PI3K, Ras-MAPK, 
Sac family kinases and phospholipase Cγ are activated.  
 
Originally isolated from platelets, PDGF isoforms are also synthesised by fibroblasts, 
macrophages, epithelial cells and capillary endothelial cells. Overexpression of PDGF has 
been reported in a number of fibrotic diseases with upregulation of PDGF and PDGFβ 
receptor in SSc fibroblasts and increased PDGF levels in bronchoalveolar lavage fluid. 
PDGF-A chain was shown to be elevated in affected skin in SSc(Yamakage et al., 1992). In 
addition, TGFβ upregulates PDGF-α mRNA and protein levels in SSc fibroblasts, 
compared to wildtype fibroblasts. In contrast, TGFβ1 and MCP-1 have been shown to 
upregulate PDGFRβ gene transcript in UIP fibroblasts. More recently, serum 
autoantibodies directed against the PDGF receptor have been detected in patients with SSc, 
and are capable of inducing fibroblast activation in vitro(Baroni et al., 2006). However, 
stimulatory autoantibodies targeted against the PDGF receptor are not specific for SSc, and 
have also been described in patients with extensive chronic graft-versus-host-
disease(Svegliati et al., 2007). 
 
1.4.3 IL-4 
CD4+ T-cell clones from SSc skin biopsies have been shown to demonstrate type-2 
cytokine profiles. Sera from this group of patients also exhibit increased levels of CD30 
expressed on activated type-2 cells. IL-4 is produced by activated memory T-cells and mast 
cells; both of which have been implicated in SSc. IL-4 is known to promote fibroblast 
proliferation, gene expression and synthesis of extracellular matrix proteins including 
collagen and tenascin(Postlethwaite et al., 1992;Makhluf et al., 1996). It also upregulates 
TIMP-2 in dermal fibroblasts via p38 Mitogen-activated protein kinases (MAPK pathway) 
(Ihn et al., 2002) and T-cells (Seder et al., 1998). IL-4 is overexpressed in the sera and also 
by activated peripheral blood mononuclear cells of patients with SSc (Needleman et al., 
1992). SSc fibroblasts express more IL-4 receptorα and produce more collagen after IL-4   93
stimulation (Serpier et al., 1997). In addition to TGFβ, it is also important in the synthesis 
of α1(I) collagen mRNA and activation of α2(I) collagen promoter in Tsk mice(McGaha et 
al., 2001). This is demonstrated with targeted mutations in the signalling chain of the IL-4 
receptor with abrogation of cutaneous hyperplasia in Tsk mice(Ong et al., 1999). 
Furthermore, neonatal Tsk mice treated with anti-IL4 antibody prevents skin fibrosis(Ong 
et al., 1998). In the bleomycin model, IL-4 was found to be detected in the sera and skin of 
the mice(Yamamoto et al., 1999). 
 
1.4.4 Regulated upon activation, normal T cell expressed and secreted 
(RANTES/CCL5) and macrophage inflammatory protein-1α/CCL3 
Elevated levels of RANTES and MIP-1α were detected in BAL of patients with 
SSc(Bolster et al., 1997) and in the lungs of patients with idiopathic pulmonary fibrosis and 
hypersensitivity pneumonitis leading to pulmonary fibrosis(Oshima et al., 1999). 
Expression of these two chemokines were demonstrated to precede the development of 
dermal and pulmonary fibrosis in the murine sclerodermatous graft-versus-host 
disease(Zhang et al., 2002). Abundant RANTES mRNA has been detected in situ in the 
skin of SSc patients compared to skin of control subjects(Anderegg et al., 2000). However, 
apart of their role in recruitment of inflammatory cells into tissue, the direct role of these 
chemokines in fibrosis remains to be clarified. 
 
1.4.5 IL-6 
IL-6 is a pleiotropic cytokine with multiple biological effects on immune regulation, 
haematopoiesis, inflammation and cancer(Kishimoto, 1989), and it has been implicated in 
SSc pathogenesis(Hasegawa et al., 1999;Kondo et al., 2001;Nishimaki et al., 1999;Sato et 
al., 2001). Increased induction of IL6 has been observed in SSc fibroblasts (Takemura et 
al., 1998)and IL-6 stimulated human dermal fibroblasts expressed increased production of 
collagen and glycosaminoglycans, hyaluronic acid and chondroitin-4/6-sulphates(Duncan 
& Berman, 1991). There was preferential increase in IL-6 in the sera from patients with 
diffuse SSc compared to limited SSc and this increase was correlated with pulmonary 
involvement (fibrosis and hypertension)(Bolster et al., 1997;Hasegawa et al., 1998). 
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1.4.6 IL-8 
This CXC chemokine is overexpressed in the dermis of lesional skin from patients with 
early dcSSc(Koch et al., 1993) and BAL fluids from affected patients(Bolster et al., 1997). 
Secreted by the alveolar macrophages and lung fibroblasts in patients with lung 
fibrosis(Ludwicka-Bradley et al., 2000;Pantelidis et al., 1997), in vitro cultured dermal 
fibroblasts have been shown to express more IL-8 than normal fibroblasts(Kadono et al., 
1998;Ludwicka-Bradley et al., 2000). Two polymorphisms in the CXCR-2 gene have been 
associated with SSc(Ludwicka-Bradley et al., 2000;Renzoni et al., 2000).  
 
1.4.7 Pulmonary and activation-regulated chemokine 
Also known as CCL18, it is highly expressed by lung macrophages. Recent evidence 
suggests that it induces collagen mRNA and protein production by dermal and lung 
fibroblasts and this appears to be mediated via ERK kinase signalling pathway(Atamas et 
al., 2003). Its protein is also elevated in BAL fluids from SSc patients with lung 
inflammation compared to those without. It is also found in BAL fluids of other fibrotic 
conditions including hypersensitivity pneumonitis, asthma and sarcoidosis. 
 
 
1.4.8 Monocyte chemoattractant protein-1 (CCL2/MCP-1) 
There is evidence to suggest that the related chemokine, MCP-1 is expressed in the skin and 
lungs of SSc and pulmonary fibrosis. One of the early studies to demonstrate chemokine 
overexpression in SSc came from in vitro studies showing that SSc fibroblasts, but not 
normal fibroblasts, selectively promote leucocyte migration across endothelial cell 
monolayers in a co-culture experimental system and that this was via an MCP-1 dependent 
mechanism(Denton et al., 1998). This lends further evidence to altered intracellular 
interaction between fibroblasts and endothelial cells and that promotion of perivascular 
inflammatory infiltrates is important in early stage lesional skin in SSc. Further in vitro 
studies showed that fibroblast lines cultured from SSc skin biopsy specimens display 
increased expression of MCP-1 compared with normal dermal fibroblast lines. 
Autoinduction of MCP-1 mRNA has been observed in cultured SSc fibroblasts.   
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Subsequent studies have also demonstrated that MCP-1 may modulate fibroblastic 
properties with stimulation of proα1(I) collagen mRNA expression in both rat lung and 
normal human dermal fibroblast cultures in vitro (Yamamoto & Nishioka, 2003). This 
effect is mediated in part by stimulating fibroblast production of TGFβ, with TGFβ acting 
in an autocrine manner to stimulate ECM formation. Immunohistochemical localisation 
studies revealed expression of MCP-1 in the lesional skin of SSc in particular fibroblasts, 
keratinocytes, perivascular mononuclear cell infiltrate and endothelial cells. In addition, 
MCP-1 mRNA is detected in BAL cells from SSc, with greater expression in patients with 
lung inflammation than those without inflammation and healthy controls. There is parallel 
increase in MCP-1 protein in the BAL fluids in SSc with active lung inflammation(Luzina 
et al., 2002). In addition, several studies have described an association between a functional 
-2518 (A/G) single nucleotide polymorphism (SNP) in the promoter region of MCP-1 and 
SSc (Fonseca & Denton, 2007)but this was not demonstrated in our larger cohort of 
Caucasian SSc patients(Carulli et al., 2008). 
 
These findings suggest that MCP-1 may contribute to dermal fibrosis through several 
mechanisms: stimulation of collagen via TGFβ, the induction of more MCP-1 production 
by SSc fibroblasts and the recruitment of monocytes to the skin(Distler et al., 2008). MCP-
1 has also been implicated in recruitment of monocytes into early atherosclerotic lesions 
and development of restenosis after coronary artery angioplasty and stenting. CCR2
-/- mice 
show greater reduction in intimal hyperplasia and intima/media ratio than in mice with 
MCP-1 gene deletion. This would suggest that other chemokines such MCP-3 which 
activates CCR2 might contribute to intimal changes.  
 
1.4.9 Fractalkine (CX3CL1) 
Fractalkine is strongly expressed on the endothelial cells in the lesional skin and affected 
lung tissues of SSc. Soluble CX3CL1 was elevated in the sera of SSc. Its cognate receptor 
CX3CR1 are overexpressed on peripheral monocytes/macrophages and T cells in SSc. 
Accordingly, immunohistochemical studies revealed that the number of 
monocytes/macrophages expressing this receptor was increased in the lesional skin and   96
lung tissues from these patients. It is postulated that the ligand-receptor interaction may 
promote endothelial injury and migration of CX3CR1 cells into the skin and lung in SSc. 
 
1.4.10 IL-13 
Originally described as an 1L-4 like molecule, it is major effector
 of Th2 inflammation and 
tissue remodelling(Corry & Kheradmand, 2002;Elias et al., 2003;Wills-Karp, 2004). It is 
overexpressed in in vivo transgenic mouse model of fibrosis, and mice infected with 
Schistosoma mansoni. In SSc, elevated sera levels of IL-13 stimulates MCP-1 and MCP-3 
production in vivo in a CCR2-dependent manner(Hasegawa et al., 1997;Zhu et al., 2002). 
This interaction with chemokine system is further supported by upregulation of IL-13 and 
its receptor by MCP-1 in fibroblasts from patients with UIP (Murray et al., 2008). In 
bleomycin-induced lung fibrosis, the IL-13 receptor is reported to mediate the induction of 
collagen deposition by IL-13 via activation of TGFβ (Fichtner-Feigl et al., 2006). 
Consistent with this, it has been demonstrated recently compared to non-fibrotic human 
lung fibroblasts, that fibrotic fibroblasts from patients with UIP, there is induction of 
TGFβ1 gene expression by IL-13 and IL-13 may upregulate TGFβ receptor(Murray et al., 
2008). Similarly, in FITC model of lung fibrosis, the fibrotic response with increased total 
collagen production is dependent on the expression of IL-13(Kolodsick et al., 2004).   97
1.5 Hypothesis 
The experimental work described in this report addresses the hypothesis that in addition to 
its key role in regulating leucocyte recruitment that the CC chemokine, MCP-3 has an 
important role in determining ECM overproduction and fibrosis. It is also likely that this 
depends on interplay with other key profibrotic mediators including the TGFβ family 
members. SSc is used as a prototypic fibrotic disease platform for these studies. 
 
To address this hypothesis, the following specific aims have been pursued: 
1. Expression of MCP-3 was examined using contemporary analysis of established murine 
model for SSc, Tsk1 and TβRIIΔk transgenic mice and relating these to key subsets of 
human SSc skin biopsies. 
 
2. The profibrotic effect of MCP-3 on ECM gene expression was assessed using dermal 
fibroblasts cultured from transgenic mice harbouring a reporter gene regulated by a 
fibroblast-specific expression cassette. 
 
3. The regulation of MCP-3 expression by TGFβ was explored using in a series of 
transfection experiment with MCP-3 promoter. The signalling pathways governing the 
activation of MCP-3 by TGFβ were investigated using a series of pharmacological 
inhibitors.  
 
4. Activation of the type I collagen promoter Col1a2 by MCP-3 and the dependence of 
TGFβ activity have been explored. Responsiveness of MCP-3 promoter and of the proα2(I) 
collagen promoter to MCP-3 in transient transfection assays in wildtype cultured dermal 
fibroblasts, and to examine the potential role of TGFβ isoforms as downstream effector of 
collagen gene activation by MCP-3.   98
 
CHAPTER 2: GENERAL METHODS 
 
2.1 Patients, Clinical Details and Dermal Biopsies 
2.1.1 Patients 
All SSc patients fulfilled the American College of Rheumatology (ARA) preliminary 
criteria for classification of SSc(Subcommittee for scleroderma criteria of the American 
Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980) as well as 
the criteria for SSc as proposed by LeRoy et al(LeRoy et al., 1988). All patients were 
undergoing treatment at the Royal Free Hospital and controls included healthy volunteers 
who do not have SSc. Informed consent and ethical approval according to local institutional 
guidelines were obtained from patients and control subjects. 
 
2.1.2 Clinical details 
Patients were classified as early dcSSc (n=14) if within the first two years of disease onset, 
defined by the appearance of the first non-Raynaud’s symptom. Patients with established 
dcSSc (n=8) had more than two years of disease. The methods used to determine the 
clinical and serological features of the SSc patients are discussed below together with the 
demographic features of the SSc and control subjects from whom the biopsies were taken. 
Major organ involvement was assessed according to standard clinical practice at the Royal 
Free Hospital, and broadly followed the SSc Severity Score (Medsger, Jr. et al., 1999). 
 
The extent of skin involvement in SSc is a reliable measurement of skin thickening and has 
been shown to reflect disease activity and associated with visceral involvement (Clements 
et al., 2000;Gifford, Jr. & Hines, 1960;Barnett & Coventry, 1969;Valentini et al., 2003).  
Several skin scoring methodologies have been presented including the modified-Rodnan 
total skin thickness score as discussed in Section 1.1.3.1, and this has been shown to be at 
least as reliable for measuring skin thickness in SSc as are the ARA and Ritchie joint 
tenderness counts for assessing joint disease in rheumatoid arthritis(Clements et al., 1995). 
The clinical and laboratory parameters used for the assessment of disease included duration 
of skin and Raynaud’s disease, pattern of major internal organ involvement and serology.   99
These patients’ characteristics are summarised in Table 2.1. Briefly, oesophageal 
involvement was determined by history, barium swallow or scintigraphy; lung fibrosis by 
high resolution CT scanning in the presence of a restrictive pattern of pulmonary function 
test abnormality; cardiac involvement by altered ECG, impaired ventricular function or 
pericardial effusion on echocardiography; PAH was determined by elevated pulmonary 
arterial peak systolic pressure on Doppler-echocardigraphy, other echocardiographic 
hallmarks of PAH and usually confirmed by right heart catheterisation. Creatinine kinase 
level elevated more than two fold defined skeletal muscle involvement.  Renal involvement 
was identified by previous SSc renal crisis or significant impairment of creatinine 
clearance.   Patients were treated with vasodilators and in most cases of dcSSc by current 
immunosuppressive regimen including anti-thymocyte globulin mycophenolate mofetil and 
cyclophosphamide according to standard protocol (Nihtyanova & Denton, 2008).   100
 
     Early  dcSSc   Established  dcSSc   lcSSc    Controls     
                            ( n=14 )    ( n=8 )        ( n=6 )      ( n=11 ) 
 
Gender  (M/F)     3/11    2/6     0/6    5/6 
Age (years,mean±sd)      49.3 ± 9.9    57.3 ± 12.4      44.3 ± 16.2              45 ± 14.4 
Duration of Disease       16.7 ± 4.2    69 ± 51.2      66 ± 58.2    - 
(months,mean±sd)  
Duration of Raynaud symptoms     18.9 ± 6.6    75 ± 53.2      154 ± 49.4    - 
(months,mean±sd) 
 
Organ Involvement, %   
    
Oesophageal           71          88         83   
Other gastrointestinal         14         25          33   
L u n g             3 6           5 0          1 7    
Muscle            14         13                    17   
Joint             14          0           0   
R e n a l             2 1             0          1 7    
Cardiac            7          0           0   
Neurological            0         13           0   
 
             A l l   d c S S c       l c S S c        
Serology, %            (  n=22  )      (  n=6  ) 
 
A n t i - n u c l e a r                   1 0 0         1 0 0    
Anti-centromere                0              67   
Anti-topoisomerase 1               32                        17   
Anti-RNA polymerase I/III                        9                         0   
A n t i  n R N P                   0               1 7    
Other                   59                         0   
 
Table 2.1 Clinical features of systemic sclerosis patients and healthy controls. Early dcSSc defined by less than 2 years duration.   101
2.1.3 Dermal biopsies 
For experiments described in this thesis, fibroblasts were grown from skin biopsies taken 
from SSc patients and from healthy volunteers or patients without SSc. For the SSc patients 
(22 patients with dcSSc and 6 with lcSSc), 3-6 mm punch biopsies were taken from the 
involved forearm skin on the non-dominant limb. Paired biopsy samples were obtained 
from patients with early dcSSc (n=14) and those with established dcSSc (n=8). Control 
biopsies were taken from normal forearm skin from 11 healthy volunteers using the same 
biopsy techniques as for SSc patients. Biopsies were immediately divided for tissue culture 
and snap frozen for histological study.  Biopsies of early stage dcSSc were taken prior to 
immunosuppressive treatment.  Patients with lcSSc were on vasodilator therapy only at the 
time of biopsy. Among patients with established dcSSc, 88% (n=7) were taking 
immunosuppressant therapy.  Three patients with lcSSc had pulmonary, renal and muscle 
involvement requiring low dose corticosteroids and immunosuppression.  
 
2.2 Cell culture 
2.2.1 Fibroblast lines 
Apart from the SSc dermal biopsies described above, murine fibroblasts derived from 
several sources were used for the experimental work in this thesis.  Tight skin (Tsk/1+), 
TβRIIΔk and 2kb-LacZ transgenic and control skin dermal fibroblasts were cultured from 
skin taken from the upper back of same-sex littermate mice. Murine and human fibroblasts 
were grown by standard explant technique(LeRoy, 1974). Briefly, tissue was dissected en-
bloc, subcutaneous fat was removed from the dermal aspect of the skin sample and finely 
minced under aseptic conditions in a laminar flow cabinet. After 15 min of drying at room 
temperature the pieces of biopsy were adherent to the tissue culture plastic and then the 
fibroblasts were grown by explant culture and maintained in Dulbecco's modified Eagle's 
medium (Gibco BRL, Grand Island, NY) supplemented with 10% fetal calf serum (Gibco), 
100 units/ml penicillin, and 100 mg/ml streptomycin, and maintained in a humidified 
atmosphere of 5% CO2 in an incubator (Hera Cell240) at 37
oC. At confluence, cells were 
trypsinized (0.125% trypsin in phosphate buffered Saline (PBS), 0.5 mM EDTA) and 
passaged. All cultures were inspected at high power using a phase-contrast inverted 
microscope to confirm absence of epithelial cells and a typical fibroblastic morphology.   102
Fibroblasts on reaching confluence were routinely re-cultured by diluting in a 1:3 ratio. For 
experiments, fibroblasts were used at the first or second passage because later-passage cells 
showed greater interculture variability. 
 
The TβRIIΔk strain was generated and characterised by Professor Christopher Denton at 
University College London and University of Texas, and has been described 
previously(Denton et al., 2003). In brief, a fibroblast-specific expression cassette was 
devised in which a target cDNA can be expressed together with a reporter marker gene 
(pCD3). The fibroblast-specific expression cassette contains a promoter enhancer fragment 
subcloned from the upstream and proximal promoter region of the proα2(I)collagen gene. 
This incorporates a fragment between -19.5 and -13.5kb upstream of the transcription start 
site linked to an endogenous minimal promoter and drives gene expression at high levels in 
fibroblasts, but not in other type I collagen-producing cells. Reporter genes linked to this 
promoter-enhancer show high level fibroblast-specific expression in embryonic 
development and postnatally. The mouse strain TβRIIΔk was generated by subcloning the 
cDNA encoding the extracellular and transmembrane portion of the human type II TGFβ 
receptor into the Sal1 site of the pCD3 expression vector. A bacterial β-galactosidase 
marker gene (LacZ) was co-expressed from a dicistronic transgene mRNA product via an 
encephalomyocarditis virus internal ribosome entry site sequence (IRES) (Kim et al., 
1992). Founders were previously shown to demonstrate consistent transgene expression in 
fibroblastic tissues.  
 
In addition, fibroblasts were cultured from a reporter transgenic mouse harbouring the LacZ 
reporter gene regulated by a central EcoRI fragment of the –19.5 kb to –13.5 kb enhancer 
described above, (–17.1 kb to –15.1 kb from the transcription start site, 2kb-LacZ) linked to 
the minimal endogenous COL1A2 promoter. In these mice, basal high-level expression of 
the reporter gene correlates with expression of that of collagen type I.  The cultured 
fibroblasts from the two transgenic murine strains were used in the functional studies of 
fibroblasts response to recombinant MCP-3 and TGFβ1 (Chapters 4 and 6). This allowed 
expression of the reporter transgene to be examined in tissue culture, and allowed the effect 
of recombinant MCP-3 and TGFβ1 on the level of transgene expression to be assessed. In   103
addition, tight-skin dermal fibroblasts were cultured from skin extracted from the upper 
back of same-sex littermate mice at different time-points: 1, 6 and 12 weeks. Selective 
upregulation of the 2kb-LacZ reporter transgene has been shown in vivo using Tsk1 mice 
and there are three Smad-binding consensus sequences within this 2kb-transgene, 
suggesting that there may be a functional TGFβ1 responsiveness for the transgene(Denton 
et al., 2001). However, this does not completely exclude that the upstream enhancer 
element may act by amplification of responses mediated via previously described TGFβ1-
responsive elements in the proximal promoter of the Col1a2 gene, which include a Smad3-
binding consensus sequence at -259 bp upstream of the transcription start site. In addition, 
human dermal fibroblasts were cultured from dcSSc patients and from age- and site-
matched control human skin. This is used for protein analysis for Western blot studies and 
ELISA (Chapters 3 and 6). 
 
2.2.2 TGF-β, MCP-3 and MCP-1 treatment 
Murine recombinant TGF-β1 and murine recombinant chemokines, MCP-3 and MCP-1 
(from R&D Systems) were used at 4 ng/ml and 200-400ng/ml respectively, unless 
otherwise stated. TGFβ, MCP-3 and MCP-1 were added to confluent fibroblast cultures and 
incubated for 24 hours unless stated otherwise, after which the cell monolayers were 
washed with fresh media and used immediately in the experiments detailed below. 
 
2.2.3 Transient transfection of promoter reporter constructs 
2.2.3.1 Promoter reporter constructs 
Apart from using primary cultures of dermal fibroblasts established from transgenic mice, 
transient transfection was used to assess MCP-3 and TGFβ responsiveness of pro 2(I) 
collagen promoter constructs. The reporter constructs are shown in Figure 2.1. These 
included minimal promoter sequences of mouse or human pro 2(I) collagen as well as 
constructs that incorporate sequences from the far-upstream fibroblast-specific enhancer 
previously defined in transgenic mice(Bou-Gharios et al., 1996). This element operates as a 
lineage-specific transcriptional enhancer in vivo and is a target for activation in Tsk1 
mice(Denton et al., 2001). Both the human and murine minimal promoter and 2kb-LacZ 
constructs were transfected into murine control fibroblasts.    104
 
To assess TGFβ1 responsiveness to MCP-3 (Chapter 7.4), an additional TGFβ-regulated 
promoter-reporter construct, 3TP-lux construct, which contains part of the promoter region 
of the plasminogen activator inhibitor-1 gene and three tandem repeats of AP-1-binding 
sites of the collagenase 1 gene (provided by Joan Massague, Memorial Sloan-Kettering 
Cancer Center, New York, New York, USA) is used. To examine the molecular 
mechanisms underlying the activation of MCP-3 by TGFβ in dermal fibroblasts, a 1kb 
upstream fragment of the murine MCP-3 promoter was generated from pUC19 plasmid 
cloning vector containing a 4.7kb MCP-3 promoter(Murakami et. al., 1997). This construct 
was cloned into the luciferase reporter vector pGL3 (Promega). 
 
For the human proα2(I) collagen gene (COL1Α2-LacZ) and murine proα2(I) collagen gene 
(Col1a2-LacZ), 1 μg of collagen reporter plasmid was cotransfected with 0.1 μg of 
pCMVluc control plasmid to allow correction of β-galactosidase expression for transfection 
efficiency.  For cells cotransfected with the 1 kb-MCP-3 promoter construct linked to 
luciferase reporter gene, the cells were cotransfected with a CMV
 promoter-driven β-
galactosidase (0.1 μg/well) expression from which was used to adjust for differences in 
transfection
 efficiencies among wells.  
 
2.2.3.2 Transfection methods 
Transient transfection of fibroblasts was performed using liposomal formulated, 
Lipofectamine Plus (Invitrogen) or non-liposomal formulated FuGENE 6 (Roche) 
transfection reagents. Briefly, fibroblasts were plated at 50-80% confluence in 12-well 
culture plates in the appropriate growth media prior to the day of experimentation. After 18 
hours seeded cells were rinsed with DMEM and maintained in 0.5 ml of DMEM containing 
0.2% FCS for 4 hours.  
 
For transfections with FuGENE 6, serum and antibiotic free DMEM was warmed to 37
oC 
and 50 µl per well, was transferred to a microfuge tube and the appropriate volume of 
FuGENE 6 per transfection added. The tube was mixed by tapping and incubated for 5 min 
at room temperature. DNA (500 ng per well) was added and the sample incubated at room   105
temperature for a further 15-30 min.  The complex was added drop-wise to its designated 
well and the plate swirled to ensure even mixing of the complex in all the wells.  The cells 
were returned to the incubator and maintained in a humidified atmosphere containing 5% 
CO2 at 37
oC. After 8 hours, media was replaced with the DMEM containing 0.2% FCS.  
 
Transient transfection of fibroblasts with Lipofectamine Plus (Invitrogen) was performed in 
a similar manner to that of FuGENE 6. Briefly, serum and antibiotic free DMEM was 
warmed to 37
oC and 50 µl per well, was transferred to a microfuge tube and DNA (500 ng 
per well) and 4 µl of Plus reagent (Invitrogen) was added and the ‘pre-complex’ sample 
incubated at room temperature for 15 min. To 50 µl of serum and antibiotic free DMEM 2 
µl lipofectamine (Invitrogen) reagent per transfection was added. The tube was mixed by 
gentle tapping and added to the ‘pre-complex’, mixed and incubated at room temperature 
for a further 15 min. The lipofectamine/DNA complex was added drop-wise to its 
designated well and the plate swirled to ensure even mixing of the complex in the wells. 
The cells were returned to the incubator and maintained in a humidified atmosphere 
containing 5% CO2 at 37
oC. After 8 hours, media was replaced with the DMEM containing 
0.2% FCS and, where appropriate, recombinant TGFβ1 and MCP-3 added for a further 24 
hours. Following this, media was collected. The cell monolayer was washed once with PBS 
and lysed in 120 µl of lysis buffer (Tropix). Both media and lysed monolayers were stored 
at -20
oC. Reporter gene activity was determined as below. All cell mono-layers were 
assessed for cell viability by visual appraisal.  
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Figure 2.1 Transgene constructs harbouring far-upstream enhancer elements of the 
mouse or human proα2(I) collagen gene. 
The minimal promoter sequences were defined from -354 bp and -378 bp upstream of the 
transcription start site for the mouse and human pro 2α(I) collagen genes, respectively. 
Larger constructs incorporated additional sequences from the evolutionarily conserved far-
upstream transcriptional enhancer that has previously been shown to be a target for 
activation in fibrosis. The 6kb-LacZ construct includes the region from -19.5 kb to -13.5 kb 
upstream of the transcription start site, and the 2kb-LacZ incorporates 2 kb of the upstream 
region linked to a minimal murine -354-bp promoter. Construction of the human 5kb-LacZ 
contains sequences -22.8 kb to -17.5 kb, which is linked to a minimal -378-bp promoter. 
 
2.2.3.3 Determination of Luciferase and β-galactosidase reporter gene activity 
Expression of luciferase and β-galactosidase was determined using the Dual light system as 
per the manufacturer’s instructions (Applied Biosystems). Briefly, to 10 µl of each lysed 
cell mono-layer 25 µl of Buffer A, equilibrated to room temperature, was added and the 
mixture incubated at room temperature. After 5 min, room temperature equilibrated Buffer 
B containing the galactosidase substrate Galacton-Plus (1:100 Galacton-plus to Buffer B) 
was added and luciferase signal read for 2 sec. After a further incubation of 30 min, 100 µl   107
of Accelerator-II was added to each well and galactosidase activity (RLU) from the co-
transfected CMV-β-Galactosidase constructs determined for 0.2 sec. All luciferase RLU 
values were normalised to galactosidase RLU in order to control for transfection 
efficiencies. 
 
2.2.3.4 Smad3 siRNA transfection studies 
RNA interference is used by most eukaryotes in vivo for anti-viral defence and gene 
regulation and this is a major tool for gene silencing. Enzymatically processed from long 
double-stranded RNAs, small interfering RNAs (siRNAs) are short RNA duplexes of 19-21 
nucleotides with two nucleotide 3 overhangs on each strand. The complex formed by an 
assembly of these siRNAs suppresses the expression of a target protein by stimulating the 
specific degradation of the target mRNA homologous to the integral siRNA. The target 
mRNA is cleaved in the region complementary to the siRNA, with the net result being 
rapid degradation of the target mRNA and decreased protein expression. 
 
Smad proteins are important downstream effectors of TGFβ signalling and Smad3 is 
involved in TGFβ and activin-mediated growth modulation. Smad3 siRNA is a pool of 3 
target-specific 20-25 nucleotide siRNAs designed to knock down expression of Smad3 
protein in murine cells. As a negative control, non-silencing or control siRNA with non-
targetting 20-25 nucleotide siRNA is used. 
 
Cells were incubated at 37
0C until 60-80% confluence was attained. A combination of 
diluted Smad3 siRNA and siRNA transfection reagent in transfection medium were gently 
mixed in a microfuge tube by pipetting in the absence of serum or antibiotics. This mixture 
was incubated for 45 minutes at room temperature. For each tube containing the siRNA, the 
total volume of mixture was made up to 1 ml with transfection medium. This mixture was 
gently agitated and overlaid onto each well of the cultured murine fibroblasts. The cells 
were incubated for 5 hours at 37
0C in a CO2 incubator. Following this, an equal volume of 
DMEM containing 5% FCS was added and the mixture was incubated overnight. The 
following day, the medium was aspirated and replaced with fresh DMEM containing 0.2% 
FCS for 4 hours. Recombinant TGFβ1 and MCP-3 was added overnight.                     108
   
2.3 Molecular Biology Techniques 
Unless stated, all chemical reagents used were molecular biology grade and supplied by 
Sigma-Aldrich. 
 
2.3.1 Bacterial culture 
E. coli were grown in Luria-Bertani broth (LB) (Tryptone 10g/l; Yeast extract 5g/l; NaCl 
10g/l supplemented with ampicillin at the specified concentration.  
 
2.3.1.1 Strains 
DH5α (genotype: F- Ф80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17 PhoA 
SupE44 thi-1 gyrA96 relA1 λ
-) competent (1x 10
8 /µg DNA) were purchased from 
Invitrogen. 
 
2.3.1.2 Selection 
For experiments with E. coli harbouring plasmids encoding the ampicillin resistance gene, 
transformed cells were plated on LB-agar (LB containing 15% agar [Sigma Aldrich]) 
containing ampicillin at 100 µg/ml. Selection was maintained during growth in liquid 
culture by the inclusion of ampicillin at 50µg/ml.  
 
For experiments using Transforming One Shot Competent E.coli cells harbouring plasmids 
encoding the kanamycin resistance gene in the TOPO cloning reaction (Invitrogen), S.O.C. 
medium containing 1.2 M NaCl and 0.06 MgCl2 was used to adjust the cloning reaction to 
the recommended final concentration of 200 mM NaCl and 10 mM MgCl2 to maximize the 
number of colonies on LB plates containing 50 µg/ml kanamycin. Once the correct clone 
was identified, a glycerol stock of the plasmid was prepared by streaking the original 
colony on LB plate containing the appropriate antibiotics. A single colony was isolated and 
inoculated into 1 ml of LB with the antibiotic and 0.85 ml of the culture was mixed with 
0.15 ml of sterile glycerol in a cryovial for storage at –80
0C. 
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2.3.2 Plasmids 
2.3.2.1 Cloning vector pGL3 
The pGL3 basic cloning vector (Promega) is derived from pUC19, with beta-lactamase 
gene conferring ampicillin resistance and a ColE1 origin of replication for propagation in E. 
coli. The synthetic multiple cloning site (MCS) contains 8 unique restriction sites. The 
plasmid also harbours contains a modified coding region for firefly (Photinus pyralis) 
luciferase that has been optimized for monitoring transcriptional activity of cis-acting 
factors such as promoters and enhancers in transfected eukaryotic cells.  
 
Using the following primers, sequencing of the 1kb MCP-3 promoter construct cloned into 
the pGL3 reporter vector was performed to confirm the correct position of the construct.  
5’-CTG CTG GCT GTT GAA GTC –3’       
5’-GCC ACC AGG ATT TAA GAC AGT G-3’     
5’-CTT TAT GTT TTT GGC GTC TTC CA-3’     
5’-CTA GCA AAA TAG GCT GTC CC-3’       
 
2.3.2.2. pCR-Blunt II-TOPO plasmid vector 
Zero blunt TOPO PCR Cloning (Invitrogen) provides a one-step cloning strategy to insert 
directly the blunt-end 1kb-MCP-3 promoter PCR product into pGL3-Basic vector. The 
pCR-Blunt II-TOPO is supplied linearised with Vaccinia virus DNA topoisomerase I 
covalently bound to the 3’ end of each DNA strand.  
 
Topoisomerase I binds to duplex DNA at specific sites and cleaves the phosphodiester 
backbone after 5’-CCCTT in one strand(Shuman, 1991). The energy released from the 
broken phosphodiester backbone is conserved by formation of a covalent bond between the 
3’phosphate of the cleaved strand and a tyrosyl residue (Tyr-274) of topoisomerase I. The 
phospho-tyrosyl bond between the DNA and enzyme can subsequently be attacked by the 
5’ hydroxyl of the original cleaved strand, reversing the reaction and releasing 
topoisomerase(Shuman, 1994). This reaction provides the mechanism in which PCR 
products is cloned and transformed into E. coli competent cells. 
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2.3.3 Transformation of competent bacteria with plasmid DNA 
Frozen competent cells (Invitrogen) of the E. coli strain DH5α were placed on ice until 
thawed.  Plasmid DNA was added to pre-chilled microfuge tubes containing 100 μl of 
competent cells, gently mixed and left on ice.  After 30 min the DNA/competent cells were 
heat shocked by placing the microfuge tubes in a water bath at 42
oC for 60 sec, and 
subsequently transferred back onto ice for a further 3 min.  900 μl of LB medium was 
added and incubated for 45 min at 37
oC with agitation.  The bacterial cells were then 
pelleted by centrifugation (Heraeus Biofuge Fresco) at 12,000 revolutions per min (rpm) 
for 30 sec and resuspended in 50 μl of LB media and plated onto selection plates.  Plates 
were dried then inverted and incubated at 37
oC overnight(Cohen et al., 1972). 
 
2.3.4 Isolation of plasmid DNA 
2.3.4.1 Mini-plasmid preps 
Individual colonies were picked from plates and inoculated into 3 ml of LB Ampicillin 
broth and the plasmid DNA isolated using an alkali lysis procedure. Briefly, 1 ml of 
medium was transferred to a microfuge tube and the bacteria were pelleted by 
centrifugation at 13,000 rpm for 1 min and resuspended in 300 µl of resuspension buffer 
(50mM Tris.Cl, pH 8.0; 10 mM EDTA; 100 µg/ml RNase A).  The cells were lysed by the 
addition of an equal volume of lysis buffer (200 mM NaOH; 1% SDS (w/v)) and the 
solution mixed gently and incubated at room temperature until the solution cleared, 
whereupon an equal volume of neutralisation buffer (3 M potassium acetate, pH 5.5) was 
added and the solution agitated strongly. The precipitate of cell debris, chromosomal DNA 
and SDS was pelleted by centrifugation at 13,000 rpm for 15 min at 4°C. The supernatant 
was removed, 0.7 volumes of propan-2-ol added and the plasmid DNA precipitate pelleted 
by centrifuged at 13,000 rpm for 30 min at 4°C. The pellet was washed with 80% EtOH air 
dried, and resuspended in 50 µl of TE buffer (10 mM Tris-HCl (pH8.0) 0.1 mM EDTA). 
All plasmids were validated by diagnostic restriction digestion and agarose gel 
electrophoresis as described in 2.3.5 and 2.3.6. 
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2.3.4.2 Maxi-plasmid preps 
100 ml of LB containing 100μg/ml Ampicillin were inoculated with 100μl of mini-prep 
culture and grown with agitation over night (as above).  Plasmid DNA was isolated based 
on a modified alkaline lysis (Birnboim & Doly, 1979) procedure followed by binding of 
plasmid DNA to an anion–exchange resin, as per the manufacturer’s instructions (Qiagen, 
UK).  In short, the overnight bacterial culture was pelleted by centrifugation at 3000 rpm 
for 10 min, and the resuspended in 20 ml of resuspension buffer.  The cells were lysed by 
the addition of an equal volume of lysis buffer, and the solution mixed gently at room 
temperature until the solution cleared, whereupon an equal volume of neutralisation buffer 
was added and the solution agitated strongly.  The precipitate of cell debris, chromosomal 
DNA and SDS was pelleted by centrifugation at 10,000 rpm for 15 min at 4°C. The 
supernatant was removed and passed over the Qiagen Anion-Exchange resin, the bound 
plasmid DNA washed with low salt buffer (1 M NaCl; 50 mM MOPS, pH 7.0; 15% 
isopropanol (v/v) and finally eluted in 5 ml space of elution buffer (1.6 M NaCl; 50 mM 
MOPS, pH 8.5; 15% isopropanol (v/v)).  The eluted DNA was precipitated with the 
addition of 0.7 volumes propan-2-ol, and the DNA pellet washed in 80% EtOH and air 
dried. The DNA pellet was resuspended in appropriate volume TE buffer and the 
concentration was determined from the absorbance at A260 of the preparation, assuming that 
a DNA solution of 50 µg/ml in water gives a value of A260 = 1 using a spectrophotometer 
(Hitachi U2001).  Plasmid DNA was stored at 1 mg/ml in TE, at 4°C (short term) or -20°C 
(long term).  
 
2.3.5 Restriction enzyme digests 
Restriction enzymes were used according to the manufacturer’s instructions (Promega). In 
general, 5μg of plasmid DNA was cut with 50 units of restriction enzyme for 18 h at 37°C 
in the presence of 150µg/ml bovine serum albumin (BSA) to stabilize the enzyme. Where 
multiple digests were to be performed, the buffer conditions were selected to be compatible 
with both enzymes.  
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2.3.6 Agarose gel electrophoresis of DNA 
Gels were prepared by boiling the appropriate mass of low melting point or general purpose 
agarose in 1x Tris-Acetate-EDTA (TAE; 242 g Tris base, 57.1 ml Acetic acid and 100ml 
0.5M EDTA to a total volume of 1 liter with ddH20 and adjusted to pH to 8.5) cooling to 
50°C before adding Ethidium Bromide (EtBr) at 1 µg/ml and then setting this in the chosen 
gel former; "mini" gels (6.5 x 10 x 1 cm, 15 sample wells). All gels were run in 1xTAE; at 
10 volts/cm. DNA fragments were satisfactorily resolved on 1-2% agarose gels.  
 
2.3.7 Detection and isolation of DNA fragments 
Ethidium bromide intercalates DNA, and in this state fluoresces when illuminated by 
ultraviolet (UV) light. DNA was visualised by illuminating the gel with short wave UV 
light on a transilluminator (Stratagene). When DNA was to be recovered from the gel, a 
hand-held long wavelength lamp was used to avoid damage to the DNA. DNA fragments, 
after restriction endonuclease digestion, were excised from the agarose gel and the slice 
containing the DNA fragment purified as per manufacturer’s instructions using QIAquick 
gel extraction (Qiagen).     113
 
2.3.8 Analysis of fibroblast mRNA by Northern Hybridisation 
2.3.8.1 RNA extraction from fibroblast monolayers 
RNA was extracted from fibroblast monolayers using TRIzol reagent (Life Technologies) 
according to the manufacturer’s instructions.  Briefly, culture medium was aspirated and 
cells were gently washed with sterile PBS at 4oC.  The PBS was removed and 1 ml of 
TRIzol per 10
6 cells was added to each dish and incubated at room temperature for 10 min 
to lyse the cells.  The lysate was pipetted several times then 1ml was transferred to a 1.5ml 
RNase free microfuge tube.  Upon transfer 0.2 ml of chloroform was added per 1ml.  Tubes 
were shaken vigorously for 15 sec and then incubated at room temperature for a further 2 
min.  The samples were then centrifuged at 13,000 rpm at 4
oC for 15 min.  After 
centrifugation the aqueous phase was transferred to a fresh 1.5ml tube and an equal volume 
of isopropanol was added to precipitate the RNA.  After 5 min incubation the sample was 
centrifuged at 12,000xg at 4
oC for 30 min.  The pellet was washed in 80% ethanol and 
resuspended in an appropriate volume of diethylpyrocarbonate (DEPC) treated water.  To 
confirm integrity a sample of the RNA was subjected to gel electrophoresis.  
 
RNA concentration and purity were measured spectrophotometrically (Hitachi U2001) by 
determining the absorbance of a diluted aliquot (of 4 µl of sample with 796 μl DEPC 
treated water in a quartz cuvette) at 260nm. The RNA concentration was determined based 
on the absorbance co-efficient of an OD260nm=1 equivalent to a RNA solution of 40 µg/ml. 
The absorbance of the solution at 280nm was also measured and a ratio of OD 
260nm:280nm was used as an index of purity.   
 
2.3.8.2 Northern blotting  
Electrophoresis of RNA and transfer to Hybond membrane. RNA samples were 
electrophoretically separated on a 1% (w/v) denaturing formaldehyde-agarose gel.  This 
was prepared by dissolving 1g of molecular biology grade agarose in 66 ml DEPC treated 
water, adding 20 ml of 5X gel running buffer (0.1M MOPS, 40mM sodium acetate, 5mM 
EDTA, pH7.0) and then 14 ml 2.2 M formaldehyde to a final gel concentration of 2.2M.  
Samples were prepared as follows: 10 μg of RNA was added to a microfuge tube and   114
DEPC-treated water added to a final volume of 4.5 µl to which formaldehyde (3.5 µl), 
formamide (10 μl) and 5X running buffer (2 μl) were added.  This sample mixture was 
incubated at 65
oC for 15 min, and kept on ice before loading. Prior to loading, 2 µl of 6X 
gel loading buffer (50% glycerol, 1mM EDTA, 0.25% bromophenol blue, 0.25% xylene 
cyanol) was added to each sample.  The gel was pre-run for 5 min at 5V/cm
 then samples 
were loaded and electrophoresis performed for 1-2 h at 3-4V/cm. 
 
The agarose gel was rinsed in DEPC-treated water to remove the formaldehyde and soaked 
in 20X sodium chloride-sodium citrate (SSC) buffer (3.0 M NaCl, 0.3 M Na-citrate) for 45 
min.  The gel was placed on blotting paper, pre-soaked in 20X SSC, hybond membrane 
placed on top of the gel and a piece of pre-soaked blotting paper placed over the membrane.  
Multiple (8-10) dry blotting papers were placed on top of the soaked layer, a glass plate 
was placed over the dry layers and transfer performed for 4-12 h at room temperature. After 
transfer the RNA was UV cross linked to the hybond membrane (15 sec at 254nm) using a 
UV stratalinker (Stratagene). 
 
Radiolabelling of cDNA probes. Labelling of DNA fragments specific for conserved region 
of the pro-α2(I)collagen mRNA was performed using a Megaprime labelling kit 
(Amersham Life Sciences) according to the manufacturer’s instructions.  The Cola2(I) 
probe was a 200bp fragment (PstI-EcoRI) coding for the C-terminal region of the mouse 
Cola2(I) gene in pBluescript II(Ponticos et al., 2004). In brief, approximately 25 ng of 
template DNA was added to 5 µl of random primers and boiled for 5 min to denature the 
DNA.  The tube was placed on ice and 10 µl labeling buffer, 5 µl of αP
32 dATP (250 uCi; 
9.25 MBq) and 2 µl of DNA polymerase (Promega) were added.  The mixture was then 
incubated for 30 min at 37
oC.  The labelling reaction was stopped by addition of 50 µl of 
4M ammonium acetate (pH4.5) and the probe purified from unincorporated radiolabel 
using a microspin G50 column (Amersham Life Sciences) as per manufacturer’s 
instructions. Using this protocol, probes were labelled to a specific activity of at least 10
9 
dpm/μg. 
 
Hybridisation. The hybridisation bottle was half-filled with 2X SSC, and the membrane 
applied to the inside wall of the bottle. The SSC was poured off and replaced with 5ml   115
Rapid-hyb (Invitrogen) buffer. The membrane was pre-hybridised in a Hybaid oven at 65
oC 
for 15 min. Prior to the addition of the labelled probe to the hybridisation buffer, cDNA 
was denatured by boiling for 5 min. The labelled probe was added and hybridisation 
performed at 65
oC for 2 h.  The membrane was washed twice with 2X SSC at room 
temperature, twice with 1X SSC at 65
oC and then rinsed in 2 X SSC.  
 
Autoradiography and quantitation. The membrane was placed against X-Ray film, and left 
at -70
 oC between 12-72 h.  X-ray films were digitised using a digital camera (UVP v1.0) 
and UVP Grab software (Synoptics, UK). 
 
2.3.9 Analysis of gene expression by cDNA microarray 
In this thesis, murine fibroblastic gene expression analysis was performed using the Atlas 
mouse cDNA expression array (Version 1.2, ClonTech, Palo Alto, CA).  
Total mRNA was prepared from confluent cultures of early passage adult Tsk1 and 
neonatal wildtype, Tsk1 and TβRIIΔk dermal fibroblasts as described in Section 2.3.8.1. 
Briefly, cell monolayer were washed twice with PBS, TRIzol
 (Invitrogen) lysis reagent 
added for 10 minutes and then RNA was recovered by alcohol precipitation.  
 
2.3.9.1 Probe labeling, prehybridisation, hybridisation and washing 
A radioactively-labelled cDNA probe was synthesised from the sample RNA by reverse 
transcription using MMLV-reverse transcriptase, α-P
32, DTT, dNTPs and a gene specific 
cDNA synthesis (CDS) primer mix supplied with the array which is enriched for sequences 
corresponding to the cDNA for the genes on the array, thus ensuring high specificity and 
increasing the rate of reaction. 
 
This probe was then purified by the Nucleospin Column protocol supplied with the arrays. 
Prehybridisation of the membranes was carried out using 5ml ExpressHyb
TM solution 
(ClonTech) and denatured sheared salmon testes DNA for two hours at 68
0C. After this 
time, the purified probe was then added directly to the hybridisation solution, and incubated 
overnight at 68
0C with constant rotation. Following this, the arrays were washed in three 
changes of Wash Solution 1 (2x SSC, 1% SDS) at 68
0C for 30 min each, and then washed   116
in Wash solution 2 (0.5x SSC, 0.5% SDS) at 68
0C for 30 mins. A final 5 min wash at room 
temperature in 2x SSC was carried out with constant agitation, before the arrays were 
quickly sealed in plastic wrap. These high-stringency washes ensured removal of all 
unbound radioactive label, leaving the arrays to be analysed using a phosphoimager screen.  
 
2.3.9.2 Analysis of cDNA microarrays 
The phosphoimager images of each filter were obtained using the ImageQuant
TM software 
package and analysed using the ClonTech AtlasImage
TM software. Normalisation using the 
sum global intensities of the arrays was chosen with the local background for each cDNA 
spot taken into account. A significance level of a 2-fold difference in gene expression was 
selected so as to decrease biological noise. 
 
2.3.9.3 Stripping of cDNA microarrays 
The procedure detailed below allowed the arrays to be stripped of radioactivity and reused 
at least three times. The arrays were heated to 95-100
0C for 5-10 mins in 0.5% SDS in 
DEPC-treated water, and then left standing for a further 10mins. The arrays were then 
rinsed in Wash Solution 1 (2x SSC, 1% SDS), and then quickly wrapped in plastic wrap 
and stored at -70
0C. At no point were the arrays allowed to even partially dry.  
 
2.3.10 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was used to clone the upstream 1kb promoter for 
MCP-3 gene contained within the pUC19 plasmid cloning vector which was donated by 
Professor Van Damme, Belgium. This fragment was amplified by the polymerase chain 
reaction (PCR). Briefly, DNA (100ng) was mixed with PCR primers (1-3μM), reaction 
buffer (67mM Tris-Base, 16.6 mM Ammonium Sulphate, 2mM Magnesium Chloride, 
0.02% (v/v) Tween20), dNTP (10mM) and Pfu DNA polymerase. Samples were overlaid 
with 10ul of mineral oil (Sigma) in order to avoid evaporation and amplified using the 
thermal cycler PTC-100 (MJ Research Inc). The resultant DNA fragments were analysed 
by agarose gel electrophoresis (0.8%) in presence of ethidium bromide (0.08% v/v). The 
PCR reaction was diluted with Orange G loading solution (2μl) (Ficoll 20% w/v, Orange G 
0.25% w/v) and then loaded into the wells of the flat-bed agarose gels. Electrophoresis was   117
carried out at 100V with TBE buffer (1x, 18 mM Tris-borate and 4mM EDTA) and the 
migration of DNA fragment was monitored. Following the electrophoresis the gels were 
visualised under UV light and documented by photography using the UVP camera (Ultra 
Violet Productions Ltd., UK) Grab-IT annotation image capture system package with Sony 
digital graphic printer (UP-D860D). 
 
2.4 Protein extraction 
2.4.1 Preparation of total protein samples 
Fibroblasts were grown to confluence in six-well tissue culture plates in DMEM with 10% 
fetal calf serum.  The medium was replaced with DMEM containing 0.2% FCS for 24 h. 
Cell monolayers were washed twice in serum-free medium and replaced with DMEM 
containing 0.2% FCS for 24 h in the presence or absence of recombinant TGF-β1or 
chemokines, MCP-3 and MCP-1 for a further 24 h.  For experiments where collagen type I 
was to be assessed, 1 ml of media was removed and 300 µl saturated ammonium sulfate 
added, and the sample incubated at 4oC with rotation overnight. The next day the samples 
were centrifuged at full speed (13,000 rpm) for 30 min at 4oC, and the pellet was 
resuspended 50 µl of RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.4 mM EDTA 1 mM 
PMSF; 1% NP-40; 1% Sodium deoxycholic acid; 0.1% SDS; 1% protease inhibitor cocktail 
inhibitor (Boehringer Mannheim).  For all cell-associated proteins, cell monolayers were 
washed twice in ice cold PBS and lysed in 150 µl RIPA buffer. The lysed cells were 
scraped and DNA sheared by repeated passage of the sample through a 23-gauge needle.   
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2.4.2 Protein Expression- Western blot analysis 
2.4.2.1 Electrophoresis and transfer of protein samples for Western blotting 
Protein samples had an appropriate volume of 6x Laemmli sample buffer (0.2 M Tris-HCl, 
pH 6.8, 8% SDS, 40% glycerol, 0.004% bromophenol blue) and 1 µl of 14.2 M β-
mercaptoethanol, added and were heat denatured at 100
0C for 3 min. The proteins are 
resolved by passing a current across a polyacrylamide gel, separating protein based on size. 
20 μl, containing 10-20 μg of protein were run upon a ready-cast 18% Tris-Glycine gel 
(Invitrogen) alongside a broad-range protein marker (New England Biotech) at 100V, until 
the dye front had reached the bottom of the gel (approximately 1 ½ h) in 1x Tris-Glycine 
Running Buffer (Invitrogen). This was carried out within an Electrophoresis tank 
(Invitrogen), ensuring that the running buffer (25 mM Tris Base, 192 mM Glycine, 0.1 % 
SDS, pH 8.3) completely covered the gel at all times. Equal sample loading was ascertained 
with 0.2% Coomassie Blue (LKB, France), followed by de-staining with a 30% methanol, 
10% acetic acid buffer (VWR, UK). 
 
Each gel was removed from the casing and placed within a transfer set-up, using 
chromatography paper, Hybond C+ membrane (Amersham), and sponge filters. All these 
components had previously been soaked in 1x transfer buffer (25 mM Tris Base, 192 mM 
Glycine, 20 % Methanol).  The transfer set-up was then carefully placed within a transfer 
module (Invitrogen) and placed in an electrophoresis tank (Invitrogen), completely 
submerged in 1x transfer buffer. Overheating during transfer was prevented, by 
surrounding the transfer module with cold water.  The transfer was then allowed to proceed 
at 30V for approximately 1½ h.  After this time, the blue dye from the protein markers 
could be clearly seen transferred onto the Hybond™ membrane, indicating that transfer had 
occurred.  Each membrane was removed from the transfer apparatus and protein transfer 
confirmed by staining for 1 min in Ponceaus solution (0.1% Ponceaus S (w/v), 5% acetic 
acid (v/v)). Membranes were washed in 0.5% PBS-Tween for three washes of 10 min, with 
constant agitation. For detection of type I collagen samples were resolved on a 6% Tris-
Glycine gel (Invitrogen) as described above. 
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2.4.2.2 Immunoblotting  
Immunoblotting was performed by incubating the membranes in PBS-Tween (0.01% (v/v) 
Tween 20) with 5% non-fat dry milk at 4oC overnight to block non-specific antibody 
binding.  The blocking solution was removed and the primary antibody added at the 
appropriate concentration to PBS-Tween (0.01% (v/v) Tween 20) with 5% non-fat dry milk 
and incubated for 2 h at room temperature. The membranes were then washed in PBS-
Tween, three times for 15 min and then incubated with the appropriate biotinylated species-
specific secondary antibody in PBS-Tween containing 5% milk at room temperature for 1 
h. The membranes were washed three times before staining with biotin substrate 
(Vectastain; Vector Laboratories, Peterborough, UK), then chemiluminescent substrate 
(Amersham Pharmacia Biotech), and developed against photographic film (Hyperfilm 
ECL;Amersham Pharmacia Biotech) for between 30 sec and 5 mins. 
For western blots for phosphorylated proteins PBS was replaced with Tris-Buffered Saline 
(TBS; 0.05M Tris Base, 0.9% NaCl, pH 7.6). Selected blots were washed and reprobed 
with a monoclonal antibody against β-actin (Sigma) or GAPDH (Abcam) to control for 
small variations in protein loading and transfer. 
 
2.4.3 Protein Expression – Measurement of MCP-3 with ELISA 
Serum, blister fluid and fibroblast cell culture supernatant samples were taken from patients 
with SSc, following
 consent, and were then stored at –20°C over
 a short period of time. 
Dermal interstitial fluid
 was derived by a suction blister technique from the lesional
 skin of 
SSc patients, and from the forearm skin of healthy
 controls(Dziadzio et al., 2005). Fluid 
obtained using this technique has the
 properties of an interstitial fluid sample, and does not 
arise
 by exudation of fluid and protein from the vascular space.  
Quantitative measurement of MCP-3 in these samples was undertaken using specific
 
enzyme-linked immunosorbant assay (ELISA) kit (Biosource Europe S.A.). All samples 
were
 tested in triplicate, the minimum detectable dose of MCP-3 was
 less than 2 pg/ml. A 
standard curve was used as reference, this
 was obtained by increasing dilutions of a stock 
solution provided
 by manufacturer to obtain eight different concentrations, each
 of which   120
was also tested in duplicate. Briefly, 100 µl of each sample was
 added into each well of a 
96-well
 microplate that was pre-coated with capture monoclonal antibody specific
 for 
MCP-3 and 50 ul of biotinylated monoclonal antibody for MCP-3. After 2 h incubation at 
room temperature, each well
 was thoroughly washed three times using an automated ELISA 
plate
 washer. 100 ul of diluted Streptavidin-peroxidase conjugate were then added to each
 
well to bind to the biotinylated antibody and incubated for 30 min. After washing, 100 µl
 of 
chromogenic solution were added and incubated for 15 min. 100
 µl of Stop solution were 
then added and the absorbance at 460nm was determined spectrophotometrically according 
to the manufacturer’s instructions. Test sample MCP-3 concentrations (range 0-1000pg/ml) 
were determined from the standard calibration curve. 
 
2.5 Immunohistochemical analysis of cryosections 
2.5.1 Tissue processing and preparation 
Murine and human dermal samples were obtained as described in Sections 2.1.3 and 2.2. 
These tissue samples were snap frozen in liquid nitrogen and mounted onto cork with 
optima cutting compound (OCT, Miles, Cal), snap frozen in liquid nitrogen cooled 
isopentane (BDH, UK). Serial frozen sections (5μm) were cut on a Bright cryostat at -25
oC 
and air-dried for at least 1 hour.  
 
2.5.2 Immunohistochemical staining 
Prior to staining, sections were fixed in ice cold acetone for 10 minutes at 4
oC and then 
washed in PBS. Endogenous peroxidase was then quenched by incubation with 0.3% (v/v) 
hydrogen peroxide in methanol (VWR, UK) at room temperature for 15 minutes in the 
dark. Sections were then washed in PBS and non-specific binding of immunoglobulins was 
blocked by treatment with 2.5% (v/v) normal serum (Vector Laboratories, UK) for 30 
minutes after which sections were incubated with primary antibodies for 1 hour at room 
temperature or overnight at 4
oC. The primary antibodies used were goat polyclonal anti-
mouse MARC/MCP-3 and goat polyclonal anti-human MCP-3 IgG antibody. Other 
monoclonal antibodies used in this thesis were directed against cell-specific antigens 
including fibroblast, endothelial cell, α-smooth muscle actin and macrophage CD68 surface 
marker.     121
 
After washing in PBS, sections were incubated with a species-specific biotinylated 
secondary antibody (Vector Laboratories, UK) for 30 minutes, rinsed in PBS and incubated 
with Vectastain avidin biotin complex (ABC)-peroxidase conjugate,(Vector Laboratories, 
UK) for 30 minutes. After washing in PBS, sections were visualised using 3-amino-9-
ethylcarbazole (AEC) (Vector Laboratories, UK). Sections were then washed in tap water, 
counterstained with Meyer’s haematoxylin and mounted with aqueous media 
(Crystalmount, Biomeda, UK). Sections were viewed and photographed on an Olympus 
BH-2 photomicroscope. Controls included omission of the primary antibodies and primary 
antibodies substituted with goat isotype-matched IgG. All incubations were carried out at 
room temperature. For haematoxylin and eosin staining, sections were stained in 
haematoxylin for 1 minute and blued in 0.5 M sodium tetraborate for 15 secs. Sections 
were then stained in eosin for 1 minute, washed in water and dehydrated through the 
ethanol solutions and cleared in xylene before mounting. 
  
2.6. Statistical Analysis 
For quantitative variables, the mean ± SEM results from replicate samples, or from 
combined independent experiments where between-experiment variation allowed reliable 
combination of raw data, were compared. Statistical
 analysis was performed by the 
Student's unpaired t test. p values
 less than 0.05 were considered statistically
 significant.   122
 
 
CHAPTER 3: MOLECULAR ANALYSIS OF MOUSE MODELS OF FIBROSIS 
IDENTIFIES OVEREXPRESSION OF MCP-3 
3.1 Introduction 
Animal models are useful in providing clues for understanding biologically complex human 
diseases and for elucidating pathogenesis of diseases. They also provide the platform in 
which pharmacokinetics, toxicities and effectiveness of potentially novel therapies may be 
studied. Although there are currently no animal models that recapitulate the major features 
of SSc (vasculopathy, autoimmunity and fibrosis), several experimental models exist for 
studying the fibrotic process. Two important models that are particularly useful in 
elucidating the pathophysiology of fibrosis are Tsk1/+, the heritable mouse model of 
fibrosis and the transgenic mouse strain, a novel genetically engineered gain-of-function 
mouse model with spontaneous development of SSc-like fibrotic phenotype. First described 
more than half a century ago, the Tsk1 mouse model demonstrates the fibrotic phenotype 
with diffuse thickening and tethering of the skin as a result of a spontaneously occurring 
mutation. Although mice homozygous for the Tsk1 mutation die in utero at 8 to 10 days of 
gestation, heterozygous mice survive to develop thickened skin that is bound firmly to the 
underlying subcutaneous tissue.  
 
The genetic basis for the phenotype has been localised to chromosome 2 as an inframe 
partial reduplication of the Fbn1 gene. The primary role of fibrillin is to form the 
scaffolding for elastic fibres. In Tsk1 mice, fibrillin appears to alter fibrillin matrix 
structure, with an increase in fibrillin in the superficial fascia of these animals. Tsk1 mice 
exhibit increased elastogenesis in the superficial fascia (gain-of-function) and a loss of the 
dense elastic fibre band normally found at the interface between the intradermal muscle and 
deep connective tissue (loss-of-function). In addition to the phenotypical similarities to 
SSc, Tsk mice also show pathological similarities to SSc in upregulated expression of 
microfibrillar proteins fibulin-2 and the expression of the mutated Fbn1 increases the 
incorporation of type I collagen and microfibril-associated glycoprotein 2 (MAGP-2) 
fibrillar structures within the ECM(Lemaire et al., 2004). More recently, analysis of   123
lesional skin has demonstrated upregulation of the Wnt-γ catenin pathway and Wnt is 
shown to increase Fbn matrix formation in vitro, a key pathogenic feature in Tsk 
hypodermis(Bayle et al., 2008). 
 
Reported evidence further indicates that the immune system plays a role in modulating the 
fibrosis observed in the tight skin-1/+ mouse. It has been reported that Tsk/1+ mice are 
hyperresponsive to CD19 transmembrane signals leading to reduced IgM expression with 
increased serum IgG levels and spontaneous autoantibody production targeted against 
topoisomerase-1(Saito et al., 2002). The reason for this aberrant immune response appeared 
to be the constitutive increase in tyrosine phosphorylation of CD19 in B cells from the 
Tsk1/+ mouse. In addition, CD19-mediated [Ca
2+]i responses, Vav phosphorylation and 
Lyn kinase activity were increased(Asano et al., 2004a). In addition, adoptive transfer
 of 
both T and B cells from Tsk1/+ mice induces cutaneous collagen
 deposition in wild-type 
mice and deficiency in TGFβ, IL-4, IL-4 receptor, Stat-6 as well as the administration of 
anti-IL-4 antibody,
 IL-12 prevent or reduce skin fibrosis
 in Tsk1/+ mice(Ong et al., 
1999;McGaha et al., 2001;Ong et al., 1998;Tsuji-Yamada et al., 2001;Kodera et al., 2002). 
Taken together, these suggest immune dysregulation contribute to the fibrotic response in 
this murine model. In addition, there is evidence that Tsk fibrillin-1 alters TGFβ activity in 
the skin as well as altering the binding of fibrillin to latent TGFβ binding proteins. In 
addition, TGFβ deleted heterozygotes appear to demonstrate less fibrosis than do littermate 
Tsk mice. Furthermore, studies using hammerhead ribozymes specifically directed against 
the mutant fibrillin-1 transcript in skin fibroblasts derived from Tsk dermal biopsies 
revealed a striking decrease in the expression of TGFβ dependent genes, including CTGF 
and plasminogen activator inhibitor-1, in Tsk skin cells where the mutant fibrillin-1 had 
been deleted(Menon et al., 2006). It is therefore logical that targeting TGFβ has been a key 
focus for the development of mouse models of SSc. Adenoviral gene transfer to transiently 
expose fibrosis-prone C57/BL6 mice to high levels of active TGFβ1 in the lung (Sime et 
al., 1997;Kolb et al., 2002) is associated with the development of profound parenchymal 
and pleural fibrosis. This transient transgene approach allows high level expression of 
active TGFβ which is largely targeted to the bronchial epithelium, although is not lineage 
specific. αvβ6 integrin knockout mice that cannot activate TGFβ1 develop an exaggerated   124
inflammatory response to bleomycin but are protected from fibrosis, suggesting that active 
TGFβ1 but not inflammation is essential for the fibrotic response(Munger et al., 1999). 
Dissecting out the exact functional role of TGFβ pathways in SSc is hampered by its 
pleiotropic effects, its role in embryonic development, and the complexity of TGFβ 
regulatory mechanisms in vivo(Sonnylal et al., 2007).  
 
Fibroblasts are likely to be key effector cells in the late fibrotic stages of SSc, and 
considerable emphasis has been placed on delineating the role of TGFβ signalling in these 
cells. Targeting fibroblasts is challenging due to the paucity of lineage-specific marker 
genes especially cell-surface markers. Regulatory elements subcloned from type I collagen 
are expressed at an early stage in differentiating mesenchymal cells and have been used to 
generate promoter constructs that function as lineage-specific transgenes in 
fibroblasts(Rossert et al., 1995).  
 
In this thesis, lineage-specificity has been achieved by the use of a far-upstream 
transcriptional enhancer from the proα2(I)collagen (Col1a2) gene linked to a minimal 
promoter that directs expression to fibroblasts(Denton et al., 2001;Bou-Gharios et al., 
1996). Delineation of DNase I-hypersensitive sites far upstream of the Col1a2 promoter 
sequence supports a key role in regulating expression of linked genes through direct 
binding of sequence specific transcription factors in collagen I producing cells(Bou-Gharios 
et al., 1996). Not all type I collagen-producing cells express the transgene. Reporter mice 
show that the transgene is expressed specifically in cells of mesenchymal origin, mainly 
fibroblasts and some osteoblasts in areas of new bone growth suggesting recent 
differentiation from mesenchymal precursors. The promoter is important in controlling 
endogenous gene expression. The far upstream enhancer drives expression of Col1a2 in a 
spatio-temporal pattern similar to the endogenous gene; Col1a2 reporter mice show high 
levels of transgene expression in fibroblasts in the embryonic and neonatal period, whereas 
little transgene is expressed in adult mice from three weeks of age(Ponticos et al., 2004). 
 
In this thesis, a recently described novel transgenic mouse strain (TβRIIΔk) was used in 
which a potent fibroblast specific expression cassette subcloned from the proα2(I)collagen   125
gene drives the expression of a mutant kinase-deficient type II TGFβ receptor in fibroblasts 
but not other cell types.  This experimental strategy with fibroblast-directed transgenesis 
allows selective disrupted TGFβ signalling while minimising effects in other cell types 
including endothelial cells or other immunological cells that are also important in the 
pathogenesis of SSc. The mutant TβRII construct encodes the extracellular and 
transmembrane portion of human TβRII; it can engage free TGFβ ligand at the cell surface, 
but cannot directly lead to the phosphorylation of TβRI or the initiation of downstream 
signalling (Weis-Garcia & Massague, 1996). This truncated receptor has previously been 
characterised as a competitive antagonist for TGFβ1 and has been shown to be a dominant 
negative inhibitor of TGFβ signalling in several experimental systems, albeit at high 
expression levels compared with wild type receptors (Brand & Schneider, 1995;Bottinger et 
al., 1997;Brand et al., 1993;Pannu et al., 2004).  
 
Modern methods of parallel examination of gene and protein expression have advanced the 
understanding of transgenic or spontaneously arising mutant mouse strains. In contrast to 
the limited numbers of mRNA transcripts that may be studied with Northern blot, the 
ability to simultaneously measure the transcription of large number of gene sequences has 
provided the opportunity to understand the pathogenesis of biologically complex diseases 
and also to potentially identify candidates for disease-related target molecules. In addition, 
it may identify biochemical pathways that can be used as targets for future therapeutic 
interventions. One of the most productive approaches has been to use gene expression 
profiling to investigate the biochemical properties of mutant mice. DNA arrays have been 
used for large-scale investigation of gene expression patterns and they are based on 
hybridisation of a labelled mixed probe onto large systematic, high intensity grids of cDNA 
fragments. In this thesis, the Clontech 1.2 Mouse Nylon Atlas Arrays were used which 
include over 1000 cDNAs spotted in a regular fashion onto a positively charged nylon 
membrane. This strategy has been used in several models for fibrotic diseases including the 
fibrotic plaques in Peyronie’s disease and the mutagenic effect of nickel in murine 
fibroblasts(Qian et al., 2004;Kowara et al., 2005). A key advantage of this approach is that 
it seeks alterations in the mRNA profiles without predefined assumptions about disease 
progression. SSc, as a disease with progressive course, heterogeneous presentation with   126
incompletely understood pathogenesis presents itself as an ideal candidate disease for study 
through this approach. Of the three sample types (skin biopsies, peripheral blood and 
explanted cultured fibroblasts) that are available for microarray analysis, dermal fibroblasts 
are an attractive model system for study in SSc due to their accessibility, amenability to ex-
vivo experimentation and they are known to retain some properties including positional 
memory and myofibroblast phenotype in cultures(Shi-Wen et al., 2004;Rinn et al., 2006).   127
3.2 Aims 
Murine models including Tsk1 strain provide an important resource to study and delineate 
potential novel growth factors and cytokines in the pathogenesis of SSc. In addition, the 
significance of TGFβ in fibrosis led to the hypothesis that, targeted transgenesis using a 
lineage-specific promoter with sustained alteration in TGFβ signalling or responsiveness in 
fibroblasts may recapitulate the SSc phenotype. Analysis of both murine models may 
suggest an important interplay of TGFβ and other factors in driving the fibrotic response.  
 
Experimental work described in this chapter aims to 
1.  Identify the most highly expressed key growth factor in Tsk1 fibroblasts, 
2.  Examine the potential expression of MCP-3 in TβRII∆k model, and 
3.  Investigate the biochemical phenotype of TβRII∆k murine model.   128
3.3 Methods 
3.3.1 Fibroblast Culture 
Fibroblast cultures were derived from skin biopsies from lower back of neonatal transgenic, 
Tsk1 or control littermate mice. Cells were cultured in the presence of antibiotics and 
passaged at confluence.  Following 24 hours of culture in low serum (0.5% FCS) medium, 
10
4 cells were seeded into each well of replicate 6 well tissue culture plates.  At 24 hour 
intervals the cell layer was recovered and resuspended.  Pharmacological inhibitor of the 
TβRI kinase (SD-208, Scios Inc., Freemont CA) was used to investigate the response of 
TGFβ regulated protein, CTGF expression to inhibition of TGFβ signalling pathway. For 
these experiments, fibroblasts were stimulated with recombinant TGFβ1 (4ng/ml) for 45 
minutes in the presence or absence of SD-208. 
The transgenic TβRIIΔk strain used in this thesis was generated by Professor Christopher 
Denton at University College London and University of Texas. In brief, a fibroblast-
specific expression cassette was subcloned from the upstream region of the 
proα2(I)collagen gene. This incorporates a fragment between -19.5 and -13.5kb upstream 
of the transcription start site that, when linked to an endogenous minimal promoter drives 
gene expression at high levels in fibroblasts, but not in other type I collagen producing 
cells. Reporter genes linked to this promoter-enhancer show high level fibroblast-specific 
expression in embryonic development and postnatally. The mouse strain TβRIIΔk was 
generated by subcloning the cDNA encoding the extracellular and transmembrane portion 
of the human type II TGFβ receptor into the Sal1 site of the pCD3 expression vector. A 
bacterial β-galactosidase marker gene (LacZ) was co-expressed from a dicistronic transgene 
mRNA product via an encephalomyocarditis virus internal ribosome entry site sequence. 
The final transgene construct is shown in Figure 3. 1. Littermate wildtype C57/B6 mice 
were used as control animals.    129
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Figure 3.1 A fibroblast-specific expression cassette for transgenic mice that incorporates a 
6kb fragment of the far upstream (-19.5 to -13.5 kb) region of the Col1a2 enhancer linked 
to a minimal Col1a2 promoter. The cDNA encoding for the kinase-deficient human TβRII 
is expressed at high levels in fibroblasts but not other type I collagen producing cells. A β-
galactosidase marker gene was included that can be co-expressed to confirm the site and 
level of transgene expression. 
 
3.3.2 Gene expression analysis 
In order to compare differences in the gene expression between wildtype fibroblasts with 
Tsk1 and transgenic TβRIIΔk fibroblasts, low-density microarray analysis was undertaken. 
Entire cDNA populations were hybridised to BD Atlas™ cDNA mouse 1.2 expression 
arrays (Clontech, USA), which incorporate oligonucleotides specific for 1,176 mouse-gene 
transcripts; the cDNA-synthesis gene-specific primer mix, used for probe synthesis, is 
enriched for sequences corresponding to the cDNA for the genes on the array. In brief, 
mRNA was extracted, purified, and treated with DNase I (Qiagen, UK) to reduce genomic 
DNA contamination, as previously. Radio-labelled cDNA probe mixtures were synthesised 
by reverse transcription of each RNA population, using the cDNA synthesis primer mix, 
according to the manufacturer’s instructions. Labelled cDNA probes were purified by 
column chromatography, using Atlas Nucleospin extraction spin columns. Label 
incorporation was assessed by scintillation counting with a Geiger counter, aiming for 2-10 
x 10
6 counts per minute. Each BD Atlas™ cDNA Expression Array membrane was pre-
hybridised (as described for northern blotting), then after denaturation to single strands, 
each radio-labelled probe mix was hybridised to separate BD Atlas arrays overnight with 
continuous agitation at 68°C. After a series of high-stringency washes, the membrane was 
exposed to a phosphorimager plate for 1-10 days at RT, depending on the signal intensity. 
Experiments were performed in parallel and so generally 4 membranes were probed at the 
same time. The hybridisation pattern and relative expression levels were analysed using 
AtlasImager software (Clontech, USA); normalisation of the expression data was achieved   130
by using the sum of the global intensities of the arrays, accounting for differences in the 
local background signal. Hybridisation signals are linearly related to the target cDNA 
concentration. A ratio of ≥2 between samples was taken to represent significant differential 
regulation and the difference must have been observed on at least two occasions in 
independent experiments to be considered significant.  To minimise the effect of genetic 
background and gender, same sex (male) mice were used and littermate animals were 
examined.  For each age of mouse pair compared, RNA was extracted independently from 
two wildtype or tight skin mice and analysed in parallel. For 6 week and neonatal samples 
each sample was analysed twice to confirm reproducibility.   
 
3.3.3.Immunohistochemistry 
For detection of MCP-3 protein on Tsk1 tissues, immunohistochemistry analysis with a 
biotin/streptavidin-based amplifying system was performed on mice skin sections. Serial 
frozen sections (5 μm) were cut on a cryostat at –30 
oC and air-dried for an hour. Sections 
were fixed in ice-cold acetone and covered with 3% hydrogen peroxide for 10 minutes in 
the dark to block endogenous peroxidase activity. Slides were then blocked with 20% 
normal horse serum, and incubated with goat polyclonal anti-mouse MARC/MCP-3 IgG 
antibody (25 μg/ml in PBS, R & D Systems) for an hour at room temperature. After 
washing with PBS, sections were incubated with biotinylated horse anti-goat IgG diluted in 
PBS (7.5 μg/ml, BA-9500, Vector Lab, CA) for 30 minutes, rinsed and finally incubated 
with Vectastain Elite STR-ABC (Vector Lab, CA) reagent for 30 minutes. After washing, 
sections were visualised using 3-amino-9-ethylcarbazole(AEC) chromogen and  H2O2 as 
substrate(SK-4200, Vector Lab, CA). Sections were then washed in tap water, 
counterstained with Carrazzis haematoxylin, and aqueously mounted with Gelmount 
(Biomeda, Foster City, CA). Sections were viewed and photographed on an Olympus BH-2 
photomicroscope. Controls included omission of the primary antibodies and primary 
antibodies substituted with goat isotype-matched IgG. For detailed histological assessment 
of transgenic tissues, haematoxylin and eosin staining of these tissues were undertaken. 
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3.3.4.Western blot analysis of fibroblast protein expression 
To extend the cDNA microarray data and to examine biochemical differences between 
Tsk1 and transgenic or wild type fibroblast cultures, a series of Western blot experiments 
were performed. In addition, responsiveness of cultured transgenic and wild type 
fibroblasts to recombinant TGFβ1 ligand were also undertaken. Fibroblast culture 
supernatants were concentrated by ammonium sulphate precipitation to selectively enrich 
samples for secreted matrix proteins. For supernatants, specific antibodies to collagen type I 
(Southern Biotechnology Inc., Birmingham, AL), fibronectin (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA), keratinocyte growth factor (FGF7) (R&D Systems) and goat anti-
mouse MCP-3 antibody (R&D Systems) were used. Other studies examined CTGF 
(antibody supplied by FibroGen Inc.) and MMP13 (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA). All other antibodies were as described in Section 2.4.3, and all protein 
extraction and western blotting methodologies performed as described in Section 2.4.3.   132
 
 
3.4 Results 
3.4.1 Gene expression analysis identifies overexpression of MCP-3 in neonatal Tsk1 
fibroblasts 
Parallel assessment of gene expression was performed using cDNA Microarray, comparing 
Tsk1 and wildtype littermate fibroblast (n=6) from skin biopsies at two time points: 
neonatal (1 week) and 12 weeks old. Neonatal fibroblasts expressed 244 (21%) of the 1176 
genes represented on the array. These included genes for ECM turnover, growth factors, 
transcription factors and cell-related genes. At 12 weeks, 94 (8%) genes were expressed 
respectively. cDNA expression array templates for Tsk1 and wildtype neonatal fibroblasts 
are shown in Figure 3.2. At this time point, there was significant upregulation of tissue 
inhibitor of matrix metalloproteinase 3 (TIMP3), laminin β2 subunit (LAMC1), fibronectin 
1 (FN1), thrombospondin 1 (TSP1), MCP-3, cytoplasmic dynein light chain 1 (dynein), 
Bcl-2 interacting protein (NIP3), inhibin βA subunit (inhibin), insulin-like growth factor 
binding protein 6 (IGFBP6), and cholecystokinin A receptor (CCKR). Conversely, there 
was down-regulation of cordon bleu protein (COBL), Cell Division Cycle 46 (CDC46), 
RAD23 ultraviolet excision repair protein (RAD23), laminin γ1 subunit (laminin), CD28 
precursor, and interleukin-1 receptor (IL1R).  
 
Differential expression was defined by 2-fold differences in hybridisation between control 
and Tsk1 RNA samples. Thus, 43 genes were differentially expressed neonatally but the 
number of differentially expressed transcript decreased to 24 at 12 weeks. For 13 genes, 
there was differential expression at either the neonatal or 12-week time point or at both of 
these time points. These genes, together with the normalised expression relative to the basal 
wild-type neonatal fibroblast levels, are listed in Table 3.1. More than half of the 43 genes 
that were differentially expressed neonatally 
were not expressed consistently in adult samples, and these were not analyzed further. 
Conversely, 3 genes that were not differentially expressed in neonatal fibroblasts were 
found to be differentially expressed in adult cells, and these are included. Six genes 
including thrombospondin-1, osteopontin, hypoxia inducible factor-1α, tissue inhibitor of   133
metalloproteinase-3 and transforming growth factor β (TGFβ) showed sustained 
overexpression at all time-points. Several genes including biglycan and MCP-3 were 
overexpressed neonatally but suppressed in fibroblasts derived from established fibrotic 
skin. In neonatal cultures MCP-3 was the most overexpressed gene with more than 15-fold 
greater expression in neonatal Tsk1 compared with non-Tsk1 fibroblasts (Figure 3.3).   134
 
 
Figure 3.2 Overexpression of monocyte chemoattractant protein 3 (MCP-3) in type 1 
tight-skin (Tsk1) neonatal mouse fibroblasts. Representative neonatal fibroblast gene-
expression profiles are shown using portions of 2 mouse Atlas 1.2 cDNA arrays, 
corresponding to cytokine and growth factor or extracellular matrix transcripts.  
Tissue inhibitor of matrix metalloproteinase 3 (TIMP3), lamininβ2 subunit (LAMC1), 
fibronectin 1 (FN1), thrombospondin 1 (TSP1), MCP-3, cytoplasmic dynein light chain 1 
(dynein), Bcl-2 interacting protein (NIP3), inhibinβA subunit (inhibin), insulin-like growth 
factor binding protein 6 (IGFBP6), cholecystokinin A receptor (CCKR), cordon bleu 
protein (COBL), Cell Division Cycle 46 (CDC46), RAD23 ultraviolet excision repair 
protein (RAD23), lamininγ1 subunit (laminin), CD28 precursor, and interleukin-1 receptor 
(IL1R).  
Genes that are upregulated and downregulated are indicated in red and blue respectively. 
Genes that are similarly expressed in both samples are indicated in green. Half green/half 
red and half green/half blue indicate that although a difference (lower portion) was 
observed between the defined samples, the ratio (upper portion) is nonsignificant. The data 
are representative of triplicate experiments. 
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Figure 3.3 Overexpression of MCP-3 transcript on gene-expression profiling was 
quantified in a representative of triplicate experiments as shown with the histogram. 
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Prelesional (Neonatal)  Established (12 weeks)   
 
Gene Name 
Non-
Tsk1 
Tsk1 Ratio* Non-
Tsk1 
Tsk1 Ratio* 
 
GenBank 
accession no. 
MCP-3(CCL7)  0.2 2.7  15.3  2.1 1.4 0.7  S71251 
Monocyte colony-
stimulating factor 1 
0.3 3.4  10.9  0.4 0.8 2.2  X05010 
Cluster differentiation 
antigen 44 
0.1 0.7 4.9 0.6 1.1 1.8  M27129 
TSP1  1.8 6.6 3.7 2.1 4.2 2.0  M87276 
Hypoxia inducible 
factor 1α 
0.2 0.7 3.0 0.4 0.2 2.0  U59496 
TIMP3  0.2 0.6 3.0 0.4 0.7 2.0  L19622 
Fibronectin  1  3.8  11.1  2.9 6.2 7.3 1.2  X82402 
Osteopontin  1.8 4.3 2.4 6.8 8.6 1.3  J04806 
Biglycan  5.1  10.1  2.0 8.4 4.2 0.5  L20276 
TGFβ1  0.4 0.7 2.0 0.2 0.3 2.0  M13177 
Integrin β1  0.4 0.6 1.6 1.0 2.1 2.2  Y00769 
Keratinocyte growth 
factor (FGF7) 
2.5 2.0 0.8 0.4 0.1 0.2  Z22703 
Decorin  0.7 1.2 1.6 1.5 0.1 0.1  X53929 
 
Table 3.1 Summary of consistently differentially expressed genes in neonatal or adult 
type 1 tight-skin (Tsk1) mouse fibroblasts. Genes listed are those with consistent 
differential expression either in early or late-stage Tsk1 in 3 experiments. Values for 
expression data are relative to the mean signal for the total signal intensity of expressed 
genes, after correction for local background signal. 
*Differential gene expression in Tsk1 fibroblasts compared with non-Tsk1 littermate cells.  137
 
 
3.4.2 Overexpression of MCP-3 protein in Tsk1 fibroblast supernatants 
Since many genes are also regulated post transcriptionally, western blot analysis was used 
to assess changes at the protein level. Upregulation of MCP-3 was observed in a series of 3 
independent experiments with 2.4 fold overexpression in Tsk1 fibroblast culture 
supernatant compared to wildtype sample as shown in Figure 3.4.  
 
 
 
 
Figure 3.4 Overexpression of MCP-3 confirmed by Western blot analysis of Tsk1 and 
control (wild-type [Wt]) fibroblast culture supernatants. Cell-layer β-actin was used as a 
protein-loading control. Protein levels were quantified in a representative experiment as 
shown with the corresponding histogram in relative density units (RDU). 
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3.4.3 Dermal upregulation of MCP-3 in Tsk1 
MCP-3 was detected abundantly in the dermal region in the skin biopsies from Tsk1 mice 
at 1 week and 3 weeks old.  Non-specific perifollicular staining with antiMCP-3 antibody 
was observed in both control and Tsk1 skin sections.  There was no inflammatory infiltrate 
detected in skin sections from both controls and Tsk1 mice (Figure 3.5), at all ages 
examined for 3 days post-natally to 12 weeks.   
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Figure 3.5 Upregulation of monocyte chemoattractant protein 3 expression in type 1 tight-
skin (Tsk1) mouse skin. Frozen skin sections from 3-week-old healthy non-tight-skin 
(pallid) mice (A and B) and Tsk1 mice at 3 weeks (C) and 10 days (D) old were 
immunostained. Healthy adult mice show perifollicular (p with arrow) staining, whereas 
there is additional dermal expression (d with arrow) in Tsk1 samples. Tsk1 skin did not 
demonstrate any staining with isotype matched control IgG (E).  (Original magnification × 
240 in A and C; × 480 in B and D.)   139
biglycan
FN1
TSP1
Wt TβRIIΔkT βRIIΔk/ W T
Extracellular 
Matrix
Cytokine/
Growth factor
MCP-3
DAD1
GADPH
biglycan
FN1
TSP1
Wt TβRIIΔkT βRIIΔk/ W T
Extracellular 
Matrix
Cytokine/
Growth factor
MCP-3
DAD1
GADPH
 
3.4.4 MCP-3 is upregulated in transgenic model with activated TGFβ phenotype 
Having identified MCP-3 as the most overexpressed transcript in the neonatal Tsk1 
fibroblasts, the gene expression profile of transgenic fibroblasts was compared with 
wildtype fibroblasts with cDNA microarrays. Using the similar criteria as stipulated in 
Section 3.4.1, 35 of the 1,176 genes represented on the array were differentially expressed 
by the neonatal transgenic fibroblasts. Representative portions of the cDNA expression 
arrays for neonatal fibroblasts are shown in Figure 3.6 and Figure 3.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 cDNA microarray hybridisation analysis of TβRII∆k and wildtype neonatal 
fibroblast RNA. Representative neonatal fibroblast gene-expression profiles are shown 
using portions of 2 mouse Atlas 1.2 cDNA arrays, corresponding to cytokine and growth 
factor or extracellular matrix transcripts.  
Fibronectin 1 (FN1), thrombospondin 1 (TSP1), MCP-3, Defender against Apoptotic 
Death-1 (DAD1), Glyceraldehyde-3-phosphate dehydrogenase (GADPH). 
Genes that are similarly expressed in both samples are indicated in green. Half green/half 
red and half green/half blue indicate that although a difference (lower portion) was 
observed between the defined samples, the ratio (upper portion) is nonsignificant. The data 
are representative of triplicate experiments.   140
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Figure 3.7 Representative neonatal fibroblast gene-expression profiles are shown using 
portions of 2 mouse Atlas 1.2 cDNA arrays, corresponding to signalling molecules-
transcription factors and cell cycle molecules.  
Prothymosin-alpha  (PTMA), Y-Box DNA Binding protein (YB-1), Interferon regulatory 
factor-1 (IRF1), Heat shock protein84 (HSP84) and Heat shock protein86 (HSP86).  
Genes that are similarly expressed in both samples are indicated in green. Half green/half 
red and half green/half blue indicate that although a difference (lower portion) was 
observed between the defined samples, the ratio (upper portion) is nonsignificant. The data 
are representative of triplicate experiments.   141
Some of the genes including those related to a range of matrix components, cytokines, 
growth factors and signalling intermediates in neonatal TβRIIΔk transgenic fibroblasts 
were significantly modulated are listed in Table 3.2.  These are consistent with the complex 
profibrotic phenotype previously reported for these transgenic fibroblasts. There wee many 
similarities between the basal gene expression of transgenic fibroblasts with previously 
reported TGFβ1-treated wild type fibroblast gene expression. These include 
thrombospondin 1 precursor, osteopontin precursor, fibronectin, 84-kDa heat shock protein, 
prothymosin α, DAD1 and YB1 DNA-binding protein. Transcript levels of a number of 
growth factors were increased including several that promote fibrosis through activation of 
fibroblasts (fibronectin, osteopontin precursor and biglycan). Taken together, these results 
suggest that these transgenic fibroblasts demonstrate basal activation of TGFβ signalling 
pathways. MCP-3 was upregulated 7.3-fold compared with a 6-fold and 3.5-fold increase in 
fibronectin and thrombospondin 1 respectively. Western blot of transgenic fibroblast 
supernatants confirms the overexpression of MCP-3 protein (Figure 3.8).    142
 
Adjusted Expression   
Gene Name 
 
Gene Code  Controls Transgenic 
 
Ratio 
Accession 
Number 
MCP-3 D12b  3  22  7.3  Q03366 
Fibronectin F06j  14  93  6.6  X82402 
Osteopontin precursor  B13b  23  115  5  P08721 
Interferon regulatory 
factor 1 
B08l 3  14 4.7  M21065 
HSP86 C09b  3  13  4.3  M57673 
GADPH G27  14  58  4.1  M32599 
Vimentin F09d  10  37  3.7  X51438 
DAD1 D03e  3  11  3.7  U83628 
STAT-induced STAT 
inhibitor 1 
E06k 3  11 3.7  AF180302 
GPI E01c  15  53  3.5  P06745 
TSP1 F07j  6  21  3.5  M87276 
ACTB G43  64  211  3.3  M12481 
Biglycan F07h  23  67  2.9  L20276 
NDK B  C08j  7  20  2.9  X68193 
YB1 DNA binding 
protein 
B07j 10  24  2.4  M60419 
PTMA B12f  11  23  2.1  X56135 
Cathepsin D  F03j  13  27  2.1  X52886 
HSP84 C09a  7  14  2  M18186 
Guanine nucleotide 
binding protein 
E13h 10  20  2  AF124384 
 
Table 3.2 Selected upregulated genes in TβRIIΔk transgenic fibroblasts compared with 
wild type littermates (Clontech Atlas cDNA microarray). 
MCP-3: Monocyte chemoattractant protein-3, HSP86: heat shock 86-kDa protein, GADPH: 
glyceraldehyde-3-phosphate dehydrogenase, DAD1: defender against cell death 1, GPI: 
glucose-6-phosphate isomerase, TSP1: thrombospondin 1 precursor, ACTB: cytoplasmic 
beta-actin, NDK B: nucleoside diphosphate kinase B, PTMA: prothymosin alpha, HSP84: 
84-kDa heat shock protein 
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Figure 3.8 Upregulation of MCP-3 transcript was confirmed with Western blot with 
increased protein secretion by neonatal transgenic fibroblasts compared with wildtype 
fibroblasts. β-actin was used as protein-loading control. Protein levels were quantified in a 
representative experiment as shown with the corresponding histogram in relative density 
units (RDU). 
RDU   144
 
 
3.4.5 Profibrotic phenotype of TβRII∆k transgenic fibroblasts 
All of the transgenic mice manifest increased thickness of the dermis by 12 weeks of age.  
This was especially apparent over the lower back with adherence of skin to underlying 
fascial layers.  Histologically the dermis in a series of age 14 week old male mice was 
thickened with loss of the subcutaneous adipose layer (Figure 3.9). 
 
 
AB
 
Figure 3.9 Dermal fibrosis in adult transgenic mice. Compared to wildtype mice(B), the 
skin of adult mice (A) was thickened and representative sections (haematoxylin and eosin) 
for littermate male mice aged 14 weeks show increased dermal thickness and loss of 
subcutaneous fat. 
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Western blotting confirms the histological changes observed for the transgenic mice with 
high levels of type I collagen expression in fibroblast supernatants and the levels were 
comparable to those seen in wildtype cells after treatment with TGFβ1. However, this was 
not further influenced by exogenous TGFβ1 (Figure 3.10). Western blot analysis was 
undertaken to extend the changes observed from the expression profiling for the neonatal 
transgenic fibroblasts in Table 3.2. Fibronectin expression by wildtype cells was strongly 
induced by TGFβ1 whilst transgenic cells had elevated basal levels.  Induction was seen in 
transgenic cells treated with TGFβ1, but the relative response was less than for wildtype 
fibroblasts.  For keratinocyte growth factor (FGF7) there was substantial down-regulation 
of the protein level in culture media from wildtype cells after treatment with TGFβ1, and 
transgenic fibroblasts had a significantly lower level of FGF7 than control cells, with a 
proportionately smaller suppressive effect of TGFβ1  (Figure 3.11).  Overall, western blot 
data confirm that expression of a truncated kinase-deficient type II TGFβ receptor in 
explanted dermal fibroblasts is associated with a profibrotic phenotype and this finding is 
consistent with the increased dermal thickness as shown in Figure 3.9. Secondly, the 
transgenic fibroblasts demonstrate a diminished albeit varied responses to exogenous 
TGFβ1, with fibronectin retaining significant responsiveness.    146
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
wildtype
c
o
l
l
a
g
e
n
(
I
)
/
a
c
t
i
n
 
d
e
n
s
i
t
o
m
e
t
r
y
0261 22 4
actin
pro(I)collagen
transgenic
0261 22 4
TGFβ1 (4ng/ml) TGFβ1 (4ng/ml)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
wildtype
c
o
l
l
a
g
e
n
(
I
)
/
a
c
t
i
n
 
d
e
n
s
i
t
o
m
e
t
r
y
0261 22 4 0261 22 4
actin
pro(I)collagen
transgenic
0261 22 4 0261 22 4
TGFβ1 (4ng/ml) TGFβ1 (4ng/ml) TGFβ1 (4ng/ml) TGFβ1 (4ng/ml)
 
Figure 3.10 Biochemical phenotype of TβRII∆k dermal fibroblasts. Pro(I) collagen 
overexpression and refractoriness to TGFβ1 demonstrated by Western blot analysis of 
dermal fibroblast supernatants after stimulation by recombinant murine TGFβ1 (4ng/ml).  
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Figure 3.11 Transgenic fibroblasts demonstrate altered protein expression and blunted 
response to recombinant TGFβ1. Transgenic (tg) or wildtype (wt) neonatal fibroblasts were 
derived from littermates treated overnight with TGFβ1. Cultured fibroblasts supernatants 
demonstrated induction of Type I collagen and fibronectin by TGFβ1 in wildtype cells and 
increased expression at basal level by transgenic fibroblasts. FGF7 is suppressed by TGFβ1 
and transgenic cells produce lower levels constitutively. FGF7 and fibronectin secretion by 
transgenic fibroblasts is modulated by TGFβ1 but the proportionate change is less than in 
wild type cells. Coomassie staining of a representative gel shows total protein loading. Data 
are representative of three independent experiments. 
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3.4.6 Transgenic fibroblasts have a TGFβ1 activated phenotype 
Plasminogen activator inhibitor-1 (PAI-1) and CCN2/CTGF represents prototypic markers 
of TGFβ activation and to explore the expression of these TGFβ regulated proteins in 
transgenic fibroblasts, a series of independent experiments confirmed that compared to 
wildtype cells, there was upregulation of PAI-1 protein by transgenic fibroblasts, and this 
expression was relatively refractory to recombinant TGFβ1 stimulation. This refractoriness 
was sustained up to examination at later time points up to 72 hours after TGFβ1 
stimulation. The TGFβ regulated profibrotic cytokine connective tissue growth factor 
(CTGF) was examined in parallel experiments.  There was extremely low level of CTGF 
expression by wildtype cells but it was strongly induced by TGFβ1 at 6 hours.  Expression 
then returned to basal over 72 hours.  Transgenic fibroblasts demonstrated substantial 
constitutive CTGF production, consistent with their in vivo fibrotic phenotype, and 
expression was further induced to a peak levels similar to TGFβ1 treated wildtype cells, 
representing an increase of around 50% from basal transgenic level, although maximum 
induction occurred at 24 rather than 6 hours (Figure 3.12). This result suggests that these 
transgenic fibroblasts have sustained refractoriness to recombinant TGFβ1.    148
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Figure 3.12 Altered basal and TGFβ-induced PAI-1 and CTGF expression by transgenic 
fibroblasts. Increased expression of PAI-1 protein in fibroblast lysates on Western blot 
returned to basal level at 72 hours for wild type cells but sustained overexpression was 
demonstrated in transgenic fibroblasts. Similar pattern of overexpression was observed for 
CTGF protein in transgenic fibroblasts but maximum expression occurred at 24 hours 
compared to 6 hours for wild type cells. These data are representative of duplicate samples 
from two independent experiments.    149
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To confirm that activation of TGFβ signalling pathway is responsible for the constitutive 
overexpression of pro(I)collagen or CTGF, SD-208, a novel TβRI-kinase (ALK5) inhibitor 
was used.  Inhibition of ALK5 reduced pro(I)collagen and CTGF expression in transgenic 
fibroblasts to levels seen in littermate wildtype cells (Figure 3.13). 
We also examined expression of the major type I collagen degrading enzyme MMP13 in 
mice.  Levels of both precursor and active enzyme were substantially increased in 
transgenic fibroblast compared with littermate wildtype cells, suggesting that protein 
overproduction rather than reduced degradation is more likely the cause of increased matrix 
collagen in the TβRII∆k transgenic mice (Figure 3.14).    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Transgenic fibroblasts demonstrate TGFβ-dependent phenotype. Collagen and 
CTGF protein overexpression is abrogated by TβRI kinase (ALK5) inhibition (SD-508). 
These data are representative of four independent experiments. 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Transgenic fibroblasts overexpress the major fibrillar collagen-degrading 
protease MMP-13. These data are representative of three independent experiments.   150
 
3.5 Discussion 
There are a number of approaches for determination broad differences in gene expression in 
different tissue or cell samples. Other studies have used a variety of technologies including 
differential-display reverse transcription-polymerase chain reaction, ribonuclease protection 
assay and Northern blotting to examine gene-expression profiles in connective tissue 
diseases, including SSc. Candidate genes suggested by these approaches have included 
fibronectin, protease nexin 1, interleukin-1α and CTGF. However, MCP-3 was not 
identified in these earlier studies, this may reflect intrinsic differences in the SSc skin 
biopsy samples examined or in the fundamental properties of each of the methods used for 
examining the differential gene expression, and emphasises the value of using multiple 
approaches to address the same question. 
 
Overexpression of chemokines and related receptor genes including MCP-3 has been 
described in gene-cluster analysis of data from high-density gene-chip experiments 
studying whole-lung samples in the bleomycin-induced model of murine pulmonary 
fibrosis. Also, in a recent analysis of Luzina et al of gene-expression profiles with lung 
inflammation, there was increased expression of chemokines and chemokine receptor genes 
associated with a greater risk for lung fibrosis(Luzina et al., 2002). These studies suggest 
that cDNA microarray approaches are valuable as a screening approach to identify potential 
targets for further study. However, these results must be interpreted with caution, and 
repetition of studies is important, including validation with independently prepared 
samples. 
 
Homogeneous populations of dermal fibroblasts from Tsk1, transgenic and wild-type mice 
were used to reduce the biological variability, which may otherwise limit data analysis. 
However, even with this starting material, there was substantial variation when 
independently prepared samples were compared, presumably due to differences in cell 
cycle and other biological parameters, thus, many of the differentially expressed genes 
initially seen in neonatal fibroblasts were observed in only some littermate pairs. 
Replication of data is essential to reduce background differences in gene expression that are   151
independent of fundamental differences in the cell lines, even in genetically homogeneous 
samples such as sex-matched littermates of inbred mouse lines. Only a few genes were 
consistently differentially expressed, and low-density microarrays such as those used for 
screening in this study have relatively few transcripts. More complete assessment using 
high-density gene chips may be more amenable to formal statistical and bioinformatic 
analyses. 
 
It has been proposed that the myriad outcomes in SSc may represent different diseases that 
might ultimately be influenced by expression profiling. Many studies have reported 
characteristic phenotypic features of explanted dermal SSc fibroblasts with upregulation of 
TGFβ pathway including members of CCN family, thrombospondin 1 and PAI-1(Gardner 
et al., 2004). Several authors have also demonstrated extensive evidence of the TGFβ and 
Wnt pathways in vivo(Gardner et al., 2006;Whitfield et al., 2003) with upregulation of 
many TGFβ targets  including extracellular matrix proteins with fibrillar collagens, small 
leucine-rich family of proteoglycans (SLRPs) and members of the CCN family. However, 
explanted fibroblasts did not display the same consistent gene expression profile in 
particular the collagen transcripts suggesting that cultured fibroblasts appear not to 
completely mirror the in vivo SSc fibrotic phenotype. The reasons for this are unclear but 
possible explanations include presence of nonfibroblast cell types that drive the disease 
process and the loss of the cytokine milieu and matrix with the process of explantation and 
growth in monolayer. On the other hand, explanted dermal fibroblasts remain an attractive 
model system to study in SSc largely due to its amenability to ex vivo experimentation and 
accessibility. In addition, some of its key features including positional memory and 
myofibroblast phenotype remain intact(Shi-Wen et al., 2004;Rinn et al., 2006).  
 
Despite recent controlled clinical trials(Hoyles et al., 2006;Nihtyanova & Denton, 2008), 
the assessment and treatment of SSc remains challenging, in part due to an incomplete 
understanding of pathogenesis.  Using murine models that recapitulate SSc phenotypes, 
modern methods of parallel examination of gene and protein expression have contributed 
significantly in the understanding of SSc pathogenesis. Gene expression profiling of these   152
animal models of SSc will permit testing of hypotheses for pathogenesis in vivo and to 
investigate the biochemical properties of mutant mice.  
 
The identification of MCP-3 as a key soluble factor, primarily known for its key role in 
leucocyte migration in two major fibrotic murine models is intriguing. This provides the 
first evidence for upregulation of MCP-3 in a murine model with TGFβ-activated 
phenotype, suggesting that MCP-3 may be dependent on TGFβ in fibrosis. In addition, 
there is now increasing evidence that the related chemokine, MCP-1 acts in concert with 
TGFβ in driving fibrosis. There is however, few studies that has directly implicate 
involvement of MCP-3 in fibrosis. This will be explored further in this thesis. It is also 
plausible that early mediators such as MCP-3 might induce other factors such as TGFβ1 
and perhaps other downstream candidates such as CTGF or platelet-derived growth factor 
are induced later. The ability of fibroblasts to secrete these factors supports a model of 
autocrine or paracrine local regulatory pathways in pathogenesis. Potential consecutive 
induction of fibroblast-derived mediators also emphasises the importance of disease stage-
specific approaches to targeted molecular therapies in SSc. 
 
Several authors have reported upregulation of MCP-3 in autoimmune diseases including 
primary biliary cirrhosis and inflammatory bowel disease. Whilst autoimmunity has been 
described in Tsk1 mice, this aspect has not been well studied in the transgenic fibroblasts. 
However, autoimmunity has been demonstrated in pancreatic acinar cells harbouring 
kinase-deficient type II TGFβ receptor construct(Hahm et al., 2000). It is therefore possible 
that whilst this effect may be tissue-specific, autoimmunity may be highly relevant in this 
fibroblast-directed transgenic murine model. Apart from these studies, other evidence that 
may suggest possible involvement of MCP-3 in fibrotic process includes, its upregulation 
in usual interstitial pneumonia and SSc-related lung fibrosis, and also, in an experimental 
model of radiation-induced lung fibrosis (Choi et. al., 2004; Yanaba et. al., 2006; Johnston 
et. al., 2002). 
 
In addition to prompting the present study of MCP-3, the gene expression analysis of Tsk1 
skin provides some additional information regarding the pathogenesis of the tight-skin   153
mouse phenotype. The lack of inflammatory infiltrate on immunohistochemistry is entirely 
consistent with the absence of vasculopathy in this murine model.  
 
While recognizing that ~fold-change in mRNA may not necessarily correlate with 
biological importance, only the most dysregulated genes were considered. The expression 
profiling of Tsk1 and transgenic fibroblasts replicates the findings from previous studies 
that have reported characteristics phenotypic features of explanted dermal SSc fibroblasts 
with upregulation of TGFβ pathway with approximately half of the constitutively 
differentially expressed genes in transgenic fibroblasts showing a similar pattern in wild 
type cells after TGFβ1 stimulation(Denton et al., 2003). Moreover, the gene expression 
analysis for neonatal Tsk1 fibroblasts revealed striking differences neonatally with 
upregulation of MCP-3 and monocyte colony-stimulating factor 1, although some of these 
differences were not sustained at later time points. A smaller number of genes, mostly 
related to ECM turnover, were consistently upregulated including TIMP3 and TGFβ at all 
time points. There is however, some disparity between protein and mRNA expression for 
MCP-3. The mRNA expression level was about ~15-fold greater in the Tsk1 than wild type 
fibroblasts; whereas the protein level was 2.4-fold greater by Western blot analysis. Similar 
discrepancy was observed for transgenic fibroblasts, albeit at lower fold difference 
compared to wild type fibroblasts. Whilst these results support overexpression of MCP-3 
secretion by Tsk1 and transgenic fibroblasts, it suggests that these may not solely 
dependent upon increased mRNA, and that posttranslational modification and even mRNA 
stability may be relevant in determining protein expression.  
 
Recent compelling evidence has demonstrated that in SSc and other fibrotic diseases, 
reduced ECM turnover is a contributory factor for collagen accumulation and the 
development of dermal fibrosis. The turnover of the ECM depends upon the balance 
between MMPs and TIMPs. Gene expression profilings for both models suggest altered 
expression of a subset of MMPs and TIMPs, and this mirrors the cohort of MMP genes 
upregulated by TGFβ in other studies. In addition to upregulation of MMP-13 in chronic 
dermal wound, several authors have documented the critical role of MMP-13 in model of 
liver fibrosis in MMP-13-/-mice, and this was associated with downregulation of   154
TGFβ(Uchinami et al., 2006). Moreover, MMPs including MMP-13 may modulate 
chemokine activity by cleaving chemokines including MCP-3 at their NH2-terminals, and 
therefore converting them into antagonistic derivatives. In addition, MMPs may also 
establish chemokine gradient in vivo and therefore regulate the migration of inflammatory 
infiltrate. For example, MMP9 was recently shown to be required for formation of 
transepithelial gradients of MCP-3 in a murine model for asthma(Corry et al., 2004). While 
inflammation is not a feature in Tsk1, it remains unclear if chemokine-regulated 
inflammation is important in TβRII∆k model. 
 
Apart from these two models that demonstrate overexpression of MCP-3, other murine 
models of pulmonary fibrosis induced by irradiation has also reveal elevation of several key 
chemokines including MCP-3 and its receptors, CCR1 and CCR2. It is likely that these 
chemokines are responsible for the chronic inflammatory recruitment and activation 
observed in this model of irradiation-induced fibrosis(Johnston et al., 2002). However, 
unlike Tsk1 and TβRII∆k mice, the fibrotic response was not observed in all murine strains. 
Myofibroblastic expression of MCP-3 was also recently described in an experimental 
murine model of bleomycin-induced lung fibrosis with resistance to Fas-induced apoptosis 
as a way of evading immune surveillance and thus allowing for their uninterrupted 
accumulation with resulting collagen deposition in the ECM(Wallach-Dayan et al., 2007). 
 
The pathogenic mechanisms for Tsk1/+ model however is not well-defined and it has been 
argued that it does not completely reproduce the SSc phenotype(Baxter et al., 2005). In 
contrast to human SSc, these mice have subcutaneous hyperplasia with relative sparing of 
the dermis. In addition, these mice demonstrate tethering and thickening of the hypodermal 
tissue in contrast to the dermal fibrosis seen in SSc. Other major phenotypical differences 
between the Tsk model and human SSc included the emphysematous lung changes in the 
murine model rather than fibrosis and the absence of vasculopathy. 
 
Transgenic models on the other hand provide an in vivo system to explore molecular 
mechanisms that account for the temporal, spatial and stimulus-responsive regulation of an 
individual transgene. Accordingly, transgenic models such as TβRII∆k have demonstrated   155
the pathophysiological fibrotic consequences of increased mouse transgene with thickened 
dermis with increased collagen deposition. The expression of a non-signalling type II TGFβ 
receptor in fibroblasts results in paradoxical activation of downstream signalling pathways 
with basally increased expression of PAI-1 and CTGF. Moreover, experiments using SD-
208 strongly suggest that activation of the type I TGFβ receptor, ALK5 is a key 
determinant of the profibrotic phenotype in this transgenic murine strain.  
 
To explain the sustained refractoriness of the transgenic fibroblasts to exogenous TGFβ1, it 
has now been demonstrated that the level of transgenic receptor expression and that of 
endogenous wildtype receptor appears to be critical; low level expression of TβRIIΔk 
appears to lead to increased wildtype receptor levels.  This may be due to 
heterodimerisation of wildtype and mutant receptors that results in a signalling receptor 
complex that is less susceptible to degradation(Denton et al., 2005). Higher levels of 
mutant receptor act as a dominant negative inhibitor of signalling.  At higher 
concentrations, homodimers of mutant receptor are likely to form and these may inhibit 
responsiveness by direct competition for ligand with wild type receptors (Figure 3.15). 
Therefore, for some proteins such as fibronectin, there is regulation and for these, inhibitory 
pathways may be preferentially activated in transgenic fibroblasts in response to exogenous 
TGFβ1.   156
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Figure 3.15 Diagram summarizing activation of the TGFβ ligand-receptor axis in TβRII∆k 
transgenic mice. A. Expression of the mutant receptor at low levels enhances activation of 
the endogenous type I TGFβ receptor. Downstream consequences include upregulation of 
TGFβ1 and other gene products that promote TGFβ activity or activate the latent TGFβ 
complex. This leads to net activation of TGFβ signalling. B. In contrast, in response to 
recombinant TGFβ1, there is significant elevation of transgene expression. Higher level of 
transgene expression is inhibitory and abrogates signalling (Denton et al., 2005). 
 
These results should be considered in the context of previous studies of other transgenic 
mice harbouring kinase-deficient type II TGFβ receptor constructs. Although this transgene 
operates as a dominant negative inhibitor of TGFβ activity in vitro, it appears to induce 
much more complex effects in vivo in transgenic mice. Most reported phenotypes are 
consistent with perturbed TGFβ signalling, seen most clearly when cell type-specific or 
tissue-specific promoters have been used. TβRIIΔk expression in mouse epidermal cells 
resulted in a hypertrophic epidermal phenotype with refractoriness to TGFβ1-induced 
growth inhibition associated with enhanced sensitivity to chemical carcinogenesis(Wang et 
al., 1997). When expressed in chondrocytes, TβRIIΔk transgene regulated by a   157
metallothionein promoter was associated with degenerative skeletal changes suggestive of 
defective TGFβ response(Serra et al., 1997). Increased trabecular bone was demonstrated 
with TβRIIΔk expression in osteoblasts(Filvaroff et al., 1999), whereas in mammary 
stromal cells, impaired mammary differentiation and development was demonstrated 
(Joseph et al., 1999). By contrast, expression in epithelial cells in the mammary gland 
(Gorska et al., 1998), prostate (Kundu et al., 2000), and intestine (Hahm et al., 2002) has 
been associated with epithelial hyperplasia, consistent with the role of TGFβ in negatively 
regulating epithelial cell proliferation. In addition, recent publications have used TβRII∆k 
to unravel the complex role of TGFβ in autoimmunity. Expression in T lymphocytes 
resulted in a lymphoproliferative disease, similar to the TGFβ1 null mouse phenotype, and 
also increased susceptibility to autoimmune hepatitis. Under the influence of a pS2 mouse 
trefoil peptide promoter in pancreatic acinar cells, TβRII∆k is associated with increased 
susceptibility to cerulein-induced pancreatitis characterised by severe inflammatory cell 
infiltration, increased cytokines IL-4 and IL-10, T- and B-cell hyperactivation, IgG-type 
autoantibodies against pancreatic acinar cells, and IgM-type autoantibodies against 
pancreatic ductal epithelial cells(Hahm et al., 2000). In addition, there was marked increase 
in MMP-3 and MMP-9 expression in pancreatic acinar cells. Interestingly, when the 
transgene is regulated by a mouse metallothionein promoter, there was increased cell 
proliferation in pancreatic acinar cells with perturbed acinar differentiation resulting in 
fibrosis, neoangiogenesis and mononuclear infiltration, associated with a paradoxical up-
regulation of TGFβ expression in transgenic acinar cells(Bottinger et al., 1997). Overall, 
previous transgenic models with tissue-directed expression of TβRIIΔk all show blunted 
ligand responsiveness. Disparate results using the same TβRIIΔk construct are likely to 
reflect tissue-specific TGFβ responses.  
 
Independent confirmation of the paradoxical activation of downstream signalling and 
increased extracellular TGFβ bioactivity through mechanisms comes from the recently 
described human Loeys-Dietz syndrome (Loeys et al., 2005). This is an autosomal 
dominant aortic aneurysm syndrome with affected patients having widely spaced eyes, cleft 
palate and widespread vascular dilatation with increased risk of aortic dissection or rupture.   158
Based on current knowledge of altered TGFβ signalling pathway in aortic dissections 
associated with Marfan syndrome, sequencing of TGFβR1 and TGFβR2 in 52 families with 
a history of Loeys-Dietz syndrome identified disease-causing somatic mutations in these 
two receptors: a majority of which occur either adjacent to or within the serine/threonine 
kinase domains of TβRII and TβRI. There were however no phenotypic differences 
between those who harbour TGFβR1 versus TGFβR2 mutations. These receptor mutations 
identified were specific to this syndrome. The paradoxical increased TGFβ signalling 
observed experimentally in the aortic wall would suggest that these mutations are either 
gain of function or compensatory mechanism to overcome these mutations. Recently, these 
receptor mutations have been described in Marfan Syndrome but these are predicted to 
result in loss of function. However, it remains unclear whether the abnormal phenotype in 
Marfan syndrome is a consequence of increased TGFβ signalling. Further support for 
potential alterations in TGFβ signalling arising in the context of this type of kinase domain 
mutation is provided by the identification of kinase domain mutations in another member of 
the TGFβ superfamily of receptors, the bone morphogenetic protein receptor type II 
(BMPRII) in familial pulmonary arterial hypertension (PAH) (Morrell et al., 2001;Lane et 
al., 2000;Thomson et al., 2000). The BMPRII receptor has an analogous role in BMP 
signalling to TβRII for TGF-β ligand; absent kinase activity leads to activation of 
downstream pathways, and smooth muscle cells from pulmonary arteries of patients 
heterozygous for mutations in the signalling domain of BMPRII show altered responses to 
TGFβ1 as well as BMPs (Morrell et al., 2001). However, this mutation has not been found 
in SSc (Tew et al., 2002).    159
 
3.6 Summary 
In conclusion, the studies presented in this chapter established the overexpression of MCP-
3 in two major murine models for fibrosis: Tsk1/+ and the novel transgenic TβRII∆k 
strains. These mice provide a valuable model for studies in human fibrosis, including SSc, 
probably best reflecting the established fibrotic phase of the disease. Taken together these 
results suggest that in addition to its major role as a chemoattractant for mononuclear cells, 
MCP-3 may be potentially profibrotic. In addition, its overexpression in the transgenic 
model with genetically determined perturbation of TGFβ signalling in fibroblasts suggests 
that both these factors may share a biological and functional significance in driving fibrosis.   
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CHAPTER 4: MCP-3 AS A PROFIBROTIC MEDIATOR IN MOUSE MODELS OF 
SCLERODERMA 
 
4.1 Introduction 
Since the first description in 1977, chemokines are primarily known for their major and 
eponymous function in induction of directional cell migration, thus coordinating leucocyte 
recruitment both in physiological and pathological conditions. There has been an increasing 
amount of information correlating the chemokine system with the pathogenesis of different 
human diseases. Most of these are thought to be attributable to its major role in chemotaxis. 
 
MCP-3, as a key member of CC chemokine family, binds cell-surface glycosaminoglycans 
and forms stable gradients in order to institute an inflammatory focus. Like MCP-1, it has 
largely been studied for its main role in recruitment of a variety of mononuclear 
inflammatory cells. Increased fibroblastic expression of MCP-3 has been demonstrated 
following stimulation by cytokines including IL-13 and IFNγ(Menten et al., 1999;Wills-
Karp, 2004;Wynn, 2004). Overexpression of MCP-3 has been associated with several 
major autoimmune and inflammatory diseases including asthma, atherosclerosis and 
multiple sclerosis. Interestingly, more recently, increased expression of MCP-3 has been 
demonstrated in sera from cohort of patients with SSc, and lung fibrosis(Yanaba et al., 
2006). The mechanisms underlying these observations are unclear but it is postulated that 
MCP-3 mediates the leucocyte chemotaxis and migration through endothelial into the 
affected organ tissues leading to the interaction between leucocytes and fibroblasts. The 
related chemokine, MCP-1 has been studied extensively in SSc and although it has been 
demonstrated that targeting MCP-1 may have a therapeutic effect in mouse models of SSc 
or fibrotic disorders, it is unknown whether this strategy is effective in human diseases.  
 
In these fibrotic diseases of which SSc is the prototypic fibrotic disorder, excessive ECM 
production notably type I collagen is a major feature. The regulation of ECM accumulation 
and type I collagen gene expression in SSc is tightly controlled at multiple coordinated 
steps, among them transcriptional regulation is a critical step. The cis acting elements that   161
control the activity of the proximal promoter are also involved in mediating the 
transcriptional response to cytokines which are central in tissue remodelling and fibrotic 
diseases. In SSc increased transcriptional activation of type I collagen has been shown in 
lesional tissues(Herrmann et al., 1991). Explanted cells from affected areas maintain this 
phenotype for several passages in vitro. The regulation of the expression of the two 
collagen I components (the α1 and α2 chains) genes has been subject of intense research 
over the last decade and several control elements have been described for both collagen I α 
chain genes. The understanding of collagen gene regulation has been greatly advanced with 
the increasing use of transgenic mice. Expression patterns of different proximal promoter 
constructs of the murine collagen gene linked to a reporter transgene revealed a modular 
arrangement of separate cell-specific cis-acting elements that can activate the mouse pro-
α(I) collagen gene in different type I collagen-producing cells, with certain critical 
sequences directing expression of collagen genes to specific mesenchymal cell types at the 
appropriate time in embryonic development(Rossert et al., 1995). A potent fibroblast-
specific enhancer element has been described in the 6-kb sequence of the murine proα2(I) 
collagen gene (Col1a2) between -19.5 kb and -13.5 kb upstream of the transcription start 
site. This region contains some DNase-hypersensitivity sites that have been demonstrated 
only in the collagen type 1 producing cells, and this element has been referred to as the far-
upstream proα2(I) enhancer element. This enhancer is capable of directing high-level 
fibroblast-specific expression to reporter genes linked to endogenous and heterologous 
minimal promoters in transgenic mouse embryos. Further experiments demonstrated that 
distinct sequences within the hypersensitive sites are essential for both the functional 
integrity of the enhancer and tissue specific elements that direct expression in mesenchymal 
cells of internal tissues(De et al., 2002). Comparison of murine and human sequences has 
led to the identification of regions of high genomic homology between both species. This 
homology encompasses the locations of the five DNase I hypersensitive sites as well as the 
composition of their sequences. These segments termed as MH-I, MH-2 and MH-3 were 
shown to have 85%, 90% and 88% homology(Antoniv et al., 2001). This positional and 
compositional conservation of intergenic sequences represent powerful evidence of critical 
ancestral role in gene regulation. In addition to the far-upstream fibroblast-specific 
enhancer in the murine Col1a2 gene, it has also been demonstrated that the human far-  162
upstream region of COL1A2 acts as a strong tissue-specific enhancer in concert with the 
proximal minimal promoter, and is required for full gene expression(Ramirez et al., 2006). 
More recently, transgenic mice experiments have revealed that the enhancer sequence is 
important in determination of the fibrotic phenotype of Tsk/1+ mice(Denton et al., 2001). 
Using different transgene constructs of the enhancer elements linked to β-galactosidase 
reporter gene, activation of LacZ in Tsk mice was demonstrated via the 2-kb and 6-kb 
sequences suggesting that these regions contain sites that respond to activating factors in 
the Tsk/1+ mice. These transgene constructs for the mouse and human proα2(I) collagen 
genes are shown in Figure 2.1. Taken together, these data demonstrate that the far 
upstream enhancer element exert significant influence on collagen production via the both 
Col1a2 and COL1A2 minimal promoters and this thesis will draw upon these elements to 
study the effect of recombinant MCP-3 on the modulation of collagen gene expression in 
the fibrotic process.  
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4.2 Aims 
Overexpression of MCP-3 has been established in two major murine models of fibrosis: 
Tsk/1+ and the transgenic TβRII∆k murine strains in which there is activated TGFβ 
activated phenotype with increased dermal collagen expression. Using a novel 
physiological bioassay with cultured dermal fibroblasts from 2kb-LacZ transgenic mice and 
also, transient transfection of the proα2(I) collagen gene promoter-constructs, the possible 
direct or indirect profibrotic effect of MCP-3 on ECM gene expression was examined.    164
 
4.3 Methods 
4.3.1 Cell culture and transfection of reporter constructs 
Fibroblasts from neonatal transgenic 2kb-LacZ line, Tsk1 and non-Tsk1 were used for 
these experiments. The 2kb-LacZ cell lines provide a physiological assay for 
transactivation of a genomic β-galactosidase reporter for which endogenous expression in 
vivo recapitulates that of endogenous type I collagen genes. All cell lines were maintained 
in DMEM (Gibco) as described in Section 2.2.   
 
4.3.2 Transfection of reporter constructs and assessment of MCP-3 responsiveness 
Transactivation of collagen(I) gene by different concentrations of recombinant MCP-3 was 
compared with recombinant MCP-1 using transgenic mice which harbours a fibroblast-
specific 2kb-LacZ reporter transgene in fibroblasts culture. In addition, transient 
transfection was used to assess MCP-3 and TGFβ1 responsiveness in control dermal 
fibroblasts with the 2kb-LacZ collagen promoter construct. Analyses were performed in 24-
well plates using Lipofectamine-plus, as described in Section 2.2.3. For each experiment, 
transfection was performed when the cell layer was 60-70% confluent in a 24-well tissue-
culture plate. Reporter gene expression was determined using the Galactolight assay kit 
(Tropix, Bedford, MA).  
 
4.3.3 Protein kinase inhibitors and neutralising antibody to TGFβ1. 
The inhibitors used in this study included SD-208, an inhibitor of the TβRI kinase (1 µM, 
Scios Inc., Fremont CA) which is a selective 2,4-disubstituted pteridine-derived TGFβ RI 
kinase that demonstrates in vitro specificity for TβRI kinase of over 100-fold compared 
with TGFβRII kinase and at least 20-fold over members of a panel of related protein 
kinases. SD-208 was kept as 20 mM stock solution at -20
0C until use. Other protein kinase 
inhibitors include SB203580 (20 µm, Calbiochem, La Jolla, CA), a highly specific and cell-
permeable inhibitor of p38 MAP kinase (IC50 = 34 nM in vitro) with no significant 
inhibition of JNK and p42 MAP kinase at 100 µM; LY294002 (50 µM, Calbiochem, La 
Jolla, CA) is a cell-permeable and specific phosphatidylinositol 3-kinase inhibitor (IC50 =   165
1.4 µM) that acts on the ATP-binding site of the enzyme and does not affect the activities 
of MAP kinase and PKC even at 50 µM and 1D11, a neutralising murine TGFβ 
monoclonal antibody which recognises both  mouse and human TGF-β1 (5 µg/ul, R&D 
Systems, Oxford UK). All inhibitors were dissolved to a desired stock concentration and 
further dilutions were prepared in sterile DMEM unless otherwise stated and carrier alone 
added as appropriate. In the experiments in which the effect of these inhibitors diluted in 
DMEM was studied, DMSO-diluted treated cells were used as controls. 
 
4.3.4 Protein Expression  
Cultured fibroblast supernatants were collected and concentrated by ammonium sulphate 
precipitation to selectively enrich samples for secreted matrix proteins. Specific antibodies 
to collagen type I, a rabbit polyIgG (1:2000 dilution, Novotec) was used. All protein 
extraction and Western blotting methodologies performed as described in Section 2.4.3, 
unless stated otherwise. Monoclonal antibody against β-actin (Sigma, St. Louis, MO) was 
used to control for variation in cell number between cultures.   166
4.4 Results 
4.4.1 Transactivation of proα2(I) collagen gene expression by MCP-3 in 2kb-LacZ 
transgenic murine fibroblasts 
Initially, transgenic fibroblasts from the 2kb-LacZ line were used, since these cells provide 
a physiological assay for transactivation of a genomic β-galactosidase reporter for which 
endogenous expression in vivo recapitulates that of endogenous type I collagen genes. 
Concentrations between 10ng/ml and 250ng/ml of recombinant chemokine were evaluated 
in early experiments. Preliminary time-course analysis from a series of duplicate 
experiments revealed that initial induction occurred at 6 hours with up-regulation of 34 ± 
15% above baseline, which subsequently rose and then declined to 25 ± 22% above 
baseline at 48 hours. There was maximal induction of the transgene expression at 24 hours 
with (Mean±Sem %) 133±28%, p=0.02 at 10 ng/ml, 186±38%, p=0.01 at 100 ng/ml and 
230±45%, p=0.05 at 250ng/ml compared to basal (Figure 4.1). This showed very similar 
dose-response characteristics to that previously observed for the related chemokine MCP-1 
(Gharaee-Kermani et al., 1996) (Figure 4.2) with maximal induction 90.0±20% and 
115±16% for MCP-3 and MCP-1 respectively at 24 hours. Concentrations between 100-
500 ng/ml gave consistent effect and these were used in the majority of later studies. A 
series of independent experiments (n = 5) showed that MCP-3 200ng/ml and 400 ng/ml 
increased the transactivation of the reporter transgene, with a maximal mean (±SEM) 
change above baseline levels of 80 ± 31% (p = 0.01) at 24 hours (Figure 4.3).    167
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Figure 4.1 Time and dose-dependent transactivation of the 2kb-LacZ transgene expression 
by variable dose of MCP-3 (10-250ng/ml). Fibroblasts were grown to 80% confluence and 
serum starved in DMEM with 0.2%FCS for 24 h. Cells were then incubated for 1, 4, 6, 8, 
24 and 48 hours in the presence of recombinant MCP-3. Values are the mean and SEM of 
triplicate samples and are representative of 3 independent experiments. * = p < 0.05 by 
Student’s paired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Dose-response in activation of 2kb-LacZ transgenic fibroblasts by MCP-3 and 
MCP-1 at 24 hours. Fibroblasts cultured from the skin of transgenic mice with high-level 
fibroblast-specific expression of β-galactosidase (2kb-LacZ) were grown to 80% 
confluence and serum starved for 24 hours before incubated with recombinant MCP-3 and 
MCP-1 to their effect on extracellular matrix gene expression. Values are the mean and 
SEM of triplicate samples and are representative of 5 independent experiments. *=P<0.05; 
**=P<0.01 as determined by Student’s unpaired t-test. RLU=relative luminescent units. 
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Figure 4.3 Activation of murine proα2(I) collagen (Col1a2) gene expression by MCP-3 in 
transgenic 2kb-LacZ fibroblasts. Fibroblasts cultured from the skin of transgenic mice with 
high-level fibroblast-specific expression of β-galactosidase (2kb-LacZ) were used to 
examine MCP-3 activation of ECM gene expression. Values are the mean and SEM of 
triplicate samples and are representative of 5 independent experiments. *=P<0.05 as 
determined by Student’s unpaired t-test. RLU=relative luminescent units.   169
 
4.4.2 Transactivation of proα2(I) collagen gene expression by MCP-3 in transient 
transfection of wildtype murine fibroblasts with murine and human collagen 
promoter constructs 
Data from transgenic mice were confirmed using transient transfection of wild-type 
fibroblasts using the same 2kb-Col1a2-LacZ construct with a mean (SEM) activation above 
baseline of 63.1 ± 23% with MCP-3 and 158 ± 54% with TGFβ1, p=0.01 respectively 
(Figure 4.4). To further delineate responsive elements in the upstream fragment of the 5’ 
region of the mouse proα2(I)collagen gene, transient transfection of cultured wildtype 
fibroblasts with a 350bp minimal promoter of Col1a2 was undertaken. As with the larger 
2kb-LacZ construct, there was a dose-dependent response in upregulation of Col1a2 
minimal promoter with (% basal expression ± sem) mean activation of 172 % ± 51 and 
185% ± 31, p = 0.02 at 200 ng/ml and 400 ng/ml respectively from a series of 3 
independent experiments as shown in Figure 4.5, suggesting that the upstream elements 
previously implicated in selective activation are not essential for the effect of MCP-3. 
 
Although sequence conservation of the proximal and distal regulatory elements of Col1a2 
has been confirmed, previous studies suggest that differences in gene regulation can occur 
between species.  Data for mouse constructs was confirmed using human promoter-reporter 
constructs. Figure 4.6 summarises the results from 3 independent experiments using this 
construct with maximal induction of collagen reporter gene expression (% basal expression 
± sem) of 152 ± 14 % at 200ng/ml. The time course for stimulation of collagen gene 
expression suggested that a second mediator may be elaborated by MCP-3 activated 
fibroblasts. Since TGFβ is found abundantly and released from activated fibroblasts and is 
known to increase the gene expression of collagen I and III in vitro, the effect of anti-TGFβ 
antibody on this stimulation of collagen reporter gene expression was examined. In 
addition, recent reports have explored the role of TGFβ in mediating the effect of other 
chemokines, MCP-1 and CCL18 on collagen expression using 1D11(R&D 
Systems)(Gharaee-Kermani et al., 1996;Luzina et al., 2006). The results show that MCP-3 
stimulation of fibroblast collagen synthesis was partially inhibited with percentage change 
(mean ± sem, % change) 31.0 ± 6.7%, p = 0.05 in the presence of anti-TGFβ antibody. In   170
addition, there was a dose-dependent response with the antibody with maximal 
neutralisation effect at 50µg/ml as shown in Figure 4.7. This is consistent with previous 
findings that MCP-1 stimulation of fibroblast collagen expression was partially inhibited in 
the presence of anti-TGFβ antibody at concentrations found to completely inhibit TGFβ 
activity in the conditioned medium(Gharaee-Kermani et al., 1996).   171
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Figure 4.4 Activation of 2kb-Col1a2-LacZ reporter gene by recombinant MCP-3 in 
transient transfection is shown as reporter gene expression in a series of independent 
experiments. Activation of 2kb-LacZ promoter construct by MCP-3 (200ng/ml) approaches 
to that of recombinant TGFβ1 (4ng/ml) at 24 hours. * = P<0.05 by Student’s unpaired t-
test. RLU=relative luminescence units. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Activation of murine proα2(I) collagen (Col1a2) gene expression by MCP-3. 
Transactivation of the LacZ reporter gene was examined in wildtype fibroblasts harbouring 
-350bp endogenous Col1a2 promoter with MCP-3 200 ng/ml and 400 ng/ml in transient 
transfection in 3 independent experiments for the minimal promoter construct.    172
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Figure 4.6 Activation of a human proα2(I) collagen (COL1A2) gene in transient 
transfection. Activation of this minimal promoter is expressed as the mean and SEM 
percentage of basal expression from 3 independent experiments and corrected for 
transfection efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Activation of a human proα2(I) collagen (COL1A2) gene reporter by MCP-3 
via a TGFβ-dependent mechanism. Anti-TGFβ antibody significantly reduces MCP-3-
induced activation of human COL1A2 promoter constructs at 24 hours. Data are 
representative of 3 independent experiments and expressed as the mean and SEM of 
triplicate samples. *=p<0.05 by Student’s paired t-test.   173
 
4.4.3 Upregulation of collagen protein expression by MCP-3 is mediated by MAPK, 
PI3K and TGFβ signalling pathways 
To extend and confirm data obtained from COL1A2 promoter activation assays, the effect 
of the specific pharmacological pathways of potential signalling pathways activated, 
directly or indirectly, in response to MCP-3 was investigated in dermal fibroblasts. 
Confluent dermal fibroblasts were stimulated with recombinant MCP-3 for 24 hours in the 
presence of inhibitors of p38 MAPK, TGFβ and its associated receptor and PI3K pathways. 
Normalised quantitation of protein expression by scanning densitometry with Western blot 
analysis demonstrated that there is an increase in type I collagen by recombinant MCP-3. 
There was consistent reduction of the collagen type I protein expression with SB203580 
and LY294002. Anti-TGFβ antibody (1D11) and receptor blockade (SD-208) also 
substantially reduced expression of collagen protein (Figure 4.8). The effect of ID11 is 
greater than that with SD-208 suggesting that complete inhibition with the former.    174
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Figure 4.8 Effect of key pharmacological inhibitors of TGFβ, PI3K and p38 pathways on 
the upregulated expression of type I collagen in wild type fibroblasts. Expression level of 
type I collagen in wild type fibroblasts was determined by immunoblotting of tissue culture 
media using antibodies to type I collagen. The addition of the selective p38 MAPK 
inhibitor (SB203580), PI3K inhibitor (LY294002) and TGFβ inhibitors (1D11 and ALK5 
inhibitor, SD-208) abolished the upregulated expression of type I collagen. Antibodies 
against β-actin were also used as loading control. Type I procollagen protein levels were 
defined as the mean band density of the α1(I) and α2(I) procollagen proteins, which was 
quantitated by scanning densitometry (bottom). Representative result of three independent 
experiments was shown in relative density units (RDU).    175
 
4.5 Discussion 
There is growing evidence that chemokines may affect the homeostasis of ECM, and 
excessive synthesis of type I collagen by fibroblasts in the dermis is a pathological hallmark 
of SSc. There is emerging interest to implicate the contribution of inflammation to fibrotic 
response and there are studies to support the pivotal role of chemokines in linking the 
association between inflammation and fibrogenesis. For example, in murine model of 
unilateral ureteral obstruction, marked interstitial macrophage infiltration was observed 
with increase induction of tubular MCP-1 in the obstructed kidney(Morrissey & Klahr, 
1998). Similarly, in a model of bleomycin-induced lung fibrosis, CXCR-2 mediated 
neutrophil recruitment appears to be essential for mediating the lung fibrosis in this 
model(Russo et al., 2008). Moreover, treatment with CXCR2 antagonists led to reduction 
in neutrophil airway transmigration and collagen deposition. Other indirect evidence to 
suggest the central role of CC chemokines in fibrosis is derived from in vitro data that 
blockade of CCR1, an important receptor for both MCP-3 and MCP-1 suppresses the renal 
fibrosis induced by unilateral ureter obstruction and the pulmonary fibrosis induced by 
bleomycin(Tokuda et al., 2000). 
 
However it is also conceivable that lung and renal fibrosis may occur as a result of other 
mechanisms in the absence of inflammation via disrupted cross-talk between epithelial cells 
and fibroblasts(Lange-Sperandio et al., 2007). Therefore, the lack of inflammatory infiltrate 
in Tsk1 as demonstrated in Chapter 3 is intriguing. For this reason, the effect of MCP-3 on 
ECM synthesis was examined in this chapter. The transcriptional regulation of the murine 
pro-α2(I) collagen gene represents a widely used experimental model to study the 
molecular mechanisms responsible for collagen I biosynthesis in particular its 
responsiveness to cytokines and growth factors that are central in the aetiopathogenesis of 
fibrotic conditions. The data showed increased proα2(I) collagen promoter activity in 
response to MCP-3 stimulation with similar dose-response characteristics to those 
previously reported for MCP-1(Gharaee-Kermani et al., 1996). Although relatively high 
concentrations of recombinant cytokine were needed for maximal effect, the threshold for 
activation was often an order of magnitude lower, and likely to reflect expression levels in   176
the pericellular space in vivo. For the promoter assay, initial studies with transgenic murine 
fibroblasts containing a 2-kb upstream fragment driving high-level fibroblast-specific 
expression to reporter genes was used. Such use of transgenic cells represents a 
physiological approach to studies of collagen-gene activation in vitro, since the transgene is 
stably integrated in chromatin and is known to reflect endogenous collagen-gene expression 
in vivo. 
 
Reporter genes regulated by different murine and human promoter sequences were also 
examined in transient transfection studies with early-passage fibroblast cultures. 
Transactivation of Col1a2 in Tsk1 skin has previously been shown to depend on far-
upstream fibroblast-specific elements as well as sequences within the proximal promoter, 
with both proximal and distal regulatory sequences appearing to be responsive to TGFβ. In 
contrast, the data presented in this chapter suggests that MCP-3-induced Col1a2 activation 
may be independent of the upstream enhancer. Whilst it has been reported that the far 
upstream elements may directly respond to TGFβ1 and the presence of several Smad-
binding elements are consistent with this, this do not completely exclude the possibility that 
the upstream enhancer element is acting by amplification of responses mediated via the 
proximal promoter of the Col1a2 which also include a Smad3-binding consensus sequence 
in addition to putative Sp1 and CBF binding sites. One of the five DNase I-hypersensitive 
sites in chromatin identified in the murine proα2(I) collagen gene lies within the 350bp 
promoter which is associated with high levels of expression, or that it provides position-
independent expression in transgenic mice and it may therefore regulate the expression of 
linked genes through the binding of sequence specific transcription factors(Liau et al., 
1986). Moreover, it has been demonstrated that the 350bp proximal proα2(I) collagen 
promoter alone can direct, albeit a low level of reporter expression in transgenic mice. 
Therefore, this raises the possibility that the profibrotic effects of MCP-3 as shown in this 
study are only partly mediated via TGFβ1. Consistent with this, the data on collagen 
protein expression supports the role of MAPK p38 kinase and PI3K in the upregulation of 
collagen by recombinant MCP-3. Moreover, collagen gene upregulation in the fibrotic Tsk1 
skin is likely to occur via a number of pathways that may depend both on TGFβ1 and on 
other factors. In the Tsk1 murine model, targeted mutations in either the signalling chain of   177
the IL-4 receptor or signal transducer and activator of transcription 6 (STAT6) prevents the 
cutaneous hyperplasia in Tsk mice, suggesting the importance of IL-4 and it has been 
shown that IL-4 may induce significant levels of MCP-1 production in stromal 
cells(McGaha et al., 2001;Ong et al., 1999;Lee et al., 2003). Conversely, MCP-1 
upregulates IL-4 mRNA expression and protein production(Lukacs et al., 1997). Thus, it is 
possible that mutual induction of IL-4 and CC chemokines may be important in the fibrotic 
response in Tsk1 mice.  
Consistent with this observation is, in this study, the time course of maximal induction, 
which was between 16 and 24 hours, with little effect before 6 hours. It nevertheless 
remains possible that TGFβ may be a co-factor as well as a potential downstream mediator 
of collagen-gene activation especially since collagen-gene activation was not completely 
abrogated by a high concentration of anti-TGFβ antibody. Conversely, there are recent 
reports suggesting overexpression of CC chemokine, CCL-18 may directly activate ECM 
gene expression in cultured human and dermal fibroblasts. The authors reported that in 
response to CCL18, recruitment of Sp1 and constitutive basal activity of Smad3 which is 
independent of TGFβ bioactivity are necessary for collagen expression in lung 
fibroblasts(Luzina et al., 2006). It is interesting that other studies have suggested that the 
collagen expression regulated by basal Smad3 activity may be mediated via p38 MAPK 
and PI3K pathways(Furukawa et al., 2003;Peron et al., 2001). Using pharmacological 
inhibitors targeted against these two key pathways, the findings presented in this chapter is 
consistent with these reported studies.  
 
At the cell surface TGFβ ligands initially engage the type II high affinity receptor TβRII, 
inducing a conformational change in this receptor to allow dimerisation with type I receptor 
(also known as activin like kinase, ALK) and its phosphorylation. The active complex 
predominantly transmits the signals via Smads, which translocate into the nucleus acting as 
transcription factors. Seven ALKs have been described of which ALK5 activates Smad2/3. 
These two Smads are specific mediators of TGFβ/activin signalling and Smad3 appears to 
be a key element in the signal transduction pathways involved in the in vivo fibrotic 
process. Smad3, but not Smad2, has been demonstrated to be involved in transducing the 
signal from TGFβ receptors to the COL1Α2 promoter. The data presented here is entirely   178
consistent with this as there is down regulation of collagen protein induction with ALK5 
inhibitor (SD208) and a pan-specific anti TGFβ antibody (1D11). TGFβ may activate other 
signalling cascades including MAPK pathways including p38, Erk and JNK kinase 
pathways, some of which regulate Smad activation but others may induce responses 
unrelated to transcription. It is noteworthy that other chemokines including CCL18 have 
been demonstrated to transcriptionally upregulates collagen expression via similar MAPK 
signalling pathways. There have been several reports to support an Akt-dependent pathway 
in basal type I procollagen expression in human dermal fibroblasts and in TGFβ1-induced 
type I procollagen expression(Kim et al., 2008). Consistent with this, a recent report 
demonstrated that mast cell-induced type I collagen expression is upregulated via a 
PI3K/Akt pathway in keloid fibroblasts(Zhang et al., 2006).   179
4.6 Summary 
Data presented in this chapter suggest that MCP-3 may have a profibrotic effect by 
induction of Type I collagen gene in both transgenic 2kb-LacZ fibroblasts and wildtype 
fibroblasts transiently transfected with murine and human minimal promoter for collagen 
gene. The data also supports that the effect on collagen gene and protein appears to be 
partly mediated via TGFβ1 bioactivity.  Additionally, a TGFβ-independent effect on 
collagen protein expression appears to be mediated via MAPK p38 and PI3K signalling 
pathways.   180
CHAPTER 5: EXPRESSION OF MCP-3 IN SCLERODERMA 
5.1 Introduction 
Animal models provide valuable insight into potential mechanisms and key mediators that 
drive the disease in particular in relation to the fibrotic response in the mouse strains 
described in Chapter 3. However, it is important to evaluate the significance of these results 
from animal models and to relate these findings to the human fibrotic diseases. A number 
of studies have demonstrated the crucial role of fibrogenic cytokines and chemokines in 
initiating and/or leading to the sequential events of fibrosis. Chemokines are chemotactic 
cytokines, and have been shown to be involved in various diseases. Moreover, chemokines 
are in an exclusive position
 to integrate inflammatory events and reparative processes and
 
are therefore, important modulators of skin wound healing. For example, unlike normal 
skin, fibroblasts expressing CXCL1 and its corresponding receptor CXCR2 have
 been 
observed recently in keloids that occur during dermal wound healing in genetically 
predisposed
 individuals(Nirodi et al., 2000). Similarly, high concentrations of CXCL4 
within and in close vicinity to the platelet
 plug as a result of platelet degranulation 
immediately after
 wounding may lead to the arrest and accumulation of 
migrating/infiltrating
 fibroblasts, and therefore limiting excessive scarring(Watson et al., 
1994). In addition,
 chemokines have been shown to act directly or indirectly on resident
 
cells, thereby regulating reepithelialisation, angiogenesis, and also myofibroblast 
differentiation(Werner & Grose, 2003). Chemokines might also be involved in
 the 
regulation of skin homeostasis as suggested for CXCL12. This chemokine is constitutively 
expressed
 in dermal fibroblasts and blood vessels of human skin but downregulated after 
injury, suggesting that it may function as a homeostatic regulator of tissue
 
remodelling(Fedyk et al., 2001). 
 
CC chemokines have been demonstrated to be upregulated in a number of different 
pathological processes, including synovial pannus of rheumatoid joints, autoimmune 
lesions of multiple sclerosis, affected mucosal surfaces in ulcerative colitis and Crohn's 
disease, lung inflammation in chronic bronchitis, sarcoidosis, and asthma, and the vascular 
inflammation that characterises atherosclerosis (Table 5.1). For example, in the rheumatoid 
synovium, macrophages not only are activated by MCP-1 but also produce this   181
chemokine(Koch et al., 1992).  More recently, elevated circulating levels of several 
chemokines have been demonstrated in SSc patients (Table 5.2).  
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Table 5.1 Chemokines and their receptors associated with major human diseases. The 
principal human diseases associated with different chemokines and their respective 
receptors are listed. As an integral part of the leucocytic recruitment to sites of infection 
and inflammatory diseases, chemokines and their receptors are implicated in the 
pathophysiology of many important diseases.   182
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2 Elevated serum levels of chemokines in SSc. 
MCP=Monocyte chemoattractant protein; MIP=Macrophage inflammatory protein; 
TARC=thymus and activation-regulated chemokine; MDC=macrophage-derived 
chemokine; CTACK=cutaneous T-cell-activating chemokine; GROα-growth-related 
oncogene α. 
 
Among the CC chemokines, there is accumulating evidence that MCP-1 is essential in the 
development of various fibrotic conditions including SSc(Distler et al., 2008). MCP-1 is 
expressed by fibroblasts, keratinocytes, inflammatory cells and endothelial cells whereas 
normal skin shows no MCP-1 expression(Distler et al., 2001). One of the earliest studies to 
suggest this identified that SSc fibroblasts, but not normal fibroblasts, promote leucocyte 
migration across endothelial cell monolayers through an MCP-1-dependent 
mechanism(Denton et al., 1998), and other studies have subsequently confirmed 
overexpression of MCP-1 in SSc tissues and by lesional fibroblasts in culture(Hasegawa et 
al., 1999;Galindo et al., 2001). Up-regulation of MCP-1 has also been described in several 
chronic inflammatory disorders(Tucci et al., 2006;Van et al., 1999). Whilst there are 
numerous studies to implicate MCP-3 in recruitment of inflammatory infiltrate in major 
inflammatory diseases including asthma and multiple sclerosis, the role of this chemokine 
in fibrotic diseases remains largely unexplored. Serum levels and spontaneous production 
Chemokines References 
CC Chemokine   
       CCL2/MCP-1 
       CCL3/MIP-1α 
       CCL4/MIP-1β 
       CCL17/TARC 
       CCL18/PARC 
       CCL22/MDC 
       CCL27/CTACK 
 
(Hasegawa et al., 
1999;Scala et al., 
2004) 
(Atamas et al., 2003) 
(Fujii et al., 2004) 
(Hayakawa et al., 
2005) 
CXC chemokine   
       CXCL1/GROα 
       CXCL8/IL-8 
(Reitamo et al., 
1993;Furuse et al., 
2003) 
CX3C chemokine   
       CX3CL1/fractalkine  (Hasegawa et al., 
2005)   183
levels of peripheral blood mononuclear cells of MIP-1α and MIP-1β were raised in SSc 
patients compared with normal controls(Hasegawa et al., 1999). In addition, elevated levels 
of MIP-1α correlated with pulmonary fibrosis and other reports have also demonstrated 
increased MIP-1α levels in BAL fluid in SSc patients with alveolitis. Similarly, CCL18 is 
increased in pulmonary fibrosis and its levels reflect the disease activity than did other 
serum markers of pulmonary fibrosis in SSc(Atamas et al., 2003). Serum cutaneous T-cell 
attracting chemokine (CTACK/CCL27) levels were increased in SSc and it is also 
overexpressed in the sclerotic skin of SSc patients(Hayakawa et al., 2005).    184
 
 
5.2 Aims 
Identification of MCP-3 as a highly overexpressed gene in fibroblasts from neonatal Tsk1 
mice raised the possibility that this chemokine might have a role in the pathogenesis of 
fibrosis in these mice. The previous chapter has shown that MCP-3 has a novel in vitro 
profibrotic activity and given that the Tsk1 strain is regarded as a model for human SSc, 
this led me to examine the expression of this chemokine in the skin biopsy specimens and 
fibroblasts cultured from a series of SSc patients. Using dermal fibroblast cell lines 
established from SSc patients and healthy age matched controls the following questions 
were addressed:  
 
1. Is MCP-3 overexpressed in SSc? 
2. If this is increased, are there any there are patterns of expression of this chemokine in 
relation to the subset and stage of disease?   185
 
5.3 Methods 
5.3.1 Cell culture 
5.3.1.1 Cell lines  
All dermal fibroblast cells from patients with dcSSc were maintained as described in 
Section 2.2.1. For experiments, cells were used between passage 2 and 5.  
 
5.3.1.2 Fibroblast conditioned media 
Control and SSc dermal fibroblast cell lines were maintained in DMEM until fully 
confluent. Media was replaced by DMEM (Invitrogen, UK) containing 0.2%FCS (Sigma, 
UK) supplemented with L-glutamine, penicillin G (100 U/ml) and streptomycin sulphate 
(100 µg/ml) (Invitrogen, UK) and the conditioned media collected 24 h later.  
 
5.3.2 Protein expression 
5.3.2.1 Collection of blister fluid 
Dermal interstitial fluid was sampled from the fibrotic forearm
 skin of patients and from the 
forearm of healthy controls using
 a suction blister device (Dermovac, Ventipress), with 
applied
 290–310 mmHg suction for 3–4 h, after which dermal
 fluid was sampled using a 
21-gauge needle and stored at –70°C
 prior to analysis. This is a standard technique used in 
dermatological research for the collection of dermal interstitial fluid. Previous studies show 
that the sieve function of the capillary basement membrane is preserved during suction 
blister formation and that the fluid collected is representative of dermal interstitial 
fluid(Vermeer et al., 1979).  
 
5.3.2.2 Western blot analysis 
To evaluate the differential expression of MCP-3 and MCP-1 in dermal fibroblasts from 
SSc and healthy controls, cultured fibroblast supernatants were collected after overnight 
incubation of skin samples in conditioned medium (200μl per well). All protein extraction 
and Western blotting methodologies performed as described in Section 2.4.3, unless stated 
otherwise.    186
 
5.3.2.3 Antibodies 
All antibodies unless stated otherwise were used as described in Section 2.4.3.3. These 
include goat anti-human MCP-1 antibody, goat anti-human MCP-3 antibody (100 μg/ml) 
(all from R&D Systems, Oxford, UK). Parallel blots of cell lysates and supernatants from 
each culture were probed with a monoclonal antibody against β-actin (Sigma, St. Louis, 
MO) to control for variation in cell number between cultures.  
 
5.3.2.4 Immunohistochemical staining 
Dermal punch biopsy samples were obtained from 22 patients with dcSSc (14 with early 
disease and 8 with established dcSSc), 6 with lcSSc, and 11 healthy controls. For detection 
of MCP-3 protein, immunohistochemistry analysis with a biotin/streptavidin-based 
amplifying system was performed on these dermal sections. Serial sections of frozen 
dermal tissues were stained for MCP-3 protein with goat polyclonal anti-human MCP-3 
IgG antibody (25 μg/ml in PBS; R&D Systems). The major patterns of distribution for 
MCP-3 staining were determined for each subset of SSc and healthy controls. Additional 
mouse monoclonal antibodies were used to identify microvascular pericytes ( SMA, clone 
1A4 1:400, Sigma-Aldrich, Poole), endothelial cells (PAL-E 1:100, Monosan, Uden, The 
Netherlands), macrophages (CD68 1:50, Dako) and fibroblasts (AS02 1:500, Oncogene). 
Controls included an exchange of primary antibodies with isotype-matched corresponding 
IgG antibodies. 
 
5.3.2.5 Assay for MCP-3 in SSc  
MCP-3 levels in the sera, cultured fibroblasts media and blister fluid were assayed by 
commercially available sandwich ELISA (R&D Systems Inc., Oxford, UK). Standard curve 
was derived from the stock solution of 10,000pg/ml with a mean minimum detectable dose 
of 1pg/ml.   187
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5.4 Results 
5.4.1 Upregulation of MCP-3 protein in SSc dermal fibroblast cultures 
Having established fibroblastic MCP-3 protein upregulation in Tsk1 and TβRII∆k 
transgenic murine models, parallel analyses of dermal fibroblast culture media from early 
stage dcSSc were compared with matched controls. The level of MCP-3 immunoreactivity 
in SSc fibroblast supernatants (mean ± SEM relative density units [RDU] 4.92 ± 1.12 in 
controls versus 8.27 ± 0.5 in SSc; p = 0.02) was greater than that observed for MCP-1 
(RDU 3.84 ± 0.73 versus 7.87 ± 0.14, respectively; p = 0.01), as shown in Figure 5.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Overexpression of MCP-3 and MCP-1 by lesional SSc human skin fibroblasts. 
Fibroblasts culture media from representative normal or SSc dermal fibroblast cultures 
were analysed using antibodies to MCP-3 and MCP-1. Cell layer β-actin staining was used 
as a loading control, and recombinant human MCP-3 and MCP-1(rH) were used to confirm 
primary antibody specificity (Top panel). Densitometry analysis summarising 3 
independent experiments shows the mean and SEM protein levels for MCP-3 and MCP-1 
in relative density units (RDU) (Bottom panel).    188
 
5.4.2 Dermal overexpression of MCP-3 in subsets of cutaneous SSc 
There was variable amount of specific immunostaining for MCP-3 in the lower epidermal 
layer, in both healthy control and SSc biopsy samples. However, as discussed in Chapter 
3.4.3 with Tsk1 skin, SSc lesional skin sections showed dermal expression of MCP-3 as 
well as additional strong MCP-3 expression in and around the blood vessels at sites of 
mononuclear cell infiltrates. The majority of the inflammatory mononuclear cells in SSc 
skin were positive for CD68 (Figure 5.2). Consistent with the data on mRNA and protein 
expression, additional immunostaining studies using anti-AS02 which recognises Thy-1 
antigen on fibroblasts suggest that MCP-3 is localised away from vascular or epithelial 
structures. Additional immunostaining with monoclonal antibody against PAL-E, an 
endothelial cell surface antigen and α-SMA antibodies suggests that MCP-3 may localise 
with endothelial and pericytes (Figure 5.3). 
 
Figure 5.2 Increased MCP-3 expression in early-stage diffuse cutaneous systemic sclerosis 
(dcSSc) skin biopsy samples. Dermal MCP-3 localisation with vascular immunostaining is 
observed in A and B respectively. Most of these samples were positive for the fibroblast 
marker AS02 and monocyte/macrophage marker CD68 in juxtaposed sections (shown in C 
and D respectively in bottom two panels). (Original magnification x240) 
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Figure 5.3 Increased perivascular MCP-3 expression in dcSSc. Shown in panel A, in these 
skin biopsies from patients with dcSSc, the pattern of immunostaining for perivascular 
MCP-3 infiltration appears to localise with endothelial cells and pericytes, demonstrated in 
panels B and C respectively. In contrast, control skin samples did not demonstrate any 
significant immunostaining with IgG with normal goat IgG as shown in panel D. (Original 
magnification x240) 
 
There was significantly more MCP-3 expression in skin biopsies from patients with early-
onset diffuse disease compared to established diffuse or limited cutaneous SSc indicating 
that it is associated with inflammatory or progressive skin disease (Figure 5.4). Negative 
controls with IgG isotype-matched antibodies showed no staining.    190
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Figure 5.4 Expression of MCP-3 in different subsets of SSc and healthy controls. There is 
a variable amount of epidermal staining (e with arrow) in skin sections from patients with 
established dcSSc (A) and in clinically uninvolved early dcSSc skin (B) or limited 
cutaneous SSc (lcSSc) skin (C) and in skin from healthy controls (D). Minimal vascular 
MCP-3 immunostaining is detected in uninvolved skin from patients with established 
dcSSc (A) and lcSSc (C). (Original magnification × 240.)  
 
Table 5.3 summarises the staining patterns observed in SSc skin biopsy specimens. 
Immunostaining for MCP-3 was associated with an inflammatory infiltrate with vascular 
localisation in the majority of skin sections from patients with early dcSSc (n=14) as well 
as more diffuse dermal staining. Diffuse dermal staining was absent in the skin sections 
from patients with established dcSSc and lcSSc. 
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0 10 0 Diffuse dermal
2 10 0 Perivascular
2 12 0 Inflammatory infiltrate
n = 8 n = 14 n = 11
Established dcSSc Early dcSSc Control
Pattern
6 14 8 Epidermal
0 10 0 Diffuse dermal
2 10 0 Perivascular
2 12 0 Inflammatory infiltrate
n = 8 n = 14 n = 11
Established dcSSc Early dcSSc Control
Pattern
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3 Histological characteristics of dermal expression of MCP-3 in SSc and healthy 
controls. The values represent the number of samples displaying the respective staining 
patterns for MCP-3. Early dcSSc is defined by <2 years’ duration. 
 
5.4.3 Overexpression of MCP-3 in biological fluids in SSc 
Having established overexpression of MCP-3 in the dermis of early active diffuse SSc on 
Western blot analysis and immunohistochemistry, I examined whether similar upregulation 
of MCP-3 is observed in the sera, cultured fibroblast media and blister fluid samples 
assayed by ELISA in 15 controls and patients with dcSSc. There was elevated sera 
expression of MCP-3 in dcSSc, 25.7 ± 4.1 (mean ± SEM) compared to controls, 13.2 ± 2.7 
pg/ml, p=0.02. Interestingly, there was heterogeneous expression of MCP-3 among the 
patients with dcSSc with a subset of patients demonstrating higher mean level, 35.8±3.9 
(Mean± SEM) (n=6) compared to the remaining patients with a mean 14.8±3.4 (Figure 
5.5).  This is in contrast to the generally increased MCP-3 immunoreactivity in the dermis 
of early dcSSc as discussed in Section 5.4.2. This may be related to MCP-3 sequestration in 
the early stage disease.    192
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Figure 5.5 Serum level of MCP-3 in early-stage dcSSc. Shown on the left is the standard 
curve for MCP-3 levels. On the right, there was increased level of MCP-3 in the sera from a 
subset of patients with early-stage dcSSc compared to matched healthy controls. O.D.: 
Optical density. 
 
There was overexpression of protein in the explanted fibroblasts supernatant (Mean±SEM) 
in SSc, 796±323 pg/ml (n=4) compared to controls 617±282 pg/ml (n=4), as shown in 
Table 5.4. This is consistent with results on Western blot experiment on cultured 
fibroblasts supernatant in Section 5.4.1. However, there was no difference in MCP-3 
expression in blister fluid with 181±16.4 in controls (n=2) and 193.4±4.9 in SSc samples 
(n=2).  
 
 
 
 
 
Table 5.4 Expression levels of MCP-3 in fibroblast culture supernatants were determined 
in pg/ml using specific ELISA kit. (p=0.04 as determined by Student’s unpaired t-test).    193
  
5.5 Discussion 
There is increasing evidence to implicate CC chemokines in various fibrotic conditions. 
Previous chapters have indicated that MCP-3 is overexpressed in murine models for 
fibrosis and the data in this chapter suggests that this chemokine is also overexpressed in 
human SSc. The array data presented in Chapter 3 suggest that MCP-3 is upregulated 
neonatally in Tsk1 skin and not overexpressed at 12 weeks. These findings are consistent 
with the more frequently observed MCP-3 overexpression in early dcSSc skin as compared 
with biopsy samples of skin with established disease. This would suggest that MCP-3 may 
be an important initiator in the cascade of mediators leading to dermal fibrosis. This is 
similar to the characteristics of other profibrotic mediators including TGFβ1 in skin 
samples which often show little expression in established lesional skin of SSc (Querfeld et 
al., 1999).  
 
The significance of the differences in staining patterns for MCP-3 in SSc is unclear. Diffuse 
dermal expression was observed in dcSSc skin samples. The lack of uniform staining for 
MCP-3 protein may suggest metabolic heterogeneity in fibroblasts activity in collagen 
synthesis. This was also observed with dermal expression of MCP-1 in SSc, with 
predilection for areas close to blood vessels (Galindo et al., 2001). More recently, our 
group also demonstrated similar heterogeneity in fibroblastic expression for CCR2, the key 
receptor for MCP-1 and MCP-3 in early stage dcSSc(Carulli et al., 2005).         
Furthermore, fibroblast cultures from various levels of involved SSc skin revealed that the 
highest collagen-producing populations were found at the lower levels of the dermis and 
that there was a synchronised increase in type I and type III collagens and fibronectin. 
These suggest that fibroblasts at the lower dermis and around the blood vessels were the 
most active, suggesting fibroblast clonal selection that expresses a phenotype for high 
matrix protein synthesis. 
 
Epidermal staining for MCP-3 was observed in the skin samples from SSc: however, this 
finding was also detected in the healthy controls. Interestingly, it has also been recently   194
reported that there is a similar lack of specificity of epidermal expression for MCP-1 
expression in early stage dcSSc(Carulli et al., 2005). However other authors have 
documented strong MCP-1 expression in keratinocytes particularly at the lower epidermal 
layers(Galindo et al., 2001). Similar perifollicular staining was also observed in both 
control and lesional samples, and these patterns are unlikely to be of pathogenic 
significance, although it is apparently specific and therefore may reflect a physiological 
function for MCP-3.  Although this present study did not examine receptor dermal 
expression, strong immunoreactivity for CCR2 and CCR3, the key receptors for MCP-3 has 
been described in SSc and atopic dermatitis respectively(Carulli et al., 2005;Wakugawa et 
al., 2001).  
 
By immunostaining, MCP-3 was more frequently expressed in vascular and perivascular 
inflammatory mononuclear cells and scattered fibroblasts in the dermis of SSc patients 
especially those with early diffuse SSc. Other chemokines are also expressed in similar 
distribution (Table 5.5). The vascular and perivascular staining observed in early-stage 
dcSSc may reflect a role for fibroblast-derived MCP-3 in mononuclear cell extravasation, 
and the colocalisation with CD68-positive cells supports this. These findings are also 
consistent with recent in vivo evidence that has established the important parallel 
contributions of MCP-3 and MCP-1 in CCR2-mediated inflammatory monocyte 
recruitment from bone marrow to inflamed tissues in murine model of thioglycollate-
induced peritonitis and L .monocytogenes infection(Jia et al., 2008;Tsou et al., 2007). It is 
possible that MCP-3 overexpression recruits macrophages into the SSc skin, leading to the 
initiation of skin fibrosis and production of other inflammatory or fibrotic cytokines.    195
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Fibroblasts 
Endothelial 
cells 
 
 
References 
CCL2/MCP1 ++  +  +  +  (Distler  et al., 
2001;Hasegawa 
et al., 
1999;Galindo et 
al., 2001) 
CCL5 ++  -  - -  (Anderegg  et al., 
2000) 
CXCL8 +  +  ++  (Koch  et al., 
1993) 
CX3CL1       ++  (Hasegawa  et 
al., 2005) 
Table 5.5 Upregulated chemokine expression in SSc skin. 
 
The localisation of MCP-3 in α-SMA pericytes is consistent with recent findings that MCP-
1 colocalised with α-SMA pericytes(Carulli et al., 2005). Pericytes are believed to be 
critical for vascular homeostasis in wound healing and fibrosis. Thus, in early dcSSc, 
microvascular pericytes become activated and expressed PDGFβ receptor and may be a 
source of tissue myofibroblasts. Myofibroblasts are important in the pathogenesis of 
fibrotic diseases. Fibroblasts when activated primarily by growth factors including TGFβ 
acquire smooth muscle cell-like features including stress fibre formation as well as de novo 
expression of α-SMA and specific ECM proteins. Persistence of myofibroblasts has been 
postulated to be the common feature of fibrotic disease.  
 
Whilst the data suggests that there was consistency in the overexpression of MCP-3 in the 
cultured fibroblasts supernatants from dcSSc compared to healthy controls, quantified by 
both ELISA and Western blot analysis, the measured expression of this chemokine in the 
sera indicates heterogeneity with a subset of patients expressing high levels of MCP-3. This 
mirrors the recently reported findings that there is considerable heterogeneity in expression 
of MCP-1 and the cognate receptor for MCP-1 and MCP-3, CCR2 between cultured 
fibroblasts from different patients with early dcSSc(Carulli et al., 2005). Interestingly, 
among these populations of early dcSSc fibroblasts, those that express CCR2 receptor   196
appear to have a myofibroblast phenotype. It is also possible that heterogeneity in the 
expression of chemokines and their receptors by fibroblasts may be partly genetically 
determined.  
 
Expression of MCP-3 in different biological fluids was studied to examine the localisation 
of this chemokine in SSc. For example, suction blister fluid measures locally produced 
growth factors and cytokines in the extracellular fluid. Although these factors may be 
localised in these body compartments, the functional significance of this is unclear. It has 
been demonstrated that N and C-terminal CTGF cleavage products are found in biological
 
fluids such as uterine flushings(Ball et al., 1998), but their biological relevance
 is not 
known. In SSc, it has been reported that although, whole CTGF and C-terminal CTGF were
 
present only at low levels and showed no difference between the different disease 
subgroups, only N-terminal
 CTGF levels were elevated in SSc blister fluids from dcSSc 
patients when
 compared to healthy controls(Dziadzio et al., 2005). Other studies have 
demonstrated elevated soluble forms of ICAM-1 and IL-2R in suction blister fluid samples 
from early SSc suggestive of activation of endothelial cells and T cells in SSc although it 
was noted there was significant overlap in the measured values for these factors in both SSc 
and control samples(Sondergaard et al., 1998). From the data presented in this chapter, 
there was no difference in MCP-3 expression in dcSSc and controls and this may reflect the 
small numbers of samples studied. However, the absence of any differential MCP-3 
expression may also suggest that MCP-3 is internalised once it is bound to GPCRs
 or 
degraded.  
 
It is interesting that in inflammatory bowel diseases, expression of MCP-3 was strictly 
correlated with disease severity (Uguccioni et al., 1999). It is possible that MCP-3 may 
serve as a severity marker in SSc. Similar correlation of chemokine expression and disease 
activity has been demonstrated in other autoimmune diseases including rheumatoid arthritis 
and SLE(Ellingsen et al., 2001;Narumi et al., 2000).   197
 
5.6 Summary 
This chapter extends the observations made from previous chapters that MCP-3, in addition 
to be overexpressed in the murine model for fibrosis, is also upregulated in SSc in 
particular in the active stage of diffuse disease with significant expression in the dermis and 
perivascular distribution albeit some heterogeneity in its expression. This may be a key 
determinant of the clinical disease phenotype and that expression of MCP-3 in early stage 
dcSSc may be a useful marker for disease severity or predictor of outcome. 
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CHAPTER 6: REGULATION OF MCP-3 EXPRESSION 
 
6.1 Introduction 
MCP-3 is one of the pluripotent CC-chemokines and may be induced in various cell types 
in response to endogeneous or exogeneous stimuli including inflammatory cytokines 
TNFα. For example, induction of MCP-3 was expressed by cultured fibroblasts treated 
with a combination of IL-1β and IFNγ and its expression in airway smooth muscle cells 
was suppressed with anti-inflammatory steroids(Menten et al., 1999;Pype et al., 1999).  In 
contrast to homeostatic chemokines (e.g. CXCL13) which are constitutively expressed, 
inflammatory or induced chemokines including MCP-3 are transcriptionally regulated 
during inflammation and mediate the recruitment of inflammatory cells to target tissues.  
 
The intracellular signalling regulating MCP-3 secretion is largely unknown. A recent study 
suggests that PI3 kinase-Akt/PKB pathway mediates MCP-3 secretion in neuronal cells, 
and therefore confers a survival advantage(Bandyopadhyay et al., 2007). Similarly, PI3K, 
and not protein kinase C mediates MCP-3 secretion by mononuclear cells stimulated by 
combination of IL-1β and LL-37, a host defence peptide which modulates the innate 
immune responses. In addition, this study supported previous reports that MCP-3 
expression, like its related chemokine, MCP-1, is regulated in part by
 the transcription 
factor NFκB (Yu et al., 2007). In contrast, other authors have reported the role of MAPK 
p38, ERK and JNK kinase in induction of MCP-3 in human airway smooth muscle 
cells(Wuyts et al., 2003). It is therefore likely that the expression of MCP-3 is regulated in 
a cell-specific and context-specific manner. 
 
The increasing number of reports that demonstrated upregulation of MCP-3 in various 
inflammatory and autoimmune diseases suggests that regulation of this chemokine 
expression may contribute to the aetiopathogenesis of these conditions.  For example, 
recent studies have demonstrated distinct regional expression regulation for MCP-3 in 
correlation with chronic inflammation in multiple sclerosis brains(Banisor et al., 2005). 
These observations are consistent with previous studies, and therefore, support the   199
involvement of MCP-3 in the development of inflammatory demyelination. Previously, 
Van Damme analysed the transcription regulation of MCP-3 promoter and identified an 
active AP-1-like element at position -37 and an Ets-like element in the region between -190 
and –172 upstream to the transcription start site that inhibited the promoter activity in MG-
63 cells(Murakami et al., 1997). Further studies have demonstrated several positive and 
negative regulatory elements in the promoter in response to various cytokines including IL-
1β in different cells lines including MG-63 cells, monocytes, osteosarcoma tumour cells 
and endothelial cells. In contrast, there have been few studies on regulation of fibroblastic 
expression of MCP-3. Upregulation of MCP-3 expression in dermal fibroblasts by IL-4 
may be mediated by the AP-2 cis element within 1.2 kb proximal to the transcription start 
site. In addition, the presence of two putative NF-κB transcription sites within the promoter 
may underlie the induction of MCP-3 mRNA expression by TNFα in dermal 
fibroblasts(Hein et al., 1999).    200
 
 
6.2 Aims 
 
The previous chapters have demonstrated that MCP-3 is overexpressed in murine models of 
fibrosis and SSc, raising the possibility of a novel role as a profibrotic mediator. Moreover, 
its upregulation in TβRIIΔk model with activated TGFβ-dependent pathways suggests 
MCP-3 may be regulated by TGFβ.  
 
To explore the potential synergism between these mediators, I examine the effect of TGFβ 
on MCP-3 bioactivity. 
This chapter aims to: 
1. Determine the regulation of MCP-3 gene and protein expression by TGFβ 
2. Elucidate signalling pathways governing the activation of MCP-3 expression by TGFβ   201
 
6.3 Methods 
6.3.1 Generation of MCP-3 1kb promoter reporter gene construct 
To explore the molecular mechanisms underlying the activation of MCP-3 induction by 
TGFβ in dermal fibroblasts, a 1kb upstream fragment of the murine MCP-3 promoter 
containing the TATAA box and transcription start site, flanked by BglII and HindIII was 
generated from the MCP-3-pUC19 construct (Figure 6.1) and cloned into the luciferase 
reporter vector pGL3 (Promega) as described below. 
 
6.3.1.1 Culture and purification of MCP-3-pUC19 
A pUC19 plasmid cloning vector containing a 4.7 kb Pst1 fragment of the MCP-3 proximal 
and upstream promoter inserted at the Pst1 site was kindly donated by Professor Van 
Damme, Rega Institute, Belgium, and this was used to generate a 1kb upstream promoter 
sequence(Murakami et al., 1997). 
 
The MCP-3 promoter-containing pUC19 DNA was transformed into the E.coli strain DH5α 
as described in Section 2.3.3. DNA was isolated using the Qiagen Plasmid Maxi Prep kit 
(Qiagen) as per the manufacturer’s instructions. Briefly, an overnight culture of the E.coli 
strain DH5α containing the pUC19 plasmid was inoculated into 500 ml of LB and agitated 
overnight. DNA was prepared as described in Section 2.3.4.2 taking care to avoid vortexing 
to prevent DNA shearing. Upon binding of the DNA to the Qiagen-tip 500, ATP-dependent 
exonuclease was applied to digest any contaminating genomic DNA, leaving only 
supercoiled pUC19 DNA remaining. The plasmid DNA was eluted, precipitated with 0.7 
volumes of isopropanol and collected by centrifugation. The DNA pellet was resuspended 
in an appropriate volume of TE buffer and the concentration was determined by UV 
spectrophotometer (Hitachi U-2001).   202
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Figure 6.1 pUC19 cloning vector incorporating the 4.4kb MCP-3 promoter inserted at the 
Pst1 restriction site. The shaded area on the promoter was amplified to generate the 1kb 
fragment upstream to the transcription start site with BglII and HindIII restriction 
sites(Murakami et al., 1997). *The HindIII restriction enzyme site was generated. 
 
6.3.1.2 Generation of MCP-3 1kb promoter-construct 
A 1kb promoter fragment was amplified using polymerase chain reaction (PCR) and 
oligonucleotides that were designed to amplify the specific region of the MCP-3 promoter 
adjacent to the BglII site at position -1025, upstream of the transcription start site. The 
oligonucleotide primers annealed to the MCP-3 promoter are forward primer 5’-
GCAGATCTTGATATGCTGTGCAG-3’ at position -1025 and reverse primer 5’-
GCAAGCTTGAGAATTGGAGGTTTCTGGTT-3’ at position +52 upstream of the 
transcription start site respectively. The forward primer contains a BglII (endogenous) 
restriction enzyme site and the reverse primer contains a HindIII (exogenous) restriction 
enzyme site (Figure 6.2). A PCR reaction mixture containing 115ng of the MCP-3 
promoter-pUC19 (57.7ng/ul) as template; 50pmol of each oligonucleotide primer; and 38ul 
of master mix (5ul 1x Pfu DNA polymerase (Promega, UK) with 10x Reaction Buffer with 
MgSO4 and 10mM dNTPs) was over laid with oil to prevent evaporation and placed in an   203
automated thermal cycler PTC-100 (MJ research, Inc). Pfu DNA polymerase which has 
proofreading properties was added after the addition of dNTPS to ensure high fidelity 
amplification.   
 
MCP3F1
5’-GCAG A T  C T T GAT ATG CTG TGC AG-3’
Purification HPSF 60.6 0C Tm 33.2 nmol
Scale     0.01 μmol 7095 g/mol Molecular weight 235 μg
GC Content  47.8% 332 μl Volume for 100 
pmol/μl
8.4 OD
Length       23-mer 33 pmol/μl Concentration 
(Volume 1 ml) Amount
MCP3R1
5’-GCA AGC TTG AGA ATT GGA GGT TTC TGG TT-3’
Purification  HPSF 65.3 0C Tm 67.3 nmol
Scale     0.01 μmol 9019 g/mol Molecular weight 607 μg
GC Content 44.8% 673 μl Volume for 100 
pmol/μl 21.8 OD
Length       29-mer 67 pmol/μl Concentration 
(Volume 1 ml) Amount
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Figure 6.2 Oligonucleotide sequences for the two primers used to amplify the 1kb-
upstream region of the murine MCP-3 promoter. The MCP3F1 contains the BglII 
restriction enzyme site and the reverse primer, MCP3R1 contains a HindIII restriction 
enzyme site.   204
After being initially denatured for 2 minutes at 95 C with a single cycle, the MCP-3 
promoter was amplified for 25 cycles (95
0C for 30 secs, 50
0C for 30 secs, 72
0C for 2 
minutes). This was followed by final extension at 72
0C for 5 minutes to ensure all the PCR 
products are completely blunted and the reaction mixture was cooled overnight at 6
0C for 
30 hours. Using the agarose gel electrophoresis (0.8%), the quality of the amplified blunt 
PCR product was verified to demonstrate a discrete band at 1kb (Figure 6.3). The 
appropriate fragment was isolated and purified using QIAquick gel extraction kit (Qiagen) 
and QIAquick PCR Purification kit (Qiagen).  
1000 bp
1 2 3
2000 bp
1000 bp
1 2 3
2000 bp
 
Figure 6.3 Generation of MCP-3 1kb promoter fragment by PCR. The 1kb upstream 
fragment of the murine MCP-3 promoter, flanked by BglII and HindIII, was amplified 
using PCR with primers containing a BglII restriction enzyme site and HindIII restriction 
enzyme site. Lane 1: 1 kb Plus DNA ladder (Invitrogen); Lane 2 and 3:1 kb fragment of 
MCP-3 promoter.   205
 
The blunt-end PCR product was directly inserted into pCR-BluntII-TOPO cloning plasmid 
vector (3.5kb) as per manufacturer’s instruction (Invitrogen, Paisley, UK). This cloning 
strategy was preferred to direct digestion of the promoter fragment with ligation into pGL3 
Basic Vector because the number of bases in the primers used in the PCR (Figure 6.2) was 
too few to ensure effective digestion for direct ligation into the reporter vector. The cloned 
plasmid was analysed with restriction digest with BglII and HindIII to confirm the presence 
of the 1kb insert (Figure 6.4). The construct is then transformed into competent E. coli 
cells, isolated and resuspended in an appropriate volume of TE buffer. Its concentration 
was determined by UV spectrophotometer at 250ng/ul. 
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Figure 6.4 Generation of 1 kb promoter-construct with pCR-BluntII-TOPO cloning 
plasmid vector. Following insertion of the PCR product with the 1kb promoter-construct 
into pCR-BluntII-TOPO cloning plasmid vector, the cloned plasmid was restriction 
digested with BglII and HindIII and the 1 kb fragment was isolated (Lanes 2 and 3). Lane 
1: 1 kb Plus DNA ladder. All restriction enzymes were used at 10 U/μg.     206
 
6.3.1.3 DNA Ligation for 1kb MCP-3 promoter fragment into pGL3 reporter vector 
To clone the 1kb promoter construct into basic pGL3-Luciferase reporter vector (Promega), 
both TOPO cloning plasmid vector containing the 1kb-MCP-3 promoter 
construct(250ng/ul) and basic pGL3-plasmid vectors(2.44μg/ul) were digested with BglII 
and  HindIII. The digested fragments were resolved by agarose gel electrophoresis as 
described in Section 2.3.6 (Figure 6.5).  
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Figure 6.5 Restriction digestion of cloned plasmid with 1kb MCP-3 promoter-construct 
and pGL3-Basic plasmid vector. Lane 1: 1kb MCP-3 promoter with TOPO cloning plasmid 
vector digested with with BglII and HindIII to yield the 1 kb fragment of MCP-3 and the 
3.5kb linearised TOPO cloning plasmid vector, Lane 2 and 3: pGL3-Basic plasmid vector 
linearised with similar restriction enzymes to yield the full-length 4.8 kb fragment. Lane 4: 
1 kb Plus DNA ladder. All restriction enzymes were used at 10 U/μg.     207
 
The appropriate fragment was gel isolated and concentration determined by UV 
spectrophotometer. The concentration of 1kb MCP-3 promoter was 15ng/μl and for 
linearised pGL3-Luciferase vector is 50ng/μl. The linearised pGL3 vector and purified 1kb 
MCP-3 fragment were ligated using T4 DNA ligase (Promega) with equal molar ratios of 
DNA fragments from pGL3 basic (BglII/HindIII digested) and MCP-3 promoter 
(BglII/HindIII digested) in 20 μl 10 mM Tris-Cl ph 7.4, 10 mM Mg
2+ , 1 mM ATP, 1 mM 
DTT using 1 U T4 DNA ligase (Promega) and 60ng of 1kb MCP-3-promoter fragment and 
75ng of linearised pGL3-Luciferase vector, at 16
0C for 16 hours. 
 
Ligation reactions were transformed into DH5α  E.coli (Invitrogen) and plasmid DNA 
amplified using DNA Miniprep method (Qiagen). The ligated product was validated by 
diagnostic restriction digestion with BglII and HindIII, and resolved with agarose gel 
electrophoresis (Figure 6.6). Two other restriction digestion sites, NheI and BamHI were 
selected to validate the ligated product as shown in Figure 6.7.   208
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Figure 6.6 A. Diagnostic restriction digestion of ligated pGL3-Basic vector containing the 
1kb-promoter fragment. A.  Lane 1: 1 kb Plus DNA ladder. Lane 2: Ligated product 
restriction digested with BglII and HindIII to yield the 1kb MCP-3 promoter fragment and 
the linearised 4.8kb pGL3-Basic vector. Lane 3: Ligated product linearised with HindIII to 
yield a 5.8kb fragment.  
B.  pGL3-Basic plasmid vector harbouring the 1kb-MCP-3 promoter construct with 
designated restriction sites for BglII and HindIII.   209
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Figure 6.7 A. Diagnostic restriction digestion of ligated pGL3-Basic vector containing the 
1kb-promoter fragment. A. Lane 1: pGL3-Basic vector linearised with BamHI to yield its 
full-length 4.8kb fragment Lane 2: pGL3-Basic vector linearised with NheI to yield its full 
length 4.8kb fragment. Lane 3: Ligated product restriction digest with BamHI to yield two 
fragments, 2.8kb and 2.9 kb fragments Lane 4: Ligated product restriction digested with 
Nhe1 to yield 2 fragments at 809bp and 4.9kb bands. Lane 5: 1 kb Plus DNA ladder. 
B. pGL3-Basic plasmid vector containing the 1kb-MCP-3 promoter construct with 
designated restriction sites for BamHI and NheI.   210
 
To verify that the correct promoter fragment has been generated and to confirm the 
direction of insertion, sequencing analysis with MWG-Biotech using the primers shown in 
Table 6.1 were undertaken. Two internal oligonucleotide primers within the 1kb promoter 
sequence and two external oligonucleotide primers adjacent to the multiple cloning sites of 
pGL3 reporter vector were used for sequencing analysis. The concentration of pGL3-Basic 
plasmid vector containing the 1kb MCP-3 promoter was determined with UV 
spectrophotometer at 3.47μg/ul. 
 
 
A.  Primers        Oligonucleotide                      No of bases of good  
          quality sequence 
TOP764:    5’-CTG CTG GCT GTT GAA GTC –3’          1035 
TOP519:    5’-GCC ACC AGG ATT TAA GAC AGT G-3’                      697 
GLP111:    5’-CTT TAT GTT TTT GGC GTC TTC CA-3’                      986 
RVP4760:  5’-CTA GCA AAA TAG GCT GTC CC-3’           886 
 
Figure 6.8 Sequencing of 1kb MCP-3 promoter fragment in pGL3 reporter vector. 
A. Oligonucleotide primers used to 
sequence the inserted promoter fragment 
in pGL3-Luciferase reporter vector. 
GLP111: This is used for sequencing 
counterclockwise upstream of luciferase 
gene (111bp on pGL3 Basic Vector), 
RVP4760: This is used for sequencing 
clockwise across the upstream multiple 
cloning sites (4760bp on pGL3 Basic 
Vector). With these two primers, there was 
an overlap of 695 bp of good quality 
sequence within the 1kb MCP-3 promoter 
fragment. For the remaining two 
oligonucleotide primers: TOP764 and 
TOP519 at –764bp and –519bp 
respectively, annealed to the MCP-3 
promoter as indicated in B, 5’ to the 
transcriptional start site and both primers 
are used for sequencing clockwise. 
MCP-3 1kb 
promoter-
pGL3
BglII HindIII TOP764 TOP519
RVP4760 GLP111
B.
MCP-3 1kb 
promoter-
pGL3
BglII HindIII TOP764 TOP519
RVP4760 GLP111
B.  211
 
6.3.2 Cell culture 
Control and transgenic TβRIIΔk fibroblast cell lines were used in the course of the studies 
presented within this chapter. All cell lines were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen, UK) supplemented with 10% fetal calf serum (FCS; 
Gibco, UK), 100 units/ml penicillin, and 100mg/ml streptomycin, and cultured in a 
humidified atmosphere of 5% CO2 in air. The cells were then serum starved with 0.2% FCS 
for 24 hours, and then stimulated with appropriate recombinant cytokines. Where 
appropriate, pharmacological inhibitors were added to cultured fibroblasts 45 minutes prior 
to stimulation with the recombinant cytokines: ERK inhibitor U0126 (20μM; Promega, 
Southampton, United Kingdom), SB203580 (20μM) and Calphostin (500nM) (all from 
Calbiochem, La Jolla, CA), Curcumin (20μm; Sigma, St. Louis, MO) and SD-208, inhibitor 
of the TβRI kinase (1μM, Scios Inc., Fremont CA) and cultured for an additional 24 hours. 
 
6.3.3. Smad3 siRNA transfection studies 
To study the effect of TGFβ signalling pathway on TGFβ-mediated expression of MCP-3 
protein in fibroblast supernatants, Smad3 siRNA (20 nM and 80 nM, Santa Cruz 
Biotechnology, Santa Cruz, CA), transfected into cultured fibroblasts stimulated with 
recombinant TGFβ1, was used to knock down expression of Smad3 protein. As a negative 
control, non-silencing or control siRNA (80 nM) with non-targetting 20-25 nucleotide 
siRNA is used, and total Smad3 and GAPDH expression in culture media and cell lysates 
were used to confirm downregulation of Smad3 and as loading control respectively. Rabbit 
polycolonal anti-total-Smad3 was obtained from Cell Signalling Technology (Beverly, 
MA). Experimental procedures were performed as outlined in 2.2.3.4.   212
                 
 
 
6.4 Results 
6.4.1 Upregulation of MCP-3 protein by TGFβ in wildtype murine fibroblast cultures 
To investigate the effect of TGFβ on the expression of MCP-3 in murine dermal 
fibroblasts, confluent dermal fibroblasts were incubated with recombinant TGFβ1. MCP-3 
protein was induced in the fibroblast supernatants treated with recombinant TGFβ1 with 
different concentrations at 4-20ng/ml (Figure 6.9). Much interest has focused on the role of 
the Smad family of proteins in TGFβ signalling in fibroblasts, that the activated TGFβ 
receptor complex phosphorylates Smad3, which in turn associates with Smad4 to form 
complexes that determine many of the major effects of TGFβ on transcriptional activation. 
Therefore, to explore the effect of this canonical Smad signalling pathway on MCP-3 
induction by TGFβ, cultured dermal fibroblasts transfected with Smad3 siRNA were 
incubated with recombinant TGFβ1. As shown in Figure 6.10, the increase in MCP-3 
protein in the fibroblast supernatants was blunted in the presence of Smad3 siRNA. 
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Figure 6.9 Upregulation of MCP-3 protein expression by recombinant TGFβ1 in wildtype 
murine fibroblast supernatants.   213
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Figure 6.10 Upregulation of MCP-3 protein expression by recombinant TGFβ1 is mediated 
by TGFβ signalling pathway. Smad3-specific siRNA dose-dependently suppresses TGFβ-
induced MCP-3 protein expression towards basal levels in murine fibroblasts without 
affecting constitutive GAPDH levels. The panels represent MCP-3 (upper), Total Smad3 
(middle) and GAPDH (bottom) Western blots. Cell lysate GAPDH was used as a protein-
loading control.   214
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6.4.2 Transcriptional activation of MCP-3 promoter by TGFβ in wildtype and 
transgenic TβRIIΔk fibroblasts 
As discussed in Chapter 3, upregulation of MCP-3 transcript and protein in transgenic 
TβRIIΔk mice provides the first evidence that MCP-3 is regulated by TGFβ. Therefore, to 
investigate if this induction may be ascribed to transcriptional activation mediated by 
TGFβ, the response of MCP-3 promoter to recombinant TGFβ1 was examined in wildtype 
fibroblasts. Recombinant TGFβ1 stimulated the promoter activity of MCP-3 and time-
course experiment demonstrated that there is little upregulation at 6-18 hrs with significant 
upregulation at later time point. Compared to basal level, there is time-dependent activation 
of MCP-3 promoter by recombinant TGFβ1 with (Mean±SEM, p = 0.01) 95.9±4.5% and 
109±6.4% at 24 and 48-hour time-points respectively (Figure 6.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11 Time course for transactivation of the murine MCP-3 gene in transient 
transfection of neonatal murine fibroblasts is shown as reporter gene expression in 3 
independent experiments for the upstream 1kb MCP-3 promoter construct linked to 
luciferase reporter gene. Assays were performed in triplicate, and the average is shown with 
the standard error of the mean, (* p<0.05, **p<0.01, by Student’s unpaired t-test. 
RLU=Relative Luminescent Units).  
 
 
Expression studies of TGFβ-regulated PAI-1 and CCN2 (Chapter 3) demonstrated that 
transgenic TβRIIΔk fibroblasts were partially refractory to recombinant TGFβ1 and that   215
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there is upregulation of MCP-3 in the transgenic fibroblasts. Therefore, to explore whether 
similar altered TGFβ responsiveness may be observed with MCP-3, the activation of MCP-
3 promoter was compared in wildtype with that of transgenic TβRIIΔk murine fibroblasts 
in the presence or absence of recombinant TGFβ1. Compared to the TGFβ1-dependent 
activation in wild type cells, there was basal promoter activation by transgenic fibroblasts 
(157 ± 57 %) but there was no further upregulation by recombinant TGFβ1(Figure 6.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12 Altered TGFβ1-dependent MCP-3 promoter activation in transgenic TβRIIΔk 
fibroblasts. Neonatal fibroblasts transiently transfected with 1kb-MCP-3 promoter construct 
were stimulated with TGFβ1 (4ng/ml). Compared to the marked induction of MCP-3 
promoter by TGFβ1 in wildtype cells, the transgenic fibroblasts are much less responsive to 
recombinant TGFβ1 although there is basal activation of the promoter in the transgenic 
fibroblasts.     216
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6.4.3 Activation of MCP-3 promoter expression by TGFβ via distinct MAPK 
pathways 
To assess the signalling pathways mediating TGFβ1 upregulation of the MCP-3 promoter, 
a series of pharmacological inhibitors were used. There was significant activation of MCP-
3 promoter by recombinant TGFβ1 with 184±15.5% (Mean±SEM % basal expression), 
p=0.02. SD208 and U0126 reduced this activation by 70.7±9.6%, p=0.03 and 73.2±9.4%, 
p=0.01 respectively (Figure 6.13). There was partial inhibition of the promoter activation 
with SB203580 and curcumin by 51.5±13.8%, p=0.05 and 38.0±14.8%, p=0.02 
respectively. Calphostin also partially abrogated the promoter response by 45.1±14.4%, 
p=0.01. These results suggest that apart from TGFβ signalling pathways, several key 
members of the MAPK family, AP-1 and PKC are also necessary for the TGFβ-mediated 
activation of MCP-3 gene expression in fibroblasts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 Regulation of activation of MCP-3 promoter by TGFβ is demonstrated in 3 
independent experiments. Transient transfections of the murine fibroblasts were carried out 
using the indicated pharmacological inhibitors as described in Methods Section 6.3.2. 
(*P<0.05 as determined by Student’s unpaired t-test, RLU = relative luminescence units.  
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6.5 Discussion 
Data presented in Chapter 3 demonstrate that MCP-3 is upregulated in a murine model with 
activated TGFβ-phenotype. This suggests that MCP-3 expression may be dependent on 
TGFβ and the results presented in this chapter showed that the upregulation of MCP-3 
protein and gene in cultured fibroblasts is transcriptionally regulated by TGFβ. This 
appears to be mediated by recruitment of ALK5 receptor and activation of both the 
canonical Smad and MAPK signalling pathways 
 
Few studies have been performed on regulation of MCP-3 expression. Several studies have 
demonstrated a significant association between polymorphisms within MCP-3 promoter 
and inflammatory diseases including multiple sclerosis(Fiten et al., 1999;Nelissen et al., 
2002). However, a more recent study on Korean patients with asthma failed to detect an 
association between four SNPs including one in the 1kb promoter region and the risk of 
developing asthma(Park et al., 2005). Other work has highlighted a novel transcriptional 
regulatory role for β-catenin, a major protein in the Wnt signalling transduction pathway, 
on MCP-3 promoter expression in dermal fibroblasts. In this study, regulation of MCP-3 
expression by activated form of β-catenin appears to involve direct association of the β-
catenin
 complex with a putative T-cell factor/lymphocyte enhancer factor (Tcf/LEF)-
binding motif,
 ATCAAAG in the
 MCP-3 promoter(Fujita et al., 2000). Because the 
Tcf/LEF complex also recruits various
 coactivators or corepressors to modulate 
transcription, it is
 conceivable that these associated molecules in combination may
 
determine the function of the complex, and this may be relevant in regulation of MCP-3 
expression by TGFβ, another key target gene for Wnt signalling in fibroblasts.  
 
It has been demonstrated that cytokine activation of the chemokines are largely 
transcriptionally regulated. For example, the induction of MCP-1 expression is mediated in 
part through two tandem AP-1 sites and an NF-κB site in the proximal promoter of this 
gene depending on the cell type and stimuli applied(Martin et al., 1997). In contrast, the 
role of Smad signalling pathway in regulation of chemokine expression has been explored 
in a small number of studies. Interestingly, a recent study has identified MCP-1 as a target 
gene in genome-wide analysis of TGFβ-modulated genes in endothelial cells(Wu et al.,   218
2006). The same group also demonstrated that TGFβ-mediated induction of MCP-1 is 
Smad-dependent and that this involves direct binding of Smad3 and Smad4 to the Smad-
binding element (SBE) with CAGAC sequence on the MCP-1 promoter in human vascular 
endothelial and hepatoma HepG2 cells(Ma et al., 2007). Putative transcription factor 
binding sites, AP-1 (-37 bp), SBE, CAGACA (-732 bp) and Sp1 (-745 bp) on the 1kb 
MCP-3 promoter have been identified using TFSEARCH (Searching Transcription Factor 
Binding Sites V1.3, putative score>0.85(Murakami et al., 1997) and these may contribute 
to the transcriptional activation of MCP-3 by TGFβ.  The moderate responsiveness of the 
1kb MCP-3 promoter to recombinant TGFβ1 in murine fibroblasts suggests that additional 
TGFβ responsive regions may be responsible, and a possible explanation for this is the 
presence of an additional putative SBE identified at -2.2kb upstream to the 1kb promoter. It 
is also well-known that Smad proteins regulate transcription in collaboration with other 
factors(Massague et al., 2005), but it is unclear what factors may work in concert with the 
Smad proteins to modulate MCP-3 expression. This may potentially involve direct DNA 
binding or through interaction with coactivators (eg. p300/CBP) or corepressors (eg. TG-
interacting factor, SnoN and c-Ski) or sequence-specific transcription factors (eg. AP-1, 
TFE3, Sp1, Evi-1 and GATA-3). The role of Smad-dependent signalling pathways and 
TGFβ in chemokine expression was also recently explored in human astrocytic lines in 
regulation of MCP-1 transcription. In this study, whilst Smad-3 stimulates transcription of 
MCP-1, Smad-4, on the other hand, had no effect on the basal activity of the MCP-1 
promoter, but it showed the ability to decrease both Smad-3-mediated transcription of the 
MCP-1 promoter(Abraham et al., 2003). Therefore, the intracellular concentrations of 
Smad3 and Smad4 can modulate expression of MCP-1 in these cells, and this interaction 
may also be relevant in the transcriptional activation of MCP-3 by recombinant TGFβ1. 
Interestingly, TGFβ was reported to inhibit MCP-1 expression in macrophages via an 
antagonistic effect of Smad3 on AP-1 activity and this discrepancy highlights the cell type-
specific regulation of CC chemokines by TGFβ(Feinberg et al., 2004). 
 
It has recently been demonstrated that histone acetylation at the upstream regulatory 
regions for MCP-1 is associated with the assembly of Sp1 is necessary for PDGF and 
TNFα induced expression of MCP-1(Ping et al., 1999;Ping et al., 2000). This will in turn   219
facilitate stabilisation of the assembly of transcription factors at both proximal and distal 
regulatory regions to drive chemokine expression. It is plausible that similar mechanism 
may underlie the induction of MCP-3 by TGFβ.  
 
The basal upregulation of MCP-3-promoter in TβRIIΔk fibroblasts is consistent with the 
basal induction of other TGFβ-regulated proteins including PAI-1 and CTGF as discussed 
in Chapter 3.  However, the suppressive effect of recombinant TGFβ1 on the  upregulation 
of MCP-3 promoter parallels the observation reported with altered response of TβRIIΔk 
fibroblasts to other TGFβ-regulated reporter constructs including Col1a2 and 
fibronectin(Denton et al., 2005). For some of these genes, differential effects were observed 
with modest induction of PAI-1 receptor activity but the basal activity for other promoter 
constructs (3TP, Col1a2 and fibronectin) was suppressed in transgenic fibroblasts. The 
apparent paradoxical downregulation of these TGFβ responsive genes including MCP-3 in 
transgenic fibroblasts at these later time points to TGFβ1 is explained by the partial 
regulation of the fibroblast-specific expression cassette in the transgene by exogenous 
TGFβ. In addition, the transgene in this transgenic model functions as a dominant negative 
inhibitor of TGFβ signalling at high expression levels in the presence of recombinant 
TGFβ1. 
 
The data in this chapter suggest that induction of ALK5 by TGFβ is important in 
transcriptional activation of MCP-3 expression. Whilst ALK5 is well-established to be 
closely associated with TGFβ signalling pathway, there is growing evidence that some of 
the downstream effects mediated by ALK5 may be independent of Smad2/3(Pannu et al., 
2007). For example, constitutive overexpression of CTGF in SSc fibroblasts is Smad2/3 
independent and blockade of Smad signalling targeting ALK5 kinase did not normalise 
CTGF levels in SSc fibroblasts(Holmes et al., 2001;Chen et al., 2006). In addition, in vitro 
experimental model on angiogenesis demonstrated that TGFβ and ALK5 pathways have a 
distinct gene expression profiling on endothelial cells(Wu et al., 2006).  
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Overexpression of MCP-3 in inflammatory diseases such as asthma has been demonstrated 
to be mediated by MAPK signalling pathways including p38, ERK and JNK in human 
airway smooth muscle cells(Wuyts et al., 2003). In addition, AP-1 has been demonstrated 
to regulate MCP-3 mRNA and protein secretion from cultured cervical fibroblasts, 
suggesting the involvement of AP-1 in the cyclic
 stretch-associated signal 
transduction(Abraham et al., 2003;Takemura et al., 2004). The signalling pathways that 
regulate chemokine activation appear to be largely cytokine-specific and tissue-specific. 
Recent studies using cultured fibroblasts infected with retroviruses encoding TAK1K63W,
 
an inactive mutant of the protein kinase, TGFβ activated kinase (TAK1) demonstrated that 
constitutive and inducible expression of MCP-3 is strikingly dependent on MAPK Jun and 
p38, but not PI3K signalling pathways(Thiefes et al., 2005). The data in this chapter 
showed that similar signalling pathways are important in MCP-3 gene activation by TGFβ 
in fibroblasts.    221
 
6.6 Summary 
Overall the experimental data presented confirms that TGFβ induces MCP-3 expression via 
elements within the proximal 1kb promoter fragment upstream to the transcription start site 
in which several putative transcriptional factor binding sites including SBE have been 
identified. The activation of MCP-3 promoter construct by TGFβ appears to be mediated by 
recruitment of ALK5 receptor and is dependent on activation of both the canonical Smad3 
and MAPK signalling pathways. In addition, the lack of responsiveness of the MCP-3 
promoter construct to exogenous TGFβ in transgenic TβRII∆k strain is entirely consistent 
with the previously reported refractoriness of similar TGFβ-regulated genes in this 
profibrotic murine model. 
 
   222
 
CHAPTER 7: INTERPLAY BETWEEN TGFβ AND MCP-3 IN FIBROSIS 
7.1 Introduction 
In the pathogenesis of fibrosis it is likely that a number of cytokines or growth factors act in 
concert to promote a fibrotic microenvironment and lead to the development of a 
profibrotic population of fibroblasts.  There is an increasing body of evidence to suggest a 
potentially important regulatory loop between chemokines and TGFβ in inflammatory and 
fibrotic diseases. TGFβ is a multifunctional cytokine that regulates the growth, 
differentiation and function of immune and non-immune cells. A major effect of TGFβ on 
mesenchymal cells is its activation of ECM deposition via induction of collagen types I, III, 
IV, VII and X, fibronectin and proteoglycans. This role is further enhanced by its inhibitory 
effect of matrix degradation, decreasing synthesis of proteases and increasing levels of 
protease inhibitors. Data from previous chapters have demonstrated MCP-3 as a potential 
profibrotic mediator. In addition, overexpression of MCP-3 was demonstrated in a murine 
model of fibrosis with a TGFβ-dependent phenotype, strongly suggesting that there is an 
important crosstalk between these two important mediators. Since intracellular signalling 
pathways activated by these ligands may be similar and there may be regulation of the level 
of activity of each ligand by the other it is plausible that interplay between them is highly 
relevant.  
 
The central role of a canonical Smad-dependent signalling pathway for TGFβ is firmly 
well-established but it is also recognised that non-Smad pathways may drive fibrosis, 
including members of the MAPK family.  The identification of non-Smad signalling 
pathways preceded the discovery of Smads (Libby et al., 1986). MAPK constitute a family 
of serine/threonine kinases that are central in the signalling cascades regulating a wide 
array of intracellular processes such as cell growth, differentiation, apoptosis and cellular 
responses to external stress signals. In response to these signals, they activate nuclear 
transcription factors such as c-jun, Elk-1 and c-Fos. Categorised into five subfamilies; 
MAPK
ERK1/2, the MAPK
p38, MAPK
ERK3/4,
 MAPK
ERK5 and the MAPK
jnk, the specific 
MAPK gives its name to the pathways that utilise them i.e. MAPK
ERK1/2 is referred to as the 
ERK1/2 pathway (Moustakas & Heldin, 2005). These protein kinases share 60-70%   223
identity but differ in the sequence and size of their activation loop, and are activated by 
different stimuli, and each MAPK subclass consists of several isoforms and members, 
which often have distinct functions.  
 
Activation of the MAPK signalling cascade involves a series of three protein kinases 
consisting of a MAPK that is activated by the dual phosphorylation of Thr and Tyr residues 
in a TXY motif by specific upstream MAPK kinases (MKKs), which in turn are 
phosphorylated by MAPK kinase kinases. The TXY motif is unique to each of the MAPK 
subclasses, where X is Glu, Pro and Gly in ERK, JNK and p38 MAPK respectively. In 
general, ERK1 and ERK2 also known as p44 and p42 MAPKs are prototypically activated 
by mitogenic stimuli and growth factors, whereas JNK and p38 MAPK are activated 
predominantly by environmental stresses such as osmotic changes, ultraviolet light, heat 
shock and inflammation. In many cell types TGF-β has been shown to activate ERK1/2, 
p38 and JNK, although the link between activated receptor and cytoplasmic effector in 
some cases remain to be determined (Derynck & Zhang, 2003;Javelaud & Mauviel, 2005). 
In addition MAPK activation by TGF-β is cell-type dependent (Abecassis et al., 
2004;Engel et al., 1999;Leask et al., 2003).  
 
Physiologically non-Smad TGF-β activated pathways elicit downstream intracellular 
effects in at least three ways. Firstly, direct modification of Smad function in which 
phosphorylation of the linker region in Smad2 and Smad3 by ERK has both positive and 
negative effects on Smad activity (Hayashida et al., 2003;Kretzschmar et al., 1999). For 
example, ERK, a MAPK family member, phosphorylates serine residues in the linker 
regions of Smad1-3 and ERK inhibition reduces TGFβ-stimulated Smad phosphorylation as 
well as collagen biosynthesis in mesangial cells, suggesting that ERK activation is 
necessary for an optimal response to TGFβ(Hayashida et al., 2003); whereas the p38 
substrate MSK1 kinase promotes the association of Smad3 with the co-activator p300 
(Abecassis et al., 2004). In contrast, it has been reported that ERK1/2 activation has a 
potent suppressive effect on type I and III collagen
 expression by normal human skin 
fibroblasts(Reunanen et al., 2000). A second mechanism involves functional modulation by 
Smads. For example, JunB is expressed at low levels in fibroblasts but is transcriptionally   224
induced by TGF-β via Smads and in turn promotes TGF-β activation of COL1A2 and PAI-
1 (Chang & Goldberg, 1995) Thirdly, activation may be independent of Smads with 
activation by TGF-β receptors directly. For example several TGF-β responsive extracellular 
matrix genes and matrix regulatory enzymes such as Urokinase-type plasminogen activator 
receptor and fibronectin genes are regulated by MAPK pathways independent of the Smad 
signalling pathway (Yue et al., 2004;Hocevar et al., 1999). A schematic overview of the 
canonical and non-canonical TGFβ signalling is shown in Figure 7.1.   225
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Figure 7.1 Schematic representation of the TGFβ signalling cascade. Modulation of the 
Smad canonical signalling through TGFβRI by additional MAPK and PI3K pathways is 
essential for most cellular responses to TGFβ. Initiation of signalling requires the binding 
of TGFβ to TGFβ receptor type II, resulting in the recruitment and phosphorylation of 
TGFβ receptor type I to produce a heteromeric complex that activates downstream 
signalling pathways. Activated TGFβRI then recruits and phosphorylates R-Smad such as 
Smad2 and Smad3, leading to the association with Smad4 and translocation of the formed 
heterocomplex into the nucleus. TGFβ also interacts with MAPK (p38, JNK and ERK) 
whereby TGFβ is able to activate MAPK signalling but also be modulated by it through 
phosphorylation of the Smad linker domain. PI3K which is activated by GPCR may also 
mediate TGFβ signalling via Smad2 phosphorylation. The translocated heterocomplex 
binds to the target gene with other transcription factors including Sp1 and cooperates with 
p300/CBP to regulate gene expression.  
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More recently, other signalling pathways besides the MAPK have also been shown to 
mediate TGFβ signalling such as the PI3K pathways. PI3Ks phosphorylate inositol-
containing lipids at the D-3 position of the inositol ring. They are divided into three classes 
in mammalian cells. Class III PI3Ks produce phosphatidylinositol (PtdIns)-3-P, which is 
constitutively present in all cells. Class I and class II PI3Ks can utilise PtdIns, PtdIns-4-P 
and PtdIns-4,5-P2. Of all the PI3K members, class I is the best characterised and they exist 
as heterodimers of a 110-kDa catalytic subunit (p110α, p110β, p110δ, and p110γ) and an 
adaptor/regulator subunit (p85α, p85β, p55, and p101)(Cantley, 2002). Unlike other PI3K 
members, PI3Kγ is activated by GPCRs via binding of the βγ subunits of G proteins. 
Following PI3K activation, PIP3 recruits the phosphoinositide-dependent kinase (PDK)-1 
and Akt/PKB, bringing these proteins into proximity at the plasma membrane where Akt is 
phosphorylated on Thr
308 by PDK-1(Cantley, 2002). This is followed by phosphorylation at 
Ser
473. Once activated, Akt leaves the plasma membrane to phosphorylate intracellular 
substrates. Akt has also been shown to translocate the nucleus where it can phosphorylate 
transcription factors(Toker, 2000). 
 
Recently Bakin et al. have shown that the inhibition of PI3K blocks TGFβ1–induced 
Smad2 phosphorylation, suggesting that Smad proteins are potential targets of the PI3K 
pathway(Bakin et al., 2000). In fact, the inhibition of PI3K was shown to result in a 
redistribution of Smad anchor for receptor activation (SARA), which directly interacts with 
Smad2/3 and functions to recruit Smad2 for phosphorylation to the activated TGFβ 
receptor complex(Tsukazaki et al., 1998), and the attenuation of both TGFβ-induced 
Smad2 phosphorylation and transcriptional activation(Itoh et al., 2002). Furthermore, the 
basal activity of PI3K was shown to be necessary for COL1A2 mRNA stabilization and to 
be indispensable for the establishment of the constitutive activation of TGFβ/Smad3 
signalling in SSc fibroblasts(Asano et al., 2004b). In addition, PI3Kγ when expressed in 
leucocytes and vascular endothelium is important in chemotaxis. Therefore, in response to 
GPCR agonists, including chemokines, PI3Kγ coordinates the leucocyte transmigration 
across the endothelium and the absence of PI3Kγ has been shown to confer resistance to the 
development of inflammatory pathologies including lung injury and airway 
inflammation(Hirsch, 2006;Medina-Tato et al., 2007). In addition, these non-Smad   227
signalling signalling pathways may be activated by other growth factors including 
epidermal growth factor, hepatocyte growth factor, oncogenic Ras, and Angiotensin II. 
These will therefore act in concert to modulate the TGFβ/Smad signalling response.   228
 
 
7.2 Aims 
Overexpression of MCP-3 in both human and animal models of fibrosis, and the 
identification of MCP-3 expression in TβRII∆k model led to the hypothesis that interaction 
between MCP-3 and TGFβ may be important in regulation of fibrotic response. Thus to 
investigate this hypothesis that the interplay between these two mediators may have in 
modulation of the signalling response in the fibrotic microenvironment, I proposed to 
investigate 
1.  To examine the effect of MCP-3 on TGFβ signalling pathways, 
2.  To examine the effect of MCP-3 and TGFβ on collagen expression and its 
regulatory pathways, 
3.  To investigate the fibroblastic gene response to MCP-3 and TGFβ.   229
7.3 Methods 
7.3.1 Cell culture 
7.3.1.1 Cell lines  
All primary dermal fibroblast cells were maintained as described in Section 2.2.1. For 
experiments, cells were used between passage 2 and 5.  
 
7.3.1.2 Fibroblast conditioned media 
Dermal fibroblast cell lines were maintained in DMEM (Invitrogen, UK) supplemented 
with 10% fetal calf serum (Gibco BRL) until fully confluent. Media was replaced by 
DMEM (Invitrogen, UK) containing 0.2% FCS (Sigma, UK) supplemented with L-
glutamine, penicillin G (100 U/ml) and streptomycin sulphate (100 µg ml
-1) (Invitrogen, 
UK) and the conditioned media (CM) collected 24 h later.  
 
7.3.2 Preparation of RNA and Northern blot Analysis for Collagen expression  
Total RNA was isolated from wildtype murine fibroblasts treated with recombinant MCP-3 
and TGFβ using TRIzol
 (Invitrogen) according to the manufacturer's instructions. Levels
 of 
specific transcripts were determined by Northern blotting,
 following separation of RNA on 
1% agarose/formaldehyde gels and capillary transfer to Hybond N+ membrane
 (Amersham 
Biosciences). Filters were hybridised and probed with
 cDNA fragment specific for 
conserved region of the pro-α2(I) collagen mRNA
 as previously described(Shi-Wen et al., 
2000). 18 S rRNA band intensity was used
 to confirm equal gel loading. Probes were 
labelled with [α-
32P]dCTP
 to a specific activity of 10
9 dpm/mg, using the Megaprime
TM 
random priming method (Amersham Biosciences). Levels of transcripts
 were determined 
from signal intensity measured by autoradiography.
  
 
7.3.3 Analysis of gene expression by microarray 
To determine the differential fibroblastic response to treatment with MCP-3 and TGFβ1, 
expression profiling was conducted as described in Section 2.3.9. Dermal fibroblasts were 
cultured to confluence. Media were changed and exposed to 200ng/ml of recombinant 
MCP-3, 4ng/ml of recombinant TGFβ1, both factors together and serum-free culture 
medium for four hours. At the end of the treatment period, total RNA was harvested as   230
described in Section 7.3.2. Each pooled RNA sample was applied to the mouse Atlas 1.2 
array as outlined in Chapter 2 and experiments were performed in parallel. Differential 
gene expression was assessed using AtlasImage software (ClonTech) according to 
manufacturer’s protocol. 
 
7.3.4 Smad3 siRNA transfection of cultured fibroblasts 
To examine whether Smad signalling pathways may regulate the crosstalk between MCP-3 
and TGFβ in fibroblastic collagen expression, a series of protein expression analyses were 
undertaken using cultured fibroblast supernatants pre-treated with recombinant MCP-3. For 
these experiments, wildtype dermal fibroblasts were transfected with Smad3 and control 
siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) following manufacturer’s instructions 
as discussed in Section 2.2.3.4. A nonsilencing siRNA with a scrambled sequence that will 
not lead to degradation of Smad3 was used as a negative control.  
 
7.3.5 Protein expression 
All antibodies were as described in Section 2.4.3, and all protein extraction and western 
blotting methodologies performed as described in Section 2.4.3, unless stated otherwise. 
For indicated experiments on activation of Smad-independent signalling pathways by 
recombinant MCP-3 and TGFβ1 at various time point intervals, antibodies against 
phospho-p38 and phospho-Akt (Cell Signalling Technology, Beverly, MA) were used and 
membranes were incubated with anti-phospho-p38 and anti-phospho-Akt (Ser473) 
monoclonal antibody (1:1,000) respectively overnight at 4°C. As a loading control, 
immunoblotting was also performed using antibodies against total p38 and total Akt 
(1:1,000) respectively. 
 
7.3.6 Protein Kinase inhibitors 
The following inhibitors were used for this study: ERK inhibitor U0126 (20μM; Promega, 
Southampton, United Kingdom), SB203580 (20μM), LY294002 (50μM), Calphostin 
(500nM) (all from Calbiochem, La Jolla, CA) and cultured for an additional 24 hours in the 
presence or absence of recombinant chemokine, MCP-3 (200ng/ml) and recombinant 
TGFβ1 (4ng/ml). Reporter gene activity was measured by luminometry
 (Turner Designs,   231
Sunnyvale, CA) using luciferase and β-galactosidase
 assays (Tropix Inc. Bedford, MA) 
according to the manufacturers'
 instructions. Values given are means ± standard errors
 of 
triplicate assays from three individual experiments.
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7.4 Results
 
7.4.1 Activation of TGFβ-regulated promoter constructs, 3TP-Luciferase and 
COL1A2-LacZ in wildtype murine fibroblasts 
To determine whether MCP-3 could activate TGFβ-regulated promoter-reporter construct, 
reasoning that this could arise as a result of direct activation of signalling intermediates that 
are also regulated by TGFβ or alternatively by secondary induction or activation of TGFβ 
ligand by MCP-3. Figure 7.2 demonstrates consistent dose-dependent activation of TGFβ-
responsive promoter 3TP-Luciferase by recombinant MCP-3 (128 ± 21.3%) 200 ng and 
(148 ± 20.5 %) 400 ng compared to (174 ± 39.6) in the presence of TGFβ 4ng/ml (mean ± 
SEM, % Basal).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2    Activation of TGFβ-regulated pathways by MCP-3  
Upregulation of transcriptional activity of 3TP-Luciferase reporter gene by MCP-3 in 
transient transfection. Values are the mean and SEM of triplicate samples and are 
representative of 3 independent experiments. *p<0.05 vs. basal cells.   233
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Similarly, as discussed in Chapter 4, recombinant MCP-3 upregulated pro-α2(I) promoter-
reporter construct (COL1A2-LacZ) in dermal fibroblasts (227 ± 91%, p=0.04).  Activity of 
this construct has been shown to reflect transcription of the endogenous COL1A2 gene and 
is also upregulated by TGFβ. Since TGFβ is a potent stimulator of ECM gene expression in 
vitro, the effect of anti-TGFβ antibody and TGFβ receptor blockade in modulating this 
activation of collagen reporter gene expression was examined to assess whether 
upregulation might be occurring via TGFβ. As shown in Figure 7.3, the collagen gene 
activation, in the presence of ID11 and SD-208, by recombinant MCP-3 was significantly 
reduced by 39.5± 11.3% (p=0.04) and 61.5± 16.5% (p=0.02) respectively. Together these 
results suggest that MCP-3 has an important role in mediating TGFβ-regulated pathways 
and its effect on ECM gene expression is also regulated by TGFβ.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 TGFβ-dependent  activation of COL1A2 gene 
expression by MCP-3 in wildtype murine fibroblasts 
Transactivation of the human proα2(I) collagen (COL1A2) gene reporter by MCP-3 via a 
TGFβ-dependent mechanism is shown. Inhibitors of TGFβ and its cognate receptor, ALK5 
were used in transient transfection in 3 independent experiments for the minimal promoter. 
* p<0.05, ** p<0.01 as determined by Student’s unpaired t-test. RLU=relative luminescent 
units.    234
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7.4.2 Upregulation of Collagen Type 1 transcript and protein by MCP-3 and TGFβ  
In parallel experiments, a time-course analysis of Col1a2 mRNA and protein levels from 
wildtype murine fibroblasts stimulated with recombinant MCP-3 and TGFβ1 were 
determined using Northern blot and Western blotting gel electrophoresis. 
 
As demonstrated in Figure 7.4, in response to recombinant MCP-3, there was upregulation 
of collagen transcript peaking at 8 hours followed by maximal protein expression at 48 
hours. Similar pattern was observed with recombinant TGFβ1 with maximal collagen 
mRNA expression at 8 hours sustained up to 24 hours with maximal protein expression at 
48 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Time course induction of type I procollagen by MCP-3 and TGFβ in 
wildtype murine fibroblasts. 
Western blot analysis of dermal fibroblast supernatants after stimulation by recombinant 
murine MCP-3 (200ng/ml) and TGFβ1 (4 ng/ml) demonstrates induction of pro(I) collagen 
(Top panel). Blots were also probed with an anti-actin antibody to establish that lanes were 
equally loaded. Bottom panel demonstrates Northern blot analysis with early induction of 
Col1a2 mRNA in response to MCP-3 and TGFβ1 in wildtype fibroblasts.    235
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7.4.3 Regulation of COL1A2 expression by MCP-3 and TGFβ 
Having established that TGFβ signalling pathway may mediate the induction of collagen 
expression by MCP-3, this was further explored using siRNA targeting one of the key 
mediators in the canonical TGFβ signalling pathway, Smad3 in murine fibroblasts. 
Consistent with the earlier observation in Figure 7.3, type I procollagen expression was 
increased with recombinant MCP-3 (200ng/ml) and in contrast to the fibroblasts transfected 
with the non-silencing siRNA, there is dose-dependent attenuation in collagen expression 
with Smad3 siRNA (20-80nM) transfection. This suggests that MCP-3-induced collagen 
secretion is partially mediated by Smad3-dependent signalling (Figure 7.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5 Activation of type I procollagen by MCP-3 via canonical Smad pathway 
MCP-3 induced type I procollagen expression is dose-dependently reduced by Smad3 
siRNA in murine dermal fibroblasts. Cells were transfected with control (80 nM) or Smad3 
siRNA (20 and 80 nM) for 24 hours and then incubated with 200 ng/ml MCP-3 in fresh 
serum-free media for 24 hours. Total Smad3 and GAPDH (in whole cell lysates) and type I 
procollagen (in culture media) expression were analysed by Western blotting. The results 
are representative of three independent experiments.    236
 
7.4.4 Activation of COL1A2 promoter expression by MCP-3 and TGFβ is mediated by 
distinct MAPK and PI3K signalling pathways 
To determine if there are distinct patterns of activation of collagen gene expression for 
MCP-3 and TGFβ, a series of pharmacological inhibitors were used following treatment of 
dermal fibroblasts for 24 hours. A series of independent experiments demonstrated that 
recombinant MCP-3 and TGFβ1 increased the transactivation of COL1A2 promoter with a 
mean (±SEM) change above baseline levels of 53.5 ± 6.1%, = 0.005 and 43.4±14.6%, 
p=0.04 respectively (Figure 7.6). This upregulation was inhibited by SB203580 by 
64.0±7.7% and 50.7±6.5% (Mean±SEM%, p=0.05) with recombinant MCP-3 and TGFβ1 
respectively. Similar inhibition was shown with LY294002 by 63.8±3.7%, p=0.005 with 
recombinant MCP-3, but a smaller degree of inhibition with recombinant TGFβ1 by 
27.4±15.4%, p=0.02. Transactivation was partially inhibited by calphostin, by 32.3±9.2%, 
p=0.04 and 32.9±15.5%, p=0.04 with recombinant MCP-3 and TGFβ1 respectively. There 
was little change in the COL1A2 activation by U0126 for both MCP-3 and TGFβ. 
Together, these results suggest a role for p38 MAPK in the activation of collagen gene 
expression by both factors.   237
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Figure 7.6 Inhibition of MCP-3 and TGFβ-activation of COL1A2 promoter 
Murine dermal fibroblasts were serum-starved for 24 h and pretreated with the indicated 
amounts of various inhibitors for 1 h prior to the addition of MCP-3 (200 ng/ml) and 
TGFβ1 (4ng/ml) for 24 h. SB203580, LY294002, Calphostin and U0126 were dissolved in 
Me2SO. The controls were incubated with an equal concentration of Me2SO. p38 MAPK 
and PI3K signalling pathways differentially mediates the upregulation of collagen promoter 
in transient transfection by MCP-3 and TGFβ1. The means ± SEM% of four independent 
experiments are shown. *= p < 0.05, ** = p < 0.01, by Student’s unpaired t-test. 
RLU=relative luminescent units.   238
 
7.4.5 Differential activation of p38 MAPK and Akt phosphorylation by MCP-3 and 
TGFβ in wildtype fibroblasts 
Since the inhibition of p38 MAPK and PI3K pathways differentially decreased the 
induction of type I collagen expression in wildtype dermal fibroblasts by both TGFβ and 
MCP-3, activation of both signalling pathways by these factors were studied with 
immunoblotting using antibodies specific for activated forms of p38 MAPK and Akt. Thus, 
p38 MAPK Thr /Tyr phosphorylation occurred as early as 20 minutes after treatment with 
recombinant MCP-3 and the response was sustained up to 1 hour. In contrast, 
phosphorylation was observed with recombinant TGFβ1 at later time points with a 
maximum at 8 hours. These results suggest that although, p38 MAPK phosphorylation 
appears to be central in regulation of collagen gene expression, the kinetics underlying this 
expression revealed differential time profile for both these factors. Similar pattern was 
demonstrated with Akt phosphorylation with recombinant MCP-3 peaking early at 20 
minutes. In contrast, Akt phosphorylation was observed to occur later at 2-4 hours with 
recombinant TGFβ1. These results are summarized in Figure 7.7.   239
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Figure 7.7 Activation of p38 and PI3K by TGFβ and MCP-3 in dermal fibroblasts. 
Phosphorylation of p38 MAPK and PI3K in normal fibroblasts was determined by 
immunoblotting using antibodies specific for phosphorylated, activated forms of p38 
MAPK (Thr180/Tyr182) and Akt respectively. Dermal fibroblasts were serum-starved for 
24 hours and treated with either 200ng/ml MCP-3 or 4ng/ml of TGFβ1 for the indicated 
times. Antibodies against p38 MAPK and PI3K were also used to confirm that the protein 
concentrations of p38 MAPK and Akt were maintained with TGFβ and MCP-3. This is a 
representative of three independent experiments   240
7.4.6 Differential gene expression in response to MCP-3 and TGFβ  
Insofar the data suggests that there may be interplay between TGFβ and MCP-3 in 
regulation of collagen activation. To test whether there are direct synergistic or additive 
effects on fibroblast gene expression, a series of gene array studies was performed 
focussing on early time point 4 hours during which previous studies have shown that there 
is significant induction of selected known direct TGFβ target genes with 4 ng/ml of 
recombinant TGFβ1(Renzoni et al., 2004). Normalisation of the expression data was 
achieved by using the sum of the global intensities of the arrays. Adjusted expression level 
was set to be at least 10 to allow meaningful comparative interpretation of the data. 
Relative changes of 2.0 or greater were defined as upregulation and downregulation 
respectively.  
 
In a series of experiments, MCP-3 alone resulted in upregulation of 8 genes more than 2-
fold. These were osteopontin precursor, rac alpha serine/threonine kinase, Osteoblast-
specific factor2 (OSF2), cytoplasmid dynein light chain 1, ubiquitin, PAI-1, vimentin and 
rab2 ras-related protein. 3 genes including MCP-3, G2/mitotic-specific cyclin A1 and 
biglycan were downregulated by MCP-3 by at least 2-fold. Incubation of dermal fibroblasts 
with recombinant TGFβ1 was associated with upregulation of 8 genes: all of which, 
excluding vimentin and PAI-1, were also upregulated by MCP-3. The remaining two genes 
were Fas1 receptor and interleukin-7 receptor alpha. Biglycan and G2/mitotic-specific A1 
were downregulated by TGFβ1. 
 
27 genes were expressed with combination with recombinant MCP-3 and TGFβ1, of which 
10 were upregulated by at least two-fold. These were brain factor1 (BF1), PAI-1, 
osteopontin precursor, rac alpha serine threonine kinase, OSF2, thrombospondin 2 
precursor (TSP2), Insulin-like growth factor binding protein-6 (IGFBP6), cytoplasmid 
dynein light chain 1, glucose-6-phosphate isomerase (Gpi1) and vimentin.  
Some of these genes including those related to a range of matrix components, cytokines, 
growth factors and signalling intermediates that are upregulated and downregulated in 
wildtype fibroblasts treated with a combination of recombinant MCP-3 and TGFβ1 are 
shown in Tables 7.1 and 7.2 respectively.    241
Adjusted Expression Ratio
Gene name
Accession
Number
Gene 
code 
Basal TGFβ MCP3
TGFβ
+MCP3 TGFβ MCP3
TGFβ
+MCP3
BF1  B02a 1 8 3 19 8 3 19
PAI M33960 F04m 2 4 11 28 2 5.5 14
OP P08721 B13b 1 37 25 10 37 25 10
RAC-PK-alpha P31749 D02l 1 16 14 10 16 14 10
OSF2  D13664 A01n 2 11 10 17 5.5 5 8.5
TSP2  L07803 F07f 4 1 5 14 0.25 1.25 3.5
IGFBP6  X81584 D13m 4 6 9 13 1.5 2.25 3.25
CDLC1 D04d 6 24 16 18 4 2.67 3
G6PI  E01c 11 14 7 29 1.27 0.64 2.64
Vimentin X51438 F09d 11 8 22 24 0.727 2 2.18
NFTFp65  B09g 50 57 75 94 1.14 1.5 1.88
TSP1  M87276 F07j 42 22 37 63 0.52 0.88 1.5
FN1  X82402 F08j 16 9 17 22 0.56 1.06 1.37
ubiquitin X51703 G11 105 238 213 139 2.26 2.03 1.32
Decorin X53929 F08g 13 4 12 16 0.31 0.92 1.23
MCP-3 S71251 D12b 24 55 10 29 2.29 0.42 1.2
IL7r M29697 D06g 7 21 5 7 3 0.71 1
DAD1 U83628 D03e 15 16 28 15 1.06 1.87 1
Tb4 D12d 14 24 8 14 1.71 0.57 1
U36760
M25825
U89408
M61909
X16053
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Table 7.1 Genes upregulated in wildtype murine fibroblasts in response to MCP-3, 
TGFβ and MCP-3 and TGFβ.  
BF1: Brain factor 1, PAI: Plasminogen activator inhibitor, OP: Osteopontin precursor, Rac-
PKα: rac alpha serine/threonine kinase, OSF2: Osteoblast-specific factor 2 precursor, 
TSP2: thrombospondin 2 precursor, IGFBP6: Insulin-like growth factor binding protein-6, 
CDLC1: Cytoplasmic dynein light chain 1, G6PI: glucose-6-phosphate isomerase, 
NFTFp65: NF-kappa-B transcription factor p65 subunit, TSP1: thrombospondin 1 
precursor, FN1: fibronectin 1 precursor, MCP-3: Monocyte chemoattractant protein-3, 
IL7rα: Interleukin-7 receptor alpha, DAD1: Defender against cell death 1, Tβ4: Thymosin 
beta-4.   242
Adjusted Expression Ratio
Gene
name
Accession 
Number
Gene 
code  Basal TGFβ MCP3 TGFβ
+MCP3
TGFβ MCP3 TGFβ
+MCP3
Cyclin A1 B09m 561 173 280 173 3.24 2.0 3.24
Granzyme C  X12822 F03e 10 4 9 5 2.5 1.1 2
KGF  Z22703 D14f 25 9 8 14 2.78 3.1 1.78
NDKb C08j 46 50 42 26 0.92 1.09 1.76
Biglycan L20276 F07h 52 11 26 30 4.72 2 1.73
BRCA2  C08i 9 14 10 7 0.64 0.9 1.28
GNBP E13h 19 11 25 15 1.72 0.76 1.26
NMLC3  F09j 12 8 14 10 1.5 0.85 1.2
X84311
X68193
U89652
AF124384
U04443
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Table 7.2 Genes downregulated in wildtype murine fibroblasts in response to MCP-3, 
TGFβ and MCP-3 and TGFβ.  
Cyclin A1: G2/mitotic-specific cyclin A1, KGF: Keratinocyte growth factor, NDKb: 
Nucleoside diphosphate kinase B, BRCA2: Breast cancer type 2 susceptibility protein, 
GNBP: Guanine nucleotide binding protein, NMLC3: non-muscle myosin light chain 3. 
 
Overall, three distinct patterns observed with the combination treatment: synergistic effect 
for BF1, PAI, OSF2, TSP2, IGFBP6, Gpi1 and vimentin; an apparent reduction in 
synergism with osteopontin precursor and breast cancer type 2 susceptibility protein 
(BRCA2), and downregulation of biglycan and keratinocyte growth factor (FGF-7). The 
differential response for representative genes is shown in Figure 7.8.   243
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Figure 7.8  Comparative differential gene expression in dermal fibroblasts treated 
with combination of MCP-3 and TGFβ1  
Expression pattern for representative genes are is shown with synergistic effect for 
plasminogen activator inhibitor (PAI-1), brain factor 1 (BF1), osteoblast-specific factor 2 
precursor (OSF2) and Insulin-like growth factor binding protein-6 (IGFBP6). This synergy 
is less marked with osteopontin and BRCA2 with downregulation of Biglycan and FGF7.   244
 
7.5 Discussion 
Persistent fibrosis is likely to be determined by interplay of key mediators with an 
appropriate microenvironment. Previous chapters have highlighted the potential interplay 
between TGFβ and MCP-3 in particular induction of MCP-3 by TGFβ may set the stage 
whereby the initial response to injury may regulate inflammation and the profibrotic effects 
of MCP-3 might contribute to progressive accumulation
 of ECM. Whether this interaction 
is bidirectional
 (that is, MCP-3 induces TGFβ and TGFβ in turn induces MCP-3)
 is an issue 
that is complex and unresolved, and has
 not been examined to date in fibroblasts as the key 
effector cells in skin fibrosis.
 Given the involvement of pathobiological events in dermal 
fibroblasts in fibrotic diseases and the fact that they produce both TGFβ and MCP-3 and 
respond
 to these cytokines, this chapter explored whether this interaction between the two 
factors may be of particular relevance in progressive dermal fibrosis because
 it provides a 
positive feedback relationship between TGFβ and
 MCP-3 and thereby confers a self-
perpetuating cycle of inflammation
 and fibrogenesis, with the latter representing a signature 
characteristic
 of fibrotic diseases. Specifically, the interplay between TGFβ and MCP-3 in 
induction of ECM gene and protein expression and activation of downstream signalling 
pathways was investigated.  
In Chapter 4, it was demonstrated that, using pharmacological inhibitors of TGFβ receptor, 
the profibrotic effect of MCP-3 appears to be mediated via TGFβ. Consistent with this, the 
data presented in this Chapter demonstrates down regulation of collagen protein expression 
with ALK5 inhibitor and Smad3 siRNA, supporting the role of canonical Smad-dependent 
pathways in MCP-3-mediated collagen expression. In addition, collagen expression is also 
influenced by the net effect of the interaction between these Smad molecules and 
transcription factors including Sp1 which is closely regulated by modifications to the 
chromatin structure. For example, the balance of the two key regulators, histone 
acetyltransferase and histone deacetylase plays a critical role in regulation of collagen 
transcription by altering the chromatin structure. Ghosh et. al. recently demonstrated that 
inhibition of histone deacetylation with trichostatin A in fibroblasts resulted in suppression 
of TGFβ-induced Sp1 level and consequently, its interaction with Smad complex and 
COL1A2 promoter activity(Ghosh et al., 2007). Apart from TGFβ, other factors may   245
activate the Smad signalling pathway. TGFBP-3 has been demonstrated to stimulate 
Smad2/3 phosphorylation and may potentiate TGFβ-stimulated Smad phosphorylation in 
vitro. This may be a novel mechanism in which other chemokines such as MCP-3 may 
interact with TGFβ in regulating fibrotic response. Experimental evidence to support this 
comes from CCR2 deficient mice model in which there is reduced TGFβ-mediated 
myofibroblast differentiation with abrogation of Smad3 and Smad4 expression suggesting 
an important crosstalk between CCR2-regulated chemokines, MCP-1 and MCP-3 with 
TGFβ, and presumably their respective receptors and signalling pathways(Gharaee-
Kermani et al., 2003). Other studies also highlighted the role of Smad3 and Smad4 in 
mediating the effect of the related chemokine, MCP-1 on epithelial-myofibroblast 
transition, vascular inflammation and angiogenesis by TGFβ(Feinberg et al., 2004;Ma et 
al., 2007;Tan et al., 2005). Given that these two chemokines are closely related, it is not 
inconceivable that MCP-3 may share some of these important biological functions that are 
increasingly recognised to be important in regulating fibrotic response. 
 
In contrast to TGFβ1, the preferential mediation of collagen gene activation via PI3K by 
MCP-3 is consistent with the well-established GPCR activation upon binding with MCP-3 
resulting in dissociation of G-protein complex into Gα and Gβγ subunits. Gα induces the 
activation of the PI3K pathway, while the Gβγ subunits activate phospholipase C and 
induce Ca
2+ influx and protein kinase C activation(Barberis & Hirsch, 2008). The role of 
the latter pathway is supported by the partial inhibition of MCP-3-mediated Collagen gene 
activation by Calphostin, a specific inhibitor targeted against protein kinase C. The early 
activation of Akt by MCP-3 in murine fibroblasts is consistent with previously reported in 
monocytic cell lines, and in some cases a biphasic response in phosphorylation of Akt has 
been reported to occur within the first hour of treatment with MCP-3(O'Boyle et al., 2007).  
 
The kinetics of p38 and PI3K pathway stimulation by both TGFβ and MCP-3 correlates 
well with the kinetics of the stimulation of collagen gene expression by both factors. The 
slow kinetics of p38 and PI3K by TGFβ compared to MCP3 is consistent with modulation 
of transcriptional activation of collagen by anti-TGFβ antibody at 24 hours. It is possible 
that at the earlier time points, other TGFβ-target genes such as PAI are upregulated by   246
MCP-3 as shown on our microarray data. Results from Western blot analysis supports this 
observation with delayed response of TGFβ on MCP-3-mediated collagen protein 
biosynthesis at 48 hours. This is consistent with other studies in which induction of 
collagen mRNA occurs after 3 hours post-TGFβ addition and remains elevated for up to 72 
h(Ishikawa et al., 1990;Varga et al., 1994). It is possible that p38 and PI3K contributes to 
maintaining the specific transcription complexes mediating collagen gene regulation by 
both these factors. 
 
Interestingly, TGFβ1 may modulate inflammatory response by altering chemokine receptor 
expression. A recent study has demonstrated that TGFβ may upregulate CCR1 in fetal 
astrocytes, and thereby facilitate the binding of its cognate receptors including MCP-3. It is 
plausible that similar mechanism may occur in fibroblasts(Han et al., 2000).  
 
Although ERKs, p38 and PI3K have been shown to interact with the TGFβ pathway in the 
regulation of ECM deposition and turnover, the mechanisms through which TGFβ mediates 
these MAPK pathways and its biological consequences are not well-characterised. The 
involvement of p38 in TGFβ stimulation of collagen and fibronectin was recently 
demonstrated in dermal fibroblasts and the TGFβ response was greatly enhanced by the 
presence of p38α(Ihn et al., 2005). PI3K is activated in response to a variety of stimuli, 
including cytokines and growth factors. TGFβ can also activate PI3K via phosphorylation 
of its effector Akt. Inhibition of this pathway can abrogate TGFβ-induced Smad2 
phosphorylation and transcription activation of the collagen 1 gene in mesangial 
cells(Runyan et al., 2004). In addition, expression of other key profibrotic mediators such 
as tenascin-C has been shown to regulated by PI3K in dermal fibroblasts in SSc(Jinnin et 
al., 2006). 
 
TGFβ may activate other signalling cascades including MAPK pathways including p38, 
Erk and JNK kinase pathways, some of which regulate Smad activation but others may 
induce responses unrelated to transcription. Significantly, TAK1 has been shown to be an 
important upstream activator of MKK6, an upstream dual specificity kinase which in turn   247
activates p38. Activation of this pathway resulted in phosphorylation of activating factor 2 
(ATF-2) and enhancement of the complex formed between Smad4 and ATF-2.This in turn 
leads to activation of the transcription partners for Smads, potentiating the TGFβ response. 
In contrast, an interesting feature of non-Smad signalling proteins such as MAPK and PI3K 
is their ability to modulate Smad activity, most frequently negatively. This may explain the 
apparent reduction of some candidate fibroblast gene expression such as osteopontin 
precursor and BRCA2 in the array data with combination of MCP-3 and TGFβ compared to 
treatment of the fibroblasts with each factor alone. 
 
For some gene products including ECM and growth factors OSF2, TSP2, IGFBP6 and 
BF1, there is synergy between MCP-3 and TGFβ whilst there is downregulation of 
Biglycan and FGF7. OSF2 or periostin can interact with other ECM proteins such as 
fibronectin and collagen I and may affect fibroblastic migration via its interaction with 
integrins(Kudo et al., 2007). Brain Factor 1 which has been shown to antagonise the TGFβ-
signalling pathway either by association with the transcriptional coactivator, FAST1(Dou et 
al., 2000) or Smad proteins(Rodriguez et al., 2001) and therefore, has an inhibitory effect 
on its transcriptional activation. IGFBP6 is important in regulating IGF bioactivity and this 
has been shown to be overexpressed in hepatic, renal and dermal fibrosis(Gentilini et al., 
1998;Seseke et al., 2004). Some of the effects by both MCP-3 and TGFβ are antagonistic, 
such as a facilitatory effect by TGFβ and an inhibitory effect by MCP-3 on prothymosin 
beta-4, important for cellular migration and angiogenesis with possible effect on reduction 
of collagenase activity(Cavasin, 2006). For genes that are downregulated, there is a 
synergistic effect for several genes including Cyclin A1, which is important in G1 phase of 
cell cycle, and FGF7 and Nucleoside diphosphate kinase B which are important for cellular 
proliferation and differentiation for skin homeostasis and wound repair(Braun et al., 2007). 
 
Previous studies have demonstrated that excessive matrix protein deposition during the 
fibrotic process is largely related to an increase in the rate of transcription of type 1 
collagen genes, COL1A1 and COL1A2. The TGFβ responsive sequences have been 
localised to the 330bp of the transcription start site of the COL1A2 promoter.   248
In addition to TGFβ, an expanding repertoire of cytokines and chemokines that regulate 
mesenchymal cell function has been demonstrated to be overexpressed or dysregulated in 
SSc. These soluble factors including IL-13 and IL-4, act in concert with TGFβ in driving 
the fibrotic response. IL-13 induces the production of latent TGFβ1 in macrophages and 
can also serve as an indirect activator of TGFβ by upregulating MMPs that cleave the LAP. 
Moreover, IL-13 is a potent inducer of MCP-3 and it is likely these mediators may be 
directly involved in the crosstalk between MCP-3 and TGFβ. Moreover, there is now 
accumulating evidence to suggest that there is an important regulatory loop between the 
related chemokine, MCP-1 and TGFβ in experimental models of inflammatory diseases 
such as Thy-1 nephritis(Schneider et al., 1999). Similar findings were detected with 
colocalisation immunohistochemical studies with CCR2 and TGFβ in renal model of 
fibrosis. Recent reports have demonstrated that in lung fibroblasts and glomerular cells, 
MCP-1 can stimulate TGFβ via transcription mechanisms(Gharaee-Kermani et al., 1996). 
In contrast, there are studies to suggest that growth factors and cytokines may act 
independently of TGFβ to stimulate collagen deposition(Kaviratne et al., 2004). 
Stimulation of COL1A2 promoter activity by CCL18 in lung fibroblasts is another example 
of Smad activation independent of TGFβ and requiring Sp1 participation(Luzina et al., 
2006). This is also supported by recent evidence that fibrocytes may be directly recruited to 
the lung by CXC chemokine receptor 4 (CXCR4), CC chemokine receptor 7 (CCR7) and 
CCR2(Moore et al., 2005;Phillips et al., 2004). In addition, the chemotactic and angiogenic 
response of chemokines may contribute to the vascular remodelling, an important aspect of 
the fibrotic response in SSc and diabetic retinopathy(Shireman, 2007).   249
 
7.6 Summary 
This results support the role of TGFβ in regulating of collagen expression by MCP-3 in 
murine fibroblasts. Although there appears to be a central role for TGFβ receptor (ALK5) 
and Smad-3 dependent pathways in driving the production of collagen by MCP-3, there is a 
significant contribution by the non-Smad signalling via p38 and PI3K pathways. An 
additive effect of these two agonists was demonstrated by comparative microarray analysis 
for key TGFβ regulated transcripts including PAI-1 and OSF2. Together, these results 
confirm cross-talk between MCP-3 and TGFβ that may be critical in the development of 
fibrosis.    250
 
 
CHAPTER 8: FINAL DISCUSSION AND FUTURE DIRECTIONS 
Activation of the immune system and replacement of specialised smooth muscle or 
epithelial structures with collagen-rich ECM by fibroblasts are hallmarks in the 
pathogenesis of SSc. The molecular mechanisms underlying the infiltration of 
inflammatory cells into the skin and the subsequent activation of fibroblasts are areas of 
major research interest. The main cell types responsible for fibrosis are the fibroblast and 
its contractile counterpart, the myofibroblast, which has a biochemical phenotype 
intermediate between a smooth muscle cell and a typical interstitial fibroblast. Most studies 
support an interaction of different cell types orchestrated by pro-inflammatory and 
profibrotic cytokines. Chemokines are leucocyte chemoattractants that cooperate with these 
profibrotic cytokines in the development of fibrosis by recruiting myofibroblasts, 
macrophages and other key effector cells to sites of tissue injury. The general aims of the 
studies presented in this thesis were to investigate the expression of MCP-3 in two major 
murine models of fibrosis and SSc, and to explore the regulation of MCP-3 expression with 
its interplay with the profibrotic TGFβ in fibroblasts. In this chapter, I will summarise and 
discuss the results presented in Chapters 3, 4, 5, 6 and 7 in particular to consider the extent 
to which results presented in this thesis support the hypotheses introduced in Chapter 1. 
 
Although a number of distinct mouse strains have been studied as putative animal models 
of SSc, most do not completely recapitulate the major attributes of the disease such as the 
overlapping vascular, immunological and fibrotic pathological states; female 
predominance; temporal and spatial evolution and progressive multiorgan damage. 
Nevertheless, they provide essential insight into specific quantifiable features in particular 
fibrosis. The two mouse models examined in this thesis offer complementary insight into 
the pathogenesis of fibrosis and permit key common pathways and mediators to be 
identified that may potentially be important in disease manifestations in SSc. In Chapter 3, 
gene expression profiling has demonstrated that MCP-3 is upregulated in both these fibrotic 
murine models for SSc. A key consideration into these gene expression studies is the tissue 
used for analysis, and these may include dermal biopsies, peripheral blood cells and as   251
presented in this thesis, cells grown in culture from explant murine dermal biopsies. It is 
known that explanted fibroblasts from lesional skin of patients with SSc display an 
abnormal activated phenotype that persists during their serial passage in vitro, indicating 
autonomous alteration in cell function. In addition, the explanted fibroblasts may also 
reflect the in vivo metabolic heterogeneity in that subpopulations of fibroblasts are selected 
to express a phenotype for high matrix synthesis. However, it has been observed that 
normal fibroblasts transfected with the TGFβ receptor demonstrate a more SSc-like 
transcript profile than fibroblasts cultured from SSc patients(Pannu et al., 2006), suggesting 
the importance of the dermal microenvironment in influencing the SSc fibroblast 
phenotype. Whilst this may imply that experiments performed on cultured fibroblasts alone 
may not completely mirror the characteristics of the fibroblasts in vivo, a potential problem 
with samples such as whole blood or dermal biopsies lies with the difficulty in reliably 
differentiating signals from the different components of these tissues. It would therefore 
potentially be difficult to evaluate this data or to dissect the specific contributions from 
each cellular component of the affected tissues. Using gene expression profiling of 
explanted cultured fibroblasts from murine models for fibrosis, the results from Chapter 3 
are supported by a similar study on murine model for chronic colitis with fibrosis. In this 
study, there was sustained upregulation of inflammation-related genes including MCP-3 
and its receptor, CCR2 at a
 stage that coincides with active and chronic inflammation(Wu 
& Chakravarti, 2007). Moreover, both MCP-3 and CCR2 remained overexpressed after the 
inflammation had subsided suggesting that MCP-3 may have additional role in 
establishment of fibrosis. This is particularly relevant in Tsk1/+ as there is absence of 
inflammatory response in this murine model and would likewise suggest that MCP-3 may 
have a profibrotic effect. Moreover, upregulation of MCP-3 and its receptors, CCR1 and 
CCR2 was also reported in a global gene expression analysis of murine graft versus host 
disease in which irradiated BALB/c (H-2d) mice transplanted across minor 
histocompatibility loci with B10.D2 (H-2d) bone marrow and spleen cells develop skin 
thickening and lung fibrosis, along with cutaneous immune cell infiltrates, TGFβ1 
overproduction, and upregulation of collagen synthesis. The authors reported that 
overexpression of these chemokines was associated with the early influx of immune cells, 
particularly macrophages and T cells into the dermis(Zhou et al., 2007), and this is   252
consistent with the primary role of chemokines in leucocyte recruitment to inflammatory 
sites.  
 
The significance of TGFβ in fibrosis led to the hypothesis that, targeted transgenesis using 
a lineage-specific promoter with sustained alteration in TGFβ signalling or responsiveness 
in fibroblasts may recapitulate the SSc phenotype. In this transgenic model described in this 
thesis, fibroblast-directed expression of a mutant kinase TβRII∆k resulted in fibrosis. 
Because TβRII∆k behaves as a dominant negative inhibitor of TGFβ signalling in cultured 
fibroblasts, this transgene was predicted to confer protection from fibrosis. However, these 
TβRIIΔk mice develop early skin fibrosis, whereas only a proportion develop spontaneous 
lung fibrosis at later time points, mimicking the variable lung involvement in SSc. Cultured 
skin fibroblasts show sustained transgene expression and a TGFβ1 activated phenotype 
with basally increased expression of PAI-1, CTGF, Collagen I and other markers of TGFβ 
signalling, similar to wildtype cells treated with TGFβ1. In addition, diminished responses 
to exogenous TGFβ1 were seen. Thus, the TβRIIΔk strain provides a more complete model 
for the late stage fibrotic phase of SSc than in other models. Like the Tsk/1+ model, 
fibroblastic MCP-3 was also upregulated in TβRIIΔk model and this suggests that MCP-3 
expression is upregulated by TGFβ. 
 
Apart from the increased markers of TGFβ signalling, there was upregulation of MMPs 
including MMP-13 in the transgenic fibroblasts. In addition, there was increased TIMP-2 
transcript in Tsk1/+ fibroblasts. MMP-13 is a major collagenolytic enzyme leading to rapid 
turnover of fibrillar
 collagens, tenascin, fibronectin and fibrillin-1 in addition to its key role 
in the MMP activation cascade. In the transgenic fibroblasts, it is likely that some of the 
overexpressed MMPs including MMP-13 are critical in activation of latent TGFβ latent 
complex which in turn contribute to fibrogenesis. In support of this, it has been 
demonstrated that the increased TGFβ bioactivity in the transgenic fibroblasts was partly 
MMP-dependent with reduction in active TGFβ activity in the supernatants from cultured 
transgenic fibroblasts treated with a broad-spectrum MMP inhibitor(Denton et al., 2005). It 
is also well-recognised that chemokines undergo posttranslational processing both by   253
glycosylation and proteolytic processing with MMPs in which minor modifications of the 
NH2-terminus of chemokines may alter the biological activity or target cell specificity. 
MCP-3 may be cleaved by MMP-1,-2,-3 and MMP-13. Interestingly, truncated MCP-3 has 
been detected in synovial fluid of inflammatory arthritis. As a result, truncated MCP-3 is 
devoid of chemotactic activity and calcium signalling activity but retains receptor-binding 
properties. Moreover, MMP bioactivity may be regulated by MCP chemokines. Since 
MMP activity would increase proteolysis and reduce ECM accumulation, these data seems 
somewhat contradictory to the outcome of increased ECM in these two models. It is likely 
that the altered balance between MMPs and TIMPs in these murine models represent a 
regulatory feedback in the fibrotic microenvironment leading to exaggerated accumulation
 
of ECM(Takeda et al., 1994;Bou-Gharios et al., 1994). Apart from activation of latent 
TGFβ by MMPs, one other possible explanation may be that a substantial increased in the 
biosynthesis or activity of TIMP overcomes the effect of the increased MMP-13 levels, and 
therefore net TIMP levels remain greater in skin lesions from these two fibrotic murine 
strains mice than in wild-type mice. Additional experiments to evaluate the effect of MMP 
on MCP-3 will clarify the extent to which proteolytic processing may have on its 
profibrotic effect. As most current immunological methods that rely on antibodies do not 
discriminate between authentic and posttranslationally modified chemokine isoforms, this 
would necessitate more detailed analysis such as mass spectrometry to identify these 
modifications. However, in a broader context, discrimination between intact and differently 
processed chemokines in body fluids is a difficult task and a challenge for future clinical 
research. 
 
In addition to the increasing evidence to support overexpression of chemokines in fibrosis, 
several studies have reported a direct effect of chemokines on fibroblasts. Yamamoto et al 
(Yamamoto et al., 2001)demonstrated a significant increase of α1(I) collagen mRNA after 
incubation of cultured dermal fibroblasts with recombinant MCP-1 by Northern blot 
analysis. The non-inflammatory role for MCP-1 was also recently explored in the 
bleomycin model of fibrosis which demonstrated increased abnormal collagen 
fibrillogenesis compared to MCP-1(-/-) murine strain(Ferreira et al., 2006). Consistent with 
this, the upregulation of MCP-3 in TβRII∆k and Tsk1/+ models suggests that MCP-3, apart   254
from its role as pro-inflammatory mediator, may modulate ECM synthesis by fibroblasts. 
This was confirmed with upregulation of collagen gene in a series of transfection 
experiments with transgenic fibroblasts harbouring a far-upstream enhancer of Type I 
collagen gene and fibroblasts transiently transfected with murine and human minimal 
promoter sequences. Additionally, the data also revealed that the induction of Col1a2 
activation might be independent of the upstream enhancer, suggesting that the profibrotic 
effect may be only partially mediated by TGFβ. Consistent with this, there was incomplete 
inhibition of collagen gene activation with the neutralising antibody against TGFβ1 by 
MCP-3. Moreover, MCP-3 mediated-induction of collagen protein appears to be mediated 
by MAPK p38 and PI3K signalling pathways. Interestingly, our group has demonstrated 
that in addition to the in vitro activation of far-upstream fibroblast-specific elements by 
TGFβ, additional fibroblast-specific pathways may be involved in the collagen gene 
upregulation in the Tsk1/+ murine model, suggesting that other factors other than TGFβ 
may be important in the fibrotic Tsk1/+ mice. Whilst it is well-established that the Col1a2 
and COL1A2 promoter is activated by TGFβ, there are instances in which the collagen 
gene is upregulated through mechanisms that are either independent of or parallel to TGFβ. 
IL-4 and IL-13, which stimulate collagen gene promoter activity are two such 
examples(Jinnin et al., 2004;McGaha et al., 2003). In these studies, the loss of IL-4 in Tsk 
mice reduces TGFβ production and abrogates cutaneous hyperplasia whereas loss of IL-13 
attenuates infection-induced liver fibrosis in mice independently of TGFβ.  
 
Although murine models provide an invaluable insight into the potential pathogenic disease 
mechanisms, it is critical to consider pathogenesis in the context of human fibrotic diseases. 
SSc represents a prototypic fibrotic disease and access to lesional skin biopsies makes them 
a useful investigative tool to test candidate mediators identified from the murine models. 
The results presented in this thesis that MCP-3 may be an important initiator in the cascade 
of mediators leading to dermal fibrosis. Interestingly, it has been reported that MCP-3 is 
upregulated in experimental models of inflammation although its physiological function, 
for example in wound healing has not been fully elucidated. It is noteworthy that recent 
studies with murine strains deficient for MCP family of CC chemokines and CCR2 genes 
have demonstrated that MCP-3 and CCR2 may play a critical role in  maintenance of   255
normal blood monocytes as well as recruitment of inflammatory circulatory monocytes to 
sites of inflammation. Compared to MCP-1(-/-) murine strains, there was significantly 
greater retention of marrow monocytes in the MCP-3(-/-) and CCR2(-/-) mice(Tsou et al., 
2007). Interestingly, this effect appears to be specific to these two members of the MCP 
chemokine family. Whilst this result supports a non-redundant activity for these 
chemokines, it is unclear whether activation of CCR1 or CCR3, the other receptors for 
MCP-3, contributes to monocyte recruitment. These results are replicated in another 
inflammatory murine model with infection to Listeria monocytogenes in which the defect 
in monocyte emigration from the marrow was again more pronounced in the MCP-3(-/-) 
mice than in MCP-1(-/-) mice strain. From these studies, it was suggested that both MCP-1 
and MCP-3 might work in parallel to monocytic recruitment in response to inflammatory 
stimuli. Taken together, these observations may be particularly relevant in the early 
inflammatory phase of SSc with increased colocalisation of MCP-3 in the perivascular 
dermis in early stage dcSSc strongly suggesting that MCP-3 may be important in its 
chemotactic function for mononuclear infiltrate in particular monocytes and T cells in early 
active disease.  
 
The extent to which each chemokine MCP-1 and MCP-3 contributes to this dermal 
inflammatory infiltrate in SSc is difficult to determine as a double knockout MCP-1 and 
MCP-3 mouse strain is not currently available. However, studies on CCR2 knockout mice 
suggest impaired monocytic recruitment to sites of injury. In contrast, studies on lung 
fibrosis with mice deficient for CCR2 demonstrated that these mice were protected from 
fibrosis and this protective effect was independent of the inflammatory infiltrate suggesting 
that CCR2 and its ligands may have a direct profibrotic effect(Moore et al., 2001). It may 
be that MCP-3 has a dual pathogenic role in both early and late stage of the SSc. 
Recruitment of inflammatory mononuclear cells by MCP-3 to the lesional dermal area 
would occur early followed by the scattered fibroblastic expression of MCP-3 in the 
established stage of the disease with secretion of ECM proteins. More recently, our group 
demonstrated that a subset of dermal fibroblasts from patients with early dcSSc expresses 
CCR2, the receptor for both MCP-1 and MCP-3, and double-labelling experiments revealed 
that CCR-2 positive fibroblasts expressed α-smooth muscle actin, suggesting that ligands   256
for CCR2 may stimulate the differentiation of a distinct subset of resting fibroblasts into 
metabolically active myofibroblasts in early stage of the disease(Carulli et al., 2005). 
Although this study did not directly examine MCP-3 expression, MCP-3 is a major ligand 
for CCR2 and these results may account for the heterogeneity in the fibroblastic expression 
of MCP-3 in the lesional skin. Interestingly, it has recently been reported that CCR2 may 
be critical for the recruitment of fibrocytes and this may account for the protective effect 
against fibrosis in mice deficient for CCR2(Moore et al., 2005). Whilst there is in vitro 
evidence that fibrocytes migrate to MCP-1, the role of MCP-3 in recruitment of fibrocytes 
remains unexplored. 
 
My findings also suggest that there is heterogeneity in MCP-3 expression levels in the sera 
in particular there was differential increase in a subset of patients with dcSSc. This 
observation is in keeping with the heterogeneity of the disease presentation and course. In 
support of this, recent studies have demonstrated that upregulation of MCP-3 is correlated 
with diffuse subset, skin score and presence and severity of lung fibrosis(Yanaba et al., 
2006;Choi et al., 2004). Whilst the number of patients studied for this experiment was 
small, its potential role of MCP-3 as a biomarker to identify prognostic and therapeutic 
response that may allow early and accurate identification of patients merits further 
assessment. 
 
The regulatory mechanisms governing the physiological expression and upregulation of 
MCP-3 expression in fibrosis have not been well studied. Whilst MCP-3 transcript is 
expressed in many human tissues including lung in low abundance, its regulatory control 
mechanisms remain unclear(Murakami et al., 1997). Like other MCPs, its gene is mapped 
to chromosome 17q11 and its transcriptional regulation has been examined using deletion 
fragments of the upstream 1kb promoter region in several cells lines including human 
osteosarcoma cell lines. Moreover, transcriptional regulation of MCP-3 expression has been 
studied in human dermal fibroblasts in response to cytokines including IL-4 and TNFα, 
suggesting that interplay between MCP-3 and other growth factors may be pivotal in its 
expression(Hein et al., 1999). Similar findings were also recently reported on the critical 
role of β-catenin on MCP-3 promoter expression in dermal fibroblasts(Fujita et al., 2000).   257
It has been proposed that this effect is mediated via putative transcriptional factor binding 
sites including AP-1 and NF-κB sites within the promoter.  
 
The initial finding with upregulation of MCP-3 transcript and protein in the TβRIIΔk 
murine model proposes that there is an important crosstalk between MCP-3 and TGFβ. 
This was further confirmed by results presented in Chapter 6 that MCP-3 gene and protein 
are transcriptionally regulated by TGFβ in murine fibroblasts. Furthermore, I demonstrated 
that this activation of MCP-3 by TGFβ is mediated via ALK5 receptor and required 
recruitment of both the canonical Smad and MAPK signalling pathways. It is likely that the 
transcriptional activation of MCP-3 expression depends on the cell type and stimuli 
applied. To further examine the transcriptional regulation of MCP-3 by TGFβ1, promoter 
reporter constructs with deletion fragments and point mutation constructs with the pGL3 
plasmid vector may be used to map the response elements within the 1kb promoter 
fragment used in this thesis. Further promoter deletion constructs may be extended to 
include the putative Smad-binding element binding site(-2.2kb) identified on TFSEARCH. 
Results from these promoter deletion mapping studies may be extended with DNase I 
footprinting and EMSA using a region of DNA spanning the transcriptional factor binding 
sites within the MCP-3 promoter as a target. This may be confirmed with Chromatin 
immunoprecipitation (ChIP) analysis. This methodology provides a mechanistic insight 
into the in vivo binding activity between transcription factors and MCP-3 promoter and 
also to dissect out the histone modifications and the assembly of transcription factors at 
these binding sites. For example, trichostatin A, a histone deacetylase inhibitor is able to 
trigger MCP-1, suggesting that histone acetylation alone can induce MCP-1 
expression(Ping et al., 1996).   
 
To explore further the crosstalk between MCP-3 and TGFβ, I established that MCP-3 may 
be important in modulating TGFβ-regulated pathways and that MCP-3 mediated activation 
of COL1A2 is also dependent on TGFβ. Further confirmation of this results may be 
undertaken with determination of the biological activity of both active and latent TGFβ in 
MCP-3 treated conditioned media from fibroblasts, using the functionally relevant PAI-1 
promoter linked to the luciferase reporter gene stably integrated into mink lung epithelial   258
cells(Abe et al., 1994). Results presented in Chapter 7 supported the pivotal role of 
canonical TGFβ signalling pathways in regulation of collagen expression by MCP-3. In 
addition, non-Smad signalling pathways via p38 and PI3K appear to contribute to the 
activation of collagen by MCP-3. The role of PI3K/AKT has been explored in several 
animal models and has been implicated in several fibrotic mechanisms including EMT. 
EMT-like changes were observed in rats exposed to chronic hyperglycaemia and TGFβ is 
thought to be the primary cytokine driver of EMT in kidney with elevated PKB/Akt 
phosphorylation in the affected kidneys compared to controls(Kattla et al., 2008). 
Treatment of animals with rapamycin has been shown to attenuate diabetes-induced kidney 
disease in rats and also reduced elevated activated mTOR (mammalian target of rapamycin) 
and PKB/Akt in the glomeruli of these animals(Lloberas et al., 2006). Consistent with this, 
a recent report showed that TGFβ-induced collagen overexpression in human dermal 
fibroblasts was completely inhibited by rapamycin(Kim et al., 2008). These findings 
suggest that therapeutic strategies targeting PKB/Akt signalling may be appropriate in 
fibrotic diseases although there may be other signalling pathways that may be activated as 
consequence to overcome the targeted inhibition.  
 
The interplay between these two factors is strongly supported by a recent report in an 
experimental model of renal allograft. In this study, both factors enhance intratubular 
cytotoxicity during acute rejection and T cell-mediated EMT leading to graft fibrosis during 
chronic allograft failure(Al-Hamidi et al., 2008). Moreover, the abrogation of fibrotic 
response in the knockout mice for CCR1 and CCR2, the major receptors for MCP-3 
provide indirect evidence of the potential role of MCP-3 in the development of fibrosis. 
Interestingly, the reduction of fibrosis in these knockout mice was associated with 
decreased IL-13 production. Previous studies have shown that the profibrotic activities of 
IL-13 involve both direct fibroblast activation and indirect mechanisms via stimulation of 
TGFβ. It is therefore likely that these factors may act in synergy to mediate the profibrotic 
effect and IL-13 would be a potential candidate for further study in its role in the crosstalk 
between TGFβ and MCP-3. Comparative gene expression analysis with these two factors 
suggests that a cohort of TGFβ-regulated transcripts including OSF2 is upregulated by 
MCP-3 and TGFβ. In support of this, fibroblastic OSF2 has also been recently   259
demonstrated to be upregulated by TGFβ and IL-13, suggesting that these factors act in 
synergy in promoting ECM accumulation(Blanchard et al., 2008). Similar interplay among 
these factors and CC chemokines has been reported to be critical in both human and murine 
model of lung fibrosis(Murray et al., 2008). 
 
There are several approaches by which the studies described in this thesis may be expanded 
and developed towards a better understanding of the expression and regulation of MCP-3 in 
fibrosis and SSc. In vivo evidence for the role of MCP-3 in fibrosis may be established with 
administration of a neutralising antibody against MCP-3 in both the Tsk1/+ and TβRII∆k 
models. Similar technique has been used to determine the effect of anti-MCP-1 antibody on 
the induction of dermal sclerosis in the bleomycin-induced fibrosis model with reduction in 
inflammatory mononuclear infiltrate and collagen expression(Yamamoto & Nishioka, 
2003). Studies from chemokine and chemokine receptor knockout targetting CCR2 and 
MCP-1 have established that CCR2 signalling is important in the fibrotic response by 
regulating chemokine expression and fibroblast responsiveness to TGFβ. MCP-1(-/-) has 
been used in models of dermal wound repair and dermal fibrosis. However, the caveat is 
that these knockout mouse models may provide unexpected results. For example, in the 
MIP-1α(-/-) murine model for dermal wound, the results suggest that MIP-1α although 
important in recruitment of inflammatory infiltrate appear to be inconsequential in normal 
wounds. It is likely that the MIP-1α(-/-) mice may have developed compensatory 
developmental mechanisms that overcame the loss of this single chemokine(Low et al., 
2001). Moreover, the redundancy property of chemokines and their corresponding receptors 
may alter the phenotype otherwise expected for the knockout mouse strain. Interestingly, in 
the MCP-1(-/-) wound model, there was no effect in inflammatory cell infiltrate compared 
to the wildtype, and the effect on epithelialisation and vasculogenesis was far more 
significant than collagen synthesis, suggesting that compensatory mechanisms may be 
operational or that there is differential requirement for MCP-1 in different inflammatory 
disease environment(Low et al., 2001). 
 
Similar studies targetting MCP-3 would be helpful to clarify and confirm the results in this 
thesis in particular with reference to its role in regulation of inflammation and fibrotic   260
response. Mice genetically deficient for MCP-3 (the 129/Sv strain) has recently been 
described and they have no obvious developmental abnormalities and were born at the 
expected Mendelian ratios(Tsou et al., 2007). The effect of subcutaneous injection of 
bleomycin into the skin of MCP-3(-/-) mice may be compared to the dermal fibrosis 
induced in wild-type mice. As discussed in Chapter 1, the bleomycin mouse model 
represents a well-established in vivo model for fibrosis that produces dermal lesions similar 
to SSc. A similar study has recently been reported for MCP-1(-/-) in bleomycin mouse 
model which demonstrated a markedly diminished response to fibrotic stimulus. 
Alternatively, MCP-3(-/-) mice may be crossed with Tsk1/+ mice to generate MCP-3
-/- 
Tsk/+ mice. Our group has previously reported the regulation of collagen gene by mating 
transgenic mice harbouring a far-upstream fibroblast-specific Col1a2 enhancer with Tsk/1+ 
mice(Denton et al., 2001). In these experiments, assessment of histological (collagen and 
inflammatory infiltrate) and biochemical response, and measurement of TGFβ levels may 
extend our understanding of the profibrotic role of MCP-3 in fibrotic process. In addition, a 
conditional knockout of the gene postnatally using the site-specific Cre/LoxP 
recombination strategy will allow controlled spatial and temporal deactivation of the 
gene(Sonnylal et al., 2007), and therefore eliminate the possibility of compensatory 
mechanisms and avoid the developmental consequences in a genetically deficient mice 
targeting MCP-3 gene. 
 
Overall, the work described in this thesis has provided evidence to support a potential role 
for MCP-3 in the pathogenesis of fibrosis and suggests that there may be important links 
between MCP-3 and the profibrotic TGFβ in ECM production. Whilst some of the activity 
of MCP-3 may be related to its recruitment of mononuclear infiltrate to affected skin, there 
is evidence to suggest that, with TGFβ, it may have an additional profibrotic effect. This 
study represents a further step towards unraveling the molecular mechanisms that underlie 
the inflammatory and fibrotic responses in SSc and has raised additional issues for further 
experimental investigations. Furthermore, demonstration that MCP-3 may at least under 
experimental conditions and in murine models lead to ECM accumulation suggests that 
therapeutic strategies aiming to modulate chemokine and chemokine receptor activity in 
vivo may eventually be beneficial in systemic sclerosis or other fibrotic diseases.   261
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